TREM2 Variants in Alzheimer's Disease

New England Journal of Medicine
368, 117-127
DOI: 10.1056/nejmoa1211851

Citation Report

#	Article	IF	Citations
1	A survey of TREM2 antibodies reveals neuronal but not microglial staining in formalin-fixed paraffin-embedded postmortem Alzheimer's brain tissues. Alzheimer's Research and Therapy, 2013, 5, 30.	3.0	18
2	Ushering in the study and treatment of preclinical Alzheimer disease. Nature Reviews Neurology, 2013, 9, 371-381.	4.9	125
3	Other Genes Implicated in Alzheimerâ€™s Disease. , 2013, , 209-230.		0
4	Brain Amyloid and Inflammation Imaging: A Convergence of Concepts. Current Radiology Reports, 2013, 1, 227-232.	0.4	0
5	Assessment of TREM2 rs75932628 association with Alzheimer's disease in a population-based sample: the Cache County Study. Neurobiology of Aging, 2013, 34, 2889.e11-2889.e13.	1.5	47
6	Genetic Variants in Alzheimer's Disease. , 2013, , .		9
7	Microglia: A new frontier for synaptic plasticity, learning and memory, and neurodegenerative disease research. Neurobiology of Learning and Memory, 2013, 105, 40-53.	1.0	209
8	Hunting human disease genes: lessons from the past, challenges for the future. Human Genetics, 2013, 132, 603-617.	1.8	31
9	Towards a â€˜systemsâ€™-level understanding of the nervous system and its disorders. Trends in Neurosciences, 2013, 36, 674-684.	4.2	38
10	CD33 Alzheimer's Risk-Altering Polymorphism, CD33 Expression, and Exon 2 Splicing. Journal of Neuroscience, 2013, 33, 13320-13325.	1.7	212
11	The therapeutics of Alzheimer's disease: Where we stand and where we are heading. Annals of Neurology, 2013, 74, 328-336.	2.8	101
12	Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. Acta Neuropathologica, 2013, 126, 401-409.	3.9	126
13	The NAD-dependent deacetylase sirtuin 2 is a suppressor of microglial activation and brain inflammation. EMBO Journal, 2013, 32, 2603-2616.	3.5	149
14	Microglial Beclin 1 Regulates Retromer Trafficking and Phagocytosis and Is Impaired in Alzheimerâ€™s Disease. Neuron, 2013, 79, 873-886.	3.8	313
15	FDG PET and the genetics of dementia. Clinical and Translational Imaging, 2013, 1, 235-246.	1.1	2
16	Treatment implications of the altered cytokine-insulin axis in neurodegenerative disease. Biochemical Pharmacology, 2013, 86, 862-871.	2.0	21
17	A Neurodegeneration-Specific Gene-Expression Signature of Acutely Isolated Microglia from an Amyotrophic Lateral Sclerosis Mouse Model. Cell Reports, 2013, 4, 385-401.	2.9	552
18	Microglia. Neurology, 2013, 81, 1079-1088.	1.5	188

#	Article	IF	Citations
19	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	9.4	3,741
20	The microglial sensome revealed by direct RNA sequencing. Nature Neuroscience, 2013, 16, 1896-1905.	7.1	1,244
21	Lysosomal Storage Disorders and Iron. International Review of Neurobiology, 2013, 110, 251-275.	0.9	10
22	Biomarker Modeling of Alzheimerâ€™s Disease. Neuron, 2013, 80, 1347-1358.	3.8	773
23	The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathologica, 2013, 126, 479-497.	3.9	366
24	ABCA7 expression is associated with Alzheimer's disease polymorphism and disease status. Neuroscience Letters, 2013, 556, 58-62.	1.0	86
25	TREM2 R47H Variant as a Risk Factor for Early-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 45-49.	1.2	136
26	TREM2 is associated with the risk of Alzheimer's disease in Spanish population. Neurobiology of Aging, 2013, 34, 1711.e15-1711.e17.	1.5	130
27	Transcriptional regulation and its misregulation in Alzheimerâ€™s disease. Molecular Brain, 2013, 6, 44.	1.3	55
28	Genome-wide Association Studies in Alzheimerâ€™s Disease: A Review. Current Neurology and Neuroscience Reports, 2013, 13, 381.	2.0	99
29	Evidence of Recessive Alzheimer Disease Loci in a Caribbean Hispanic Data Set. JAMA Neurology, 2013, 70, 1261-7.	4.5	37
30	Increased Expression of TREM2 in Peripheral Blood of Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2013, 38, 497-501.	1.2	75
31	Insights into TREM2 biology by network analysis of human brain gene expression data. Neurobiology of Aging, 2013, 34, 2699-2714.	1.5	145
32	TREM2and Neurodegenerative Disease. New England Journal of Medicine, 2013, 369, 1564-1570.	13.9	174
33	Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease?. Alzheimer's Research and Therapy, 2013, 5, 11.	3.0	4
34	Advances in blood-based protein biomarkers for Alzheimer's disease. Alzheimer's Research and Therapy, 2013, 5, 18.	3.0	8
35	Microglia: Scapegoat, Saboteur, or Something Else?. Science, 2013, 339, 156-161.	6.0	726
36	A novel compound heterozygous mutation in TREM2 found in a Turkish frontotemporal dementia-like family. Neurobiology of Aging, 2013, 34, 2890.e1-2890.e5.	1.5	113

#	Article	IF	Citations
37	Androgen receptor gene and sex-specific Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2077.e19-2077.e20.	1.5	13
38	Different patterns of gray matter atrophy in early- and late-onset Alzheimerâ€™s disease. Neurobiology of Aging, 2013, 34, 2014-2022.	1.5	156
39	Expression of the phagocytosis-essential protein TREM2 is down-regulated by an aluminum-induced miRNA-34a in a murine microglial cell line. Journal of Inorganic Biochemistry, 2013, 128, 267-269.	1.5	54
40	NLRP3 polymorphisms are associated with late-onset Alzheimer's disease in Han Chinese. Journal of Neuroimmunology, 2013, 265, 91-95.	1.1	74
41	Finding Risk in All the Right Places. Neuron, 2013, 78, 207-208.	3.8	0
42	TREM2 in Alzheimerâ€™s disease. Molecular Neurobiology, 2013, 48, 180-185.	1.9	105
43	TREM2 linked to late-onset AD. Nature Reviews Neurology, 2013, 9, 5-5.	4.9	16
44	Review: Activation patterns of microglia and their identification in the human brain. Neuropathology and Applied Neurobiology, 2013, 39, 3-18.	1.8	792
45	GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimerâ€™s Disease. Neuron, 2013, 78, 256-268.	3.8	344
46	Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2077.e11-2077.e18.	1.5	124
47	Alzheimerâ€™s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta. Neuron, 2013, 78, 631-643.	3.8	776
48	Peripheral inflammation in neurodegeneration. Journal of Molecular Medicine, 2013, 91, 673-681.	1.7	37
49	Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimerâ€™s Disease. Cell, 2013, 153, 707-720.	13.5	1,505
50	Phagocyte dysfunction, tissue aging and degeneration. Ageing Research Reviews, 2013, 12, 1005-1012.	5.0	91
51	Progress in Alzheimer's disease research circa 2013: Is the glass half empty or half full?. Alzheimer's Research and Therapy, 2013, 5, 26.	3.0	1
52	Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease. Alzheimer's Research and Therapy, 2013, 5, 24.	3.0	33
53	The role of inflammation in sporadic and familial Parkinsonâ€™s disease. Cellular and Molecular Life Sciences, 2013, 70, 4259-4273.	2.4	153
54	Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration. Seminars in Immunopathology, 2013, 35, 601-612.	2.8	447

#	Article	IF	Citations
55	Microglia as Dynamic and Essential Components of the Amyloid Hypothesis. Neuron, 2013, 78, 575-577.	3.8	64
56	Molecular Basis of Etiological Implications in Alzheimerâ€™s Disease: Focus on Neuroinflammation. Molecular Neurobiology, 2013, 48, 412-428.	1.9	71
57	The quest for Alzheimer disease genesâ€"focus on CSF tau. Nature Reviews Neurology, 2013, 9, 368-370.	4.9	5
58	Complement Gene Single Nucleotide Polymorphisms and Biomarker Endophenotypes of Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 51-57.	1.2	6
59	Microglia actions in Alzheimerâ€™s disease. Acta Neuropathologica, 2013, 126, 461-477.	3.9	247
60	Sequential Proteolytic Processing of the Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) Protein by Ectodomain Shedding and Î³-Secretase-dependent Intramembranous Cleavage. Journal of Biological Chemistry, 2013, 288, 33027-33036.	1.6	236
61	Inflammatory components in human Alzheimerâ€™s disease and after active amyloid-Î²42 immunization. Brain, 2013, 136, 2677-2696.	3.7	234
62	Triggering Receptor Expressed on Myeloid Cells-2: A New Ally against Sepsis. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 125-126.	2.5	1
63	Has the Twitching Hour Arrived for the Ventilated Patient?. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 126-128.	2.5	2
64	Alzheimer's disease: Mapping the brain's decline. Nature, 2013, 502, S84-S85.	13.7	17
65	STUDYING THE ROLE OF ApoE IN ALZHEIMER'S DISEASE PATHOGENESIS USING A SYSTEMS BIOLOGY MODEL. Journal of Bioinformatics and Computational Biology, 2013, 11, 1342003.	0.3	9
66	The PSEN1, p.E318G Variant Increases the Risk of Alzheimer's Disease in APOE-Îµ4 Carriers. PLoS Genetics, 2013, 9, e1003685.	1.5	55
67	The Innate Immune System in Alzheimerâ€™s Disease. International Journal of Cell Biology, 2013, 2013, 1-7.	1.0	57
68	Proteolytic Cleavage of Apolipoprotein E4 as the Keystone for the Heightened Risk Associated with Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2013, 14, 14908-14922.	1.8	53
69	The Role of ABCA1 Gene Sequence Variants on Risk of Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 38, 897-906.	1.2	45
71	Variant TREM2 as Risk Factor for Alzheimer's Disease. New England Journal of Medicine, 2013, 368, 182-184.	13.9	122
72	TREM2, Frontotemporal Dementiaâ€“Like Disease, Nasu-Hakola Disease, and Alzheimer Dementia: A Chicken and Egg Problem?. JAMA Neurology, 2013, 70, 805.	4.5	7
73	An Inflection Point in Gene Discovery Efforts for Neurodegenerative Diseases. JAMA Neurology, 2013, 70, 719.	4.5	17

#	Article	IF	Citations
74	Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease. Current Opinion in Psychiatry, 2013, 26, 276-282.	3.1	20
75	Inflammation in Alzheimerâ€™s disease: insights from immunotherapy. Brain, 2013, 136, 2654-2656.	3.7	38
76	Genetics of Alzheimerâ€™s Disease. BioMed Research International, 2013, 2013, 1-13.	0.9	75
77	Toward a better comprehension of genetics of Alzheimerâ€²s disease and frontotemporal lobar degeneration. International Journal of Nutrition, Pharmacology, Neurological Diseases, 2013, 3, 162.	0.6	0
78	Epigenetic studies in Alzheimer's disease: Current findings, caveats, and considerations for future studies. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 789-799.	1.1	68
79	Neuro2013. Clinical and Experimental Neuroimmunology, 2013, 4, 243-245.	0.5	0
80	Triggering Receptor Expressed on Myeloid Cells-2 Correlates to Hypothermic Neuroprotection in Ischemic Stroke. Therapeutic Hypothermia and Temperature Management, 2013, 3, 189-198.	0.3	27
81	Possible role of microgliopathy in the pathogenesis of Nasuâ€“Hakola disease. Clinical and Experimental Neuroimmunology, 2013, 4, 17-26.	0.5	4
82	Biomarker-Driven Therapeutic Management of Alzheimerâ€™s Disease: Establishing the Foundations. Clinical Pharmacology and Therapeutics, 2013, 95, 67-77.	2.3	19
83	CSF protein biomarkers predicting longitudinal reduction of CSF Î²-amyloid42 in cognitively healthy elders. Translational Psychiatry, 2013, 3, e293-e293.	2.4	51
84	LRRK2: Cause, Risk, and Mechanism. Journal of Parkinson's Disease, 2013, 3, 85-103.	1.5	128
85	Current concepts in Alzheimerâ€™s Disease: molecules, models and translational perspectives. Molecular Neurodegeneration, 2013, 8, 33.	4.4	11
86	TREM2 variants and Alzheimerâ€™s disease. Future Neurology, 2013, 8, 407-410.	0.9	1
87	Regulation of TREM2 expression by an NF-ÐºB-sensitive miRNA-34a. NeuroReport, 2013, 24, 318-323.	0.6	104
88	Differential Modulation of TREM2 Protein during Postnatal Brain Development in Mice. PLoS ONE, 2013, 8, e72083.	1.1	40
89	Alzheimerâ€™s Disease: Analyzing the Missing Heritability. PLoS ONE, 2013, 8, e79771.	1.1	257
90	Reduced brain somatostatin in mood disorders: a common pathophysiological substrate and drug target?. Frontiers in Pharmacology, 2013, 4, 110.	1.6	103
91	Circulating inflamma-miRs in aging and age-related diseases. Frontiers in Genetics, 2013, 4, 121.	1.1	154

#	Article	IF	Citations
92	Nodes and biological processes identified on the basis of network analysis in the brain of the senescence accelerated mice as an Alzheimer's disease animal model. Frontiers in Aging Neuroscience, 2013, 5, 65.	1.7	57
93	TREM2 signaling, miRNA-34a and the extinction of phagocytosis. Frontiers in Cellular Neuroscience, 2013, 7, 131.	1.8	25
94	Exploratory Bioinformatics Study of lncRNAs in Alzheimerâ€™s Disease mRNA Sequences with Application to Drug Development. Computational and Mathematical Methods in Medicine, 2013, 2013, 1-8.	0.7	14
95	The Triggering Receptor Expressed on Myeloid Cells 2: â€œTREM-mingâ€•the Inflammatory Component Associated with Alzheimer's Disease. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-8.	1.9	36
96	Evidence of Trem2 Variant Associated with Triple Risk of Alzheimerâ€™s Disease. PLoS ONE, 2014, 9, e92648.	1.1	42
97	Tau Overexpression Impacts a Neuroinflammation Gene Expression Network Perturbed in Alzheimerâ€™s Disease. PLoS ONE, 2014, 9, e106050.	1.1	103
98	Clinical Genetics of Alzheimerâ€™s Disease. BioMed Research International, 2014, 2014, 1-10.	0.9	39
99	Lack of Genetic Association Between TREM2 and Late-Onset Alzheimer's Disease in a Japanese Population. Journal of Alzheimer's Disease, 2014, 41, 1031-1038.	1.2	60
100	The low-density lipoprotein receptor-related protein 1 and amyloid-ÃŽÂ² clearance in AlzheimerÃ¢â‚¬â„¢s disease. Frontiers in Aging Neuroscience, 2014, 6, 93.	1.7	199
101	Deficits in the miRNA-34a-regulated endogenous TREM2 phagocytosis sensor-receptor in Alzheimer's disease (AD); an update. Frontiers in Aging Neuroscience, 2014, 6, 116.	1.7	28
102	New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease. Frontiers in Neuroscience, 2014, 8, 235.	1.4	116
103	The Role of TREM2 in Alzheimerâ€™s Disease and Other Neurological Disorders. , 2014, 04, .		25
104	Adaptors for disorders of the brain? The cancer signaling proteins NEDD9, CASS4, and PTK2B in Alzheimerâ€™s disease. Oncoscience, 2014, 1, 486-503.	0.9	38
105	Alzheim(i)R: MicroRNAs in Alzheimerâ€™s Disease. Journal of Cytology & Histology, 2014, 05, .	0.1	1
106	Genomic insights into the etiology of Alzheimer's disease: a review. Advances in Genomics and Genetics, 0, , 59.	0.8	1
108	Genomics in Neurological Disorders. Genomics, Proteomics and Bioinformatics, 2014, 12, 156-163.	3.0	23
109	The rare TREM2 R47H variant exerts only a modest effect on Alzheimer disease risk. Neurology, 2014, 83, 1353-1358.	1.5	40
110	Temporal gene profiling of the 5XFAD transgenic mouse model highlights the importance of microglial activation in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2014, 9, 33.	4.4	138

#	Article	IF	Citations
111	PLD3 is accumulated on neuritic plaques in Alzheimerâ€™s disease brains. Alzheimer's Research and Therapy, 2014, 6, 70.	3.0	37
112	Transcriptome analysis of distinct mouse strains reveals kinesin light chain-1 splicing as an amyloid-Î² accumulation modifier. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 2638-2643.	3.3	31
113	Role of BRI2 in Dementia. Journal of Alzheimer's Disease, 2014, 40, 481-494.	1.2	21
114	Emerging roles for triggering receptor expressed on myeloid cells receptor family signaling in inflammatory diseases. Expert Review of Clinical Immunology, 2014, 10, 243-256.	1.3	73
115	Genetics of Alzheimer's Disease. Neurotherapeutics, 2014, 11, 732-737.	2.1	134
116	Identification of rare variants in AlzheimerÃ¢â‚¬â„¢s disease. Frontiers in Genetics, 2014, 5, 369.	1.1	30
117	Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. Croatian Medical Journal, 2014, 55, 347-365.	0.2	34
118	Triggering receptor expressed on myeloid cells-1 (TREM-1): a new player in antiviral immunity?. Frontiers in Microbiology, 2014, 5, 627.	1.5	78
119	Using Gene Genealogies to Detect Rare Variants Associated with Complex Traits. Human Heredity, 2014, 78, 117-130.	0.4	7
120	RNA-Seq Data Mining: Downregulation of NeuroD6 Serves as a Possible Biomarker for Alzheimerâ€™s Disease Brains. Disease Markers, 2014, 2014, 1-10.	0.6	36
121	The Triggering Receptor Expressed on Myeloid Cells 2 Inhibits Complement Component 1q Effector Mechanisms and Exerts Detrimental Effects during Pneumococcal Pneumonia. PLoS Pathogens, 2014, 10, e1004167.	2.1	46
122	ABCC5, a Gene That Influences the Anterior Chamber Depth, Is Associated with Primary Angle Closure Glaucoma. PLoS Genetics, 2014, 10, e1004089.	1.5	68
123	Epigenetic mechanisms in Alzheimer's disease. Degenerative Neurological and Neuromuscular Disease, 2014, 4, 85.	0.7	8
124	Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2014, 4, 297-304.	0.6	82
125	Unresolved questions in Alzheimerâ€™s research: will biomarkers help?. Biomarkers in Medicine, 2014, 8, 61-63.	0.6	2
126	Soluble Interleukinâ€6 Receptor Levels and Risk of Dementia: One More Signpost on a Long Road Ahead. Journal of the American Geriatrics Society, 2014, 62, 772-774.	1.3	4
127	Epigenetic memory: the Lamarckian brain. EMBO Journal, 2014, 33, 945-967.	3.5	85
128	Frontobasal gray matter loss is associated with the TREM2 p.R47H variant. Neurobiology of Aging, 2014, 35, 2681-2690.	1.5	39

#	Article	IF	Citations
129	A rare mutation in UNC5C predisposes to late-onset Alzheimer's disease and increases neuronal cell death. Nature Medicine, 2014, 20, 1452-1457.	15.2	116
130	Investigating the role of rare coding variability in Mendelian dementia genes (APP , PSEN1 , PSEN2 , GRN) Tj ETQq1 1 0.784314 rgBT	1.5	53
131	Cognitive decline and brain pathology in aging â€“ need for a dimensional, lifespan and systems vulnerability view. Scandinavian Journal of Psychology, 2014, 55, 244-254.	0.8	42
132	Coding variants in TREM2 increase risk for Alzheimer's disease. Human Molecular Genetics, 2014, 23, 5838-5846.	1.4	263
133	Pharmacogenomics in Developing Countries. , 2014, , 327-351.		0
134	Comparison of multi-sample variant calling methods for whole genome sequencing. , 2014, 2014, 59-62.		11
135	TREM2Variant p.R47H as a Risk Factor for Sporadic Amyotrophic Lateral Sclerosis. JAMA Neurology, 2014, 71, 449.	4.5	221
136	Sporadic inclusion body myositis: the genetic contributions to the pathogenesis. Orphanet Journal of Rare Diseases, 2014, 9, 88.	1.2	28
137	Molecular neurodegeneration: basic biology and disease pathways. Molecular Neurodegeneration, 2014, 9, 34.	4.4	4
138	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Science Translational Medicine, 2014, 6, 243ra86.	5.8	600
139	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	4.5	166
140	Elevated Serum Pesticide Levels and Risk for Alzheimer Disease. JAMA Neurology, 2014, 71, 284.	4.5	173
142	Microglia in the Aging Retina. Advances in Experimental Medicine and Biology, 2014, 801, 207-212.	0.8	27
143	From Genome-Wide Association Studies to Next-Generation Sequencing. JAMA Neurology, 2014, 71, 5.	4.5	17
144	Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. Neurobiology of Aging, 2014, 35, 444.e1-444.e4.	1.5	92
145	Single-nucleotide polymorphisms studied for associations with urinary toxicity from 125I prostate brachytherapy implants. Brachytherapy, 2014, 13, 285-291.	0.2	6
146	Investigation of TREM2, PLD3, and UNC5C variants in patients with Alzheimer's disease from mainland China. Neurobiology of Aging, 2014, 35, 2422.e9-2422.e11.	1.5	61
147	Investigation of triggering receptor expressed on myeloid cells 2 variant in the Wisconsin Registry for Alzheimer's Prevention. Neurobiology of Aging, 2014, 35, 1252-1254.	1.5	10

#	Article	IF	Citations
148	Triggering receptor expressed on myeloid cells 2 variant is rare in late-onset Alzheimer's disease in Han Chinese individuals. Neurobiology of Aging, 2014, 35, 937.e1-937.e3.	1.5	55
149	Preparation, crystallization, and preliminary crystallographic analysis of wild-type and mutant human TREM-2 ectodomains linked to neurodegenerative and inflammatory diseases. Protein Expression and Purification, 2014, 96, 32-38.	0.6	14
150	Genetics of dementia. Lancet, The, 2014, 383, 828-840.	6.3	253
151	Biomarkers in Amyloid-Î² Immunotherapy Trials in Alzheimerâ€™s Disease. Neuropsychopharmacology, 2014, 39, 189-201.	2.8	66
152	Impairment of in vivo calcium signaling in amyloid plaque-associated microglia. Acta Neuropathologica, 2014, 127, 495-505.	3.9	88
153	Sorting Through the Roles of Beclin 1 in Microglia and Neurodegeneration. Journal of NeuroImmune Pharmacology, 2014, 9, 285-292.	2.1	24
154	Biomarker Modelling of Early Molecular Changes in Alzheimerâ€™s Disease. Molecular Diagnosis and Therapy, 2014, 18, 213-227.	1.6	4
155	Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nature Reviews Neuroscience, 2014, 15, 300-312.	4.9	1,069
156	Microglial priming in neurodegenerative disease. Nature Reviews Neurology, 2014, 10, 217-224.	4.9	827
157	Alzheimer's disease and other dementias: advances in 2013. Lancet Neurology, The, 2014, 13, 3-5.	4.9	29
158	Genetic Discoveries in AD Using CSF Amyloid and Tau. Current Genetic Medicine Reports, 2014, 2, 23-29.	1.9	10
159	Modulation of inflammation in transgenic models of Alzheimerâ€™s disease. Journal of Neuroinflammation, 2014, 11, 25.	3.1	99
160	C9ORF72: grabbing a tiger by the tail. Acta Neuropathologica, 2014, 127, 311-318.	3.9	1
161	Neuroimaging and genetic risk for Alzheimerâ€™s disease and addiction-related degenerative brain disorders. Brain Imaging and Behavior, 2014, 8, 217-233.	1.1	14
162	Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. Brain Imaging and Behavior, 2014, 8, 183-207.	1.1	161
163	Microglial phagocytosis of live neurons. Nature Reviews Neuroscience, 2014, 15, 209-216.	4.9	666
164	ApoE and AÎ² in Alzheimerâ€™s Disease: Accidental Encounters or Partners?. Neuron, 2014, 81, 740-754.	3.8	460
165	Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. Biochemical Pharmacology, 2014, 88, 508-516.	2.0	196

#	Article	IF	Citations
166	Microglial dysfunction in brain aging and Alzheimer's disease. Biochemical Pharmacology, 2014, 88, 594-604.	2.0	469
167	Neurodegenerative Diseases. , 2014, , .		3
168	Calcium regulation of neural rhythms, memory and Alzheimer's disease. Journal of Physiology, 2014, 592, 281-293.	1.3	154
169	Microglial derived tumor necrosis factor-Î± drives Alzheimer's disease-related neuronal cell cycle events. Neurobiology of Disease, 2014, 62, 273-285.	2.1	120
170	Apolipoprotein E in Alzheimer's Disease: An Update. Annual Review of Neuroscience, 2014, 37, 79-100.	5.0	340
171	Next generation sequencing techniques in neurological diseases: redefining clinical and molecular associations. Human Molecular Genetics, 2014, 23, R47-R53.	1.4	57
172	Review: The genetics of <scp>A</scp>lzheimer's disease; putting flesh on the bones. Neuropathology and Applied Neurobiology, 2014, 40, 97-105.	1.8	61
173	Genetic loci associated with Alzheimerâ€™s disease. Future Neurology, 2014, 9, 119-122.	0.9	14
174	Understanding the cause of sporadic Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2014, 14, 621-630.	1.4	47
175	Whole-genome analyses of whole-brain data: working within an expanded search space. Nature Neuroscience, 2014, 17, 791-800.	7.1	112
176	Cerebrospinal fluid analysis in Alzheimerâ€™s disease: technical issues and future developments. Journal of Neurology, 2014, 261, 1234-1243.	1.8	30
177	HTT-lowering reverses Huntingtonâ€™s disease immune dysfunction caused by NFÎºB pathway dysregulation. Brain, 2014, 137, 819-833.	3.7	147
178	Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiology of Aging, 2014, 35, 726.e11-726.e19.	1.5	158
179	Rare coding variants in the phospholipase D3 gene confer risk for Alzheimerâ€™s disease. Nature, 2014, 505, 550-554.	13.7	425
180	TREM2 and the neuroimmunology of Alzheimer's disease. Biochemical Pharmacology, 2014, 88, 495-498.	2.0	168
181	The behavioral, pathological and therapeutic features of the senescence-accelerated mouse prone 8 strain as an Alzheimer's disease animal model. Ageing Research Reviews, 2014, 13, 13-37.	5.0	104
182	Tau-aggregation inhibitor therapy for Alzheimer's disease. Biochemical Pharmacology, 2014, 88, 529-539.	2.0	221
183	Alzheimerâ€™s disease and CADASIL are heritable, adult-onset dementias that both involve damaged small blood vessels. Cellular and Molecular Life Sciences, 2014, 71, 949-955.	2.4	19

#	Article	IF	Citations
184	Opposing Effects of Membrane-Anchored CX3CL1 on Amyloid and Tau Pathologies via the p38 MAPK Pathway. Journal of Neuroscience, 2014, 34, 12538-12546.	1.7	98
185	Triggering receptor expressed on myeloid cells receptor family modulators: a patent review. Expert Opinion on Therapeutic Patents, 2014, 24, 1383-1395.	2.4	58
186	R47H TREM2 variant increases risk of typical earlyâ€onset Alzheimer's disease but not of prion or frontotemporal dementia. Alzheimer's and Dementia, 2014, 10, 602.	0.4	94
187	CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility. Human Molecular Genetics, 2014, 23, 2729-2736.	1.4	128
188	Genetics of Alzheimerâ€™s Disease. Advances in Genetics, 2014, 87, 245-294.	0.8	159
189	Rare and low-frequency variants in human common diseases and other complex traits. Journal of Medical Genetics, 2014, 51, 705-714.	1.5	29
190	Molecular Mechanisms of Alzheimer Disease Protection by the A673T Allele of Amyloid Precursor Protein. Journal of Biological Chemistry, 2014, 289, 30990-31000.	1.6	153
191	Association study ofTREM2polymorphism rs75932628 with late-onset Alzheimerâ€™s disease in Chinese Han population. Neurological Research, 2014, 36, 894-896.	0.6	40
192	A Novel Test for Recessive Contributions to Complex Diseases Implicates Bardet-Biedl Syndrome Gene BBS10 in Idiopathic Type 2 Diabetes and Obesity. American Journal of Human Genetics, 2014, 95, 509-520.	2.6	29
193	Genetic Determinants of Disease Progression in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 649-655.	1.2	53
194	CSF in Alzheimer's Disease. Advances in Clinical Chemistry, 2014, 65, 143-172.	1.8	19
195	Integrative DNA, RNA, and Protein Evidence Connects TREML4 to Coronary Artery Calcification. American Journal of Human Genetics, 2014, 95, 66-76.	2.6	30
196	Recent advances in the neuroimmunology of cell-surface CNS autoantibody syndromes, Alzheimerâ€™s disease, traumatic brain injury and schizophrenia. Journal of Neurology, 2014, 261, 2037-2042.	1.8	7
197	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. Neurobiology of Aging, 2014, 35, 2657.e13-2657.e19.	1.5	34
198	Upregulation of TREM2 Ameliorates Neuropathology and Rescues Spatial Cognitive Impairment in a Transgenic Mouse Model of Alzheimerâ€™s Disease. Neuropsychopharmacology, 2014, 39, 2949-2962.	2.8	226
199	Origin and Functions of Tissue Macrophages. Immunity, 2014, 41, 21-35.	6.6	1,191
200	Human stem cell models of dementia. Human Molecular Genetics, 2014, 23, R35-R39.	1.4	23
201	Innate immune activation in neurodegenerative disease. Nature Reviews Immunology, 2014, 14, 463-477.	10.6	1,053

#	Article	IF	Citations
202	Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. Journal of Neuroinflammation, 2014, 11, 98.	3.1	1,285
203	Epidemiology of dementia in Central Africa (EPIDEMCA): protocol for a multicentre population-based study in rural and urban areas of the Central African Republic and the Republic of Congo. SpringerPlus, 2014, 3, 338.	1.2	47
205	Microglia as a critical player in both developmental and late-life CNS pathologies. Acta Neuropathologica, 2014, 128, 333-345.	3.9	64
206	Pathways to Alzheimer's disease. Journal of Internal Medicine, 2014, 275, 296-303.	2.7	159
207	Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiology of Aging, 2014, 35, 934.e7-934.e10.	1.5	134
208	Microglia convert aggregated amyloid-Î² into neurotoxic forms through the shedding of microvesicles. Cell Death and Differentiation, 2014, 21, 582-593.	5.0	219
209	Alzheimerâ€™s Disease Genetics: From the Bench to the Clinic. Neuron, 2014, 83, 11-26.	3.8	396
210	From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease?. Biochemical Society Transactions, 2014, 42, 587-592.	1.6	45
211	Late-Onset Alzheimerâ€™s Disease Genes and the Potentially Implicated Pathways. Current Genetic Medicine Reports, 2014, 2, 85-101.	1.9	134
212	Rare Variants and Transcriptomics in Alzheimer disease. Current Genetic Medicine Reports, 2014, 2, 75-84.	1.9	9
213	Population substructure in Cache County, Utah: the Cache County study. BMC Bioinformatics, 2014, 15, S8.	1.2	7
214	Microglia receptors and their implications in the response to amyloid Î² for Alzheimerâ€™s disease pathogenesis. Journal of Neuroinflammation, 2014, 11, 48.	3.1	269
215	IVIg protects the 3xTg-AD mouse model of Alzheimerâ€™s disease from memory deficit and AÎ² pathology. Journal of Neuroinflammation, 2014, 11, 54.	3.1	67
216	Altered microglial response to AÎ² plaques in APPPS1-21 mice heterozygous for TREM2. Molecular Neurodegeneration, 2014, 9, 20.	4.4	257
217	Early miR-155 upregulation contributes to neuroinflammation in Alzheimer's disease triple transgenic mouse model. Human Molecular Genetics, 2014, 23, 6286-6301.	1.4	133
218	Microglia in Health and Disease. , 2014, , .		19
219	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Alzheimer's and Dementia, 2014, 10, 477.	0.4	167
220	Homozygous TREM2 mutation in a family with atypical frontotemporal dementia. Neurobiology of Aging, 2014, 35, 2419.e23-2419.e25.	1.5	84

#	Article	IF	Citations
221	Triggering receptor expressed on myeloid cells 2 knockdown exacerbates aging-related neuroinflammation and cognitive deficiency in senescence-accelerated mouse prone 8 mice. Neurobiology of Aging, 2014, 35, 1243-1251.	1.5	83
222	The C9ORF72 expansion does not affect the phenotype in Nasu-Hakola disease with the DAP12 mutation. Neurobiology of Aging, 2014, 35, 1780.e13-1780.e17.	1.5	3
223	Association of LRRTM3 polymorphisms with late-onset Alzheimer's disease in Han Chinese. Experimental Gerontology, 2014, 52, 18-22.	1.2	10
224	Alzheimerâ€™s Disease: New Data Highlight Nonneuronal Cell Types and the Necessity for Presymptomatic Prevention Strategies. Biological Psychiatry, 2014, 75, 553-557.	0.7	11
225	Missense variant in TREML2 protects against Alzheimer's disease. Neurobiology of Aging, 2014, 35, 1510.e19-1510.e26.	1.5	110
226	Alzheimer's disease susceptibility variants in the MS4A6A gene are associated with altered levels of MS4A6A expression in blood. Neurobiology of Aging, 2014, 35, 279-290.	1.5	56
227	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020. Biochemical Pharmacology, 2014, 88, 426-449.	2.0	105
228	Molecular Basis for Increased Risk for Late-onset Alzheimer Disease Due to the Naturally Occurring L28P Mutation in Apolipoprotein E4. Journal of Biological Chemistry, 2014, 289, 12931-12945.	1.6	20
229	Human CNS immune senescence and neurodegeneration. Current Opinion in Immunology, 2014, 29, 93-96.	2.4	73
230	Genetics of Alzheimerâ€™s Disease in Caribbean Hispanic and African American Populations. Biological Psychiatry, 2014, 75, 534-541.	0.7	57
231	A nonsense mutation in PRNP associated with clinical Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2656.e13-2656.e16.	1.5	26
233	ApoE variant p.V236E is associated with markedly reduced risk of Alzheimerâ€™s disease. Molecular Neurodegeneration, 2014, 9, 11.	4.4	57
234	P2-030: INVESTIGATING THE ROLE OF CLU, PICALM, AND CR1 IN ALZHEIMER'S DISEASE. , 2014, 10, P481-P481.		0
236	Regulation of microglial survival and proliferation in health and diseases. Seminars in Immunology, 2015, 27, 410-415.	2.7	37
237	Rare coding mutations identified by sequencing of <scp>A</scp>lzheimer disease genomeâ€wide association studies loci. Annals of Neurology, 2015, 78, 487-498.	2.8	126
238	<scp>TREM</scp>2 Protein Expression Changes Correlate with <scp>A</scp>lzheimer's Disease Neurodegenerative Pathologies in Postâ€Mortem Temporal Cortices. Brain Pathology, 2015, 25, 469-480.	2.1	131
239	Direct Evidence of Internalization of Tau byÂMicroglia In Vitro and InÂVivo. Journal of Alzheimer's Disease, 2016, 50, 77-87.	1.2	165
240	Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Scientific Reports, 2015, 5, 11161.	1.6	170

#	Article	IF	Citations
241	Prostaglandin signaling suppresses beneficial microglial function in Alzheimerâ€™s disease models. Journal of Clinical Investigation, 2015, 125, 350-364.	3.9	117
242	Biomarkers in Sporadic and Familial Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 47, 291-317.	1.2	75
243	Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLD-TDP brains. Acta Neuropathologica Communications, 2015, 3, 68.	2.4	13
244	Epistasis analysis links immune cascades and cerebral amyloidosis. Journal of Neuroinflammation, 2015, 12, 227.	3.1	10
245	Integrative biomarker discovery in neurodegenerative diseases. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2015, 7, 357-379.	6.6	4
246	Gene expression and functional annotation of human choroid plexus epithelium failure in Alzheimerâ€™s disease. BMC Genomics, 2015, 16, 956.	1.2	48
247	Genetics ignite focus on microglial inflammation in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2015, 10, 52.	4.4	128
248	Familyâ€based genome scan for age at onset of lateâ€onset Alzheimer's disease in whole exome sequencing data. Genes, Brain and Behavior, 2015, 14, 607-617.	1.1	13
249	Potassium Channel Kv1.3 Is Highly Expressed by Microglia in Human Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 797-808.	1.2	87
250	Cerebrospinal fluid biomarkers for AlzheimerÊ¼s disease. Current Opinion in Psychiatry, 2015, 28, 402-409.	3.1	39
251	Promising Targets for the Treatment of Neurodegenerative Diseases. Clinical Pharmacology and Therapeutics, 2015, 98, 492-501.	2.3	22
252	A DAP12â€Dependent signal promotes proâ€inflammatory polarization in microglia following nerve injury and exacerbates degeneration of injured neurons. Glia, 2015, 63, 1073-1082.	2.5	35
253	Immunohistochemical characterization of CD33 expression on microglia in Nasuâ€Hakola disease brains. Neuropathology, 2015, 35, 529-537.	0.7	6
254	Genetic advances in sporadic inclusion body myositis. Current Opinion in Rheumatology, 2015, 27, 586-594.	2.0	8
255	Inflammatory Cyclooxygenase Activity and PGE₂ Signaling in Models of Alzheimerâ€™s Disease. Current Immunology Reviews, 2015, 11, 125-131.	1.2	22
256	Genetic Determinants of Survival in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 651-658.	1.2	11
257	Alzheimerâ€™s Disease: Mechanism and Approach to Cell Therapy. International Journal of Molecular Sciences, 2015, 16, 26417-26451.	1.8	82
258	Microglial cell dysregulation in brain aging and neurodegeneration. Frontiers in Aging Neuroscience, 2015, 7, 124.	1.7	421

#	Article	IF	Citations
259	Phenotypic Heterogeneity of Monogenic Frontotemporal Dementia. Frontiers in Aging Neuroscience, 2015, 7, 171.	1.7	90
260	Systemic Inflammation and the Brain: Novel Roles of Genetic, Molecular, and Environmental Cues as Drivers of Neurodegeneration. Frontiers in Cellular Neuroscience, 2015, 9, 28.	1.8	248
261	Immune aging, dysmetabolism, and inflammation in neurological diseases. Frontiers in Neuroscience, 2015, 9, 172.	1.4	211
262	Loss of tau rescues inflammation-mediated neurodegeneration. Frontiers in Neuroscience, 2015, 9, 196.	1.4	89
263	Neurobiology of Alzheimerâ€™s Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. Current Alzheimer Research, 2015, 12, 712-722.	0.7	134
264	Pathway-Based Analysis of Genome-Wide siRNA Screens Reveals the Regulatory Landscape of App Processing. PLoS ONE, 2015, 10, e0115369.	1.1	19
265	Uncovering the Molecular Mechanism of Actions between Pharmaceuticals and Proteins on the AD Network. PLoS ONE, 2015, 10, e0144387.	1.1	3
266	Polygenic Analysis of Late-Onset Alzheimerâ€™s Disease from Mainland China. PLoS ONE, 2015, 10, e0144898.	1.1	66
267	The Contribution of Proteinase-Activated Receptors to Intracellular Signaling, Transcellular Transport and Autophagy in AlzheimerÂ´s Disease. Current Alzheimer Research, 2015, 12, 2-12.	0.7	8
268	Bridging the Gap between Statistical and Biological Epistasis in Alzheimerâ€™s Disease. BioMed Research International, 2015, 2015, 1-7.	0.9	26
269	TREM2 sustains microglial expansion during aging and response to demyelination. Journal of Clinical Investigation, 2015, 125, 2161-2170.	3.9	376
270	Metals Involvement in Alzheimerâ€™s Disease â€” A Patho-Genetic View. , 2015, , .		1
271	More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer's disease risk. Neurobiology of Aging, 2015, 36, 2443.e21-2443.e26.	1.5	39
272	TREM2 variants and risk of Alzheimerâ€™s disease: a meta-analysis. Neurological Sciences, 2015, 36, 1881-1888.	0.9	30
273	Rodent models of neuroinflammation for Alzheimerâ€™s disease. Journal of Neuroinflammation, 2015, 12, 74.	3.1	191
274	Post-mortem analysis of neuroinflammatory changes in human Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2015, 7, 42.	3.0	99
275	Cruchaga & Goate reply. Nature, 2015, 520, E5-E6.	13.7	8
276	Variable expression of microglial DAP12 and TREM2 genes in Nasu-Hakola disease. Neurogenetics, 2015, 16, 265-276.	0.7	26

#	Article	IF	Citations
277	TREM2 in CNS homeostasis and neurodegenerative disease. Molecular Neurodegeneration, 2015, 10, 43.	4.4	115
278	Disease-related microglia heterogeneity in the hippocampus of Alzheimerâ€™s disease, dementia with Lewy bodies, and hippocampal sclerosis of aging. Acta Neuropathologica Communications, 2015, 3, 32.	2.4	197
279	Linkage analyses in Caribbean Hispanic families identify novel loci associated with familial lateâ€onset Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1397-1406.	0.4	24
280	Novel susceptibility loci for Alzheimer's disease. Future Neurology, 2015, 10, 547-558.	0.9	7
281	Arginase 1+ microglia reduce AÎ² plaque deposition during IL-1Î²-dependent neuroinflammation. Journal of Neuroinflammation, 2015, 12, 203.	3.1	111
282	Beta-Amyloid and Tau-Protein: Structure, Interaction, and Prion-Like Properties. Biochemistry (Moscow), 2015, 80, 1800-1819.	0.7	31
283	Stress Granules Modulate SYK to Cause Microglial Cell Dysfunction in Alzheimer's Disease. EBioMedicine, 2015, 2, 1785-1798.	2.7	42
284	Genetic Architecture of Complex Human Traits: What Have We Learned from Genome-Wide Association Studies?. Current Genetic Medicine Reports, 2015, 3, 143-150.	1.9	3
285	Association Study of the TREM2 Gene and Identification of a Novel Variant in Exon 2 in Iranian Patients with Late-Onset Alzheimer's Disease. Medical Principles and Practice, 2015, 24, 351-354.	1.1	19
286	Imaging neuroinflammation in Alzheimer's disease and other dementias: Recent advances and future directions. Alzheimer's and Dementia, 2015, 11, 1110-1120.	0.4	66
287	A <scp>TREM</scp>1 variant alters the accumulation of Alzheimerâ€related amyloid pathology. Annals of Neurology, 2015, 77, 469-477.	2.8	69
289	Association of CD33 polymorphism rs3865444 with Alzheimer's disease pathology and CD33 expression in human cerebral cortex. Neurobiology of Aging, 2015, 36, 571-582.	1.5	75
290	Retromer in Alzheimer disease, Parkinson disease and other neurological disorders. Nature Reviews Neuroscience, 2015, 16, 126-132.	4.9	197
291	IL-10 Alters Immunoproteostasis in APP Mice, Increasing Plaque Burden and Worsening Cognitive Behavior. Neuron, 2015, 85, 519-533.	3.8	292
292	TREM2 regulates microglial cell activation in response to demyelination in vivo. Acta Neuropathologica, 2015, 129, 429-447.	3.9	224
293	<scp>APOE</scp>â€modulated AÎ²â€induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective. Journal of Neurochemistry, 2015, 133, 465-488.	2.1	123
294	The Evolving Biology of Microglia in Alzheimer's Disease. Neurotherapeutics, 2015, 12, 81-93.	2.1	63
295	Explorative and targeted neuroproteomics in Alzheimer's disease. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 769-778.	1.1	41

#	Article	IF	Citations
296	Genetic diagnosis and prognosis of Alzheimerâ€™s disease: challenges and opportunities. Expert Review of Molecular Diagnostics, 2015, 15, 339-348.	1.5	68
297	A Genome-wide Gene-Expression Analysis and Database in Transgenic Mice during Development of Amyloid or Tau Pathology. Cell Reports, 2015, 10, 633-644.	2.9	247
298	Microglia constitute a barrier that prevents neurotoxic protofibrillar AÎ²42 hotspots around plaques. Nature Communications, 2015, 6, 6176.	5.8	450
299	CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid. Neuroscience, 2015, 302, 112-120.	1.1	39
300	Different mechanisms of apolipoprotein E isoformâ€dependent modulation of prostaglandin E ₂ production and triggering receptor expressed on myeloid cells 2 (TREM2) expression after innate immune activation of microglia. FASEB Journal, 2015, 29, 1754-1762.	0.2	44
301	Multiple system atrophy: the application of genetics in understanding etiology. Clinical Autonomic Research, 2015, 25, 19-36.	1.4	20
302	The Role of Neuroinflammation in Dementias. Current Neurology and Neuroscience Reports, 2015, 15, 17.	2.0	112
303	A Multiancestral Genome-Wide Exome Array Study of Alzheimer Disease, Frontotemporal Dementia, and Progressive Supranuclear Palsy. JAMA Neurology, 2015, 72, 414.	4.5	37
304	TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimerâ€™s Disease Model. Cell, 2015, 160, 1061-1071.	13.5	1,236
305	TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimerâ€™s disease mouse models. Journal of Experimental Medicine, 2015, 212, 287-295.	4.2	538
306	<scp>F</scp>yn inhibition rescues established memory and synapse loss in <scp>A</scp>lzheimer mice. Annals of Neurology, 2015, 77, 953-971.	2.8	282
307	The epigenetics of aging and neurodegeneration. Progress in Neurobiology, 2015, 131, 21-64.	2.8	334
308	Genetics of Parkinsonâ€™s Disease. , 2015, , 19-34.		3
309	Lossâ€ofâ€function mutation in ABCA1 and risk of Alzheimer's disease andÂcerebrovascular disease. Alzheimer's and Dementia, 2015, 11, 1430-1438.	0.4	106
310	Alzheimerâ€™s and Parkinsonâ€™s diseases: The prion concept in relation to assembled AÎ², tau, and Î±-synuclein. Science, 2015, 349, 1255555.	6.0	753
311	Inflammation in Alzheimerâ€™s Disease and Molecular Genetics: Recent Update. Archivum Immunologiae Et Therapiae Experimentalis, 2015, 63, 333-344.	1.0	67
312	Homozygous carriers of APP A713T mutation in an autosomal dominant Alzheimer disease family. Neurology, 2015, 84, 2266-2273.	1.5	30
313	Assessment of TREM2 rs75932628 association with amyotrophic lateral sclerosis in a Chinese population. Journal of the Neurological Sciences, 2015, 355, 193-195.	0.3	9

#	Article	IF	Citations
314	TREM2 and Risk of Alzheimerâ€™s Disease â€” Friend or Foe?. New England Journal of Medicine, 2015, 372, 2564-2565.	13.9	49
315	R47H Variant ofTREM2Associated With Alzheimer Disease in a Large Late-Onset Family. JAMA Neurology, 2015, 72, 920.	4.5	122
316	Current and future implications of basic and translational research on amyloid-Î² peptide production and removal pathways. Molecular and Cellular Neurosciences, 2015, 66, 3-11.	1.0	56
317	A 22â€single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ₄₂. Alzheimer's and Dementia, 2015, 11, 1452-1460.	0.4	96
318	Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. Alzheimer's and Dementia, 2015, 11, 792-814.	0.4	241
319	Role of Triggering Receptor Expressed on Myeloid Cells-1/3 inKlebsiella-Derived Pneumosepsis. American Journal of Respiratory Cell and Molecular Biology, 2015, 53, 647-655.	1.4	14
320	Assessment of TREM2 rs75932628 association with Parkinsonâ€™s disease and multiple system atrophy in a Chinese population. Neurological Sciences, 2015, 36, 1903-1906.	0.9	16
321	Expanding the genomic roadmap of Alzheimer's disease. Lancet Neurology, The, 2015, 14, 783-785.	4.9	11
322	Alzheimerâ€™s Disease and the Search for Environmental Risk Factors. , 2015, , 315-327.		0
323	Nuclear Receptors License Phagocytosis by Trem2⁺Myeloid Cells in Mouse Models of Alzheimer's Disease. Journal of Neuroscience, 2015, 35, 6532-6543.	1.7	144
324	Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain, 2015, 138, 1738-1755.	3.7	417
325	Alzheimer's disease is associated with low density of the long CR1 isoform. Neurobiology of Aging, 2015, 36, 1766.e5-1766.e12.	1.5	33
326	Triggering receptor expressed on myeloid cells-2 is involved in prion-induced microglial activation but does not contribute to prion pathogenesis in mouse brains. Neurobiology of Aging, 2015, 36, 1994-2003.	1.5	36
327	Microglia in action: how aging and injury can change the brainÃ¢â‚¬â„¢s guardians. Frontiers in Cellular Neuroscience, 2015, 9, 54.	1.8	74
328	TREM2 R47H variant and risk of essential tremor: A cross-sectional international multicenter study. Parkinsonism and Related Disorders, 2015, 21, 306-309.	1.1	28
329	PLD3 and sporadic Alzheimer's disease risk. Nature, 2015, 520, E1-E1.	13.7	54
330	Genetic Variants and Related Biomarkers in Sporadic Alzheimerâ€™s Disease. Current Genetic Medicine Reports, 2015, 3, 19-25.	1.9	3
331	DAP12 Stabilizes the C-terminal Fragment of the Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) and Protects against LPS-induced Pro-inflammatory Response. Journal of Biological Chemistry, 2015, 290, 15866-15877.	1.6	119

#	Article	IF	Citations
332	Additional mechanisms conferring genetic susceptibility to AlzheimerÃ¢â‚¬â„¢s disease. Frontiers in Cellular Neuroscience, 2015, 9, 138.	1.8	27
333	Prion-like transmission of neuronal huntingtin aggregates to phagocytic glia in the Drosophila brain. Nature Communications, 2015, 6, 6768.	5.8	139
334	Immune attack: the role of inflammation in Alzheimer disease. Nature Reviews Neuroscience, 2015, 16, 358-372.	4.9	1,677
335	TREM2 is associated with increased risk for Alzheimerâ€™s disease in African Americans. Molecular Neurodegeneration, 2015, 10, 19.	4.4	130
336	Association of Brain DNA Methylation inSORL1,ABCA7,HLA-DRB5,SLC24A4, andBIN1With Pathological Diagnosis of Alzheimer Disease. JAMA Neurology, 2015, 72, 15.	4.5	239
337	Protein Misfolding, Neurodegeneration and Tau. , 2015, , 1-38.		0
338	Alzheimer Amyloid Peptide AÎ²42 Regulates Gene Expression of Transcription and Growth Factors. Journal of Alzheimer's Disease, 2015, 44, 613-624.	1.2	47
339	Neuroinflammation in Alzheimer's disease. Lancet Neurology, The, 2015, 14, 388-405.	4.9	4,129
340	Glia: guardians, gluttons, or guides for the maintenance of neuronal connectivity?. Annals of the New York Academy of Sciences, 2015, 1351, 1-10.	1.8	34
341	Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease. Nature Genetics, 2015, 47, 445-447.	9.4	283
342	Infection, systemic inflammation, and Alzheimer's disease. Microbes and Infection, 2015, 17, 549-556.	1.0	81
343	Precision medicine: Clarity for the clinical and biological complexity of Alzheimerâ€™s and Parkinsonâ€™s diseases. Journal of Experimental Medicine, 2015, 212, 601-605.	4.2	34
344	The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia. Alzheimer's and Dementia, 2015, 11, 1163-1170.	0.4	70
345	The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. Alzheimer's and Dementia, 2015, 11, 1407-1416.	0.4	152
346	PLD3 variants in population studies. Nature, 2015, 520, E2-E3.	13.7	49
347	Biomarkers of cognitive decline in Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 431-443.	1.1	71
348	PLD3 in non-familial Alzheimer's disease. Nature, 2015, 520, E3-E5.	13.7	58
349	Alterations in global <scp>DNA</scp> methylation and hydroxymethylation are not detected in <scp>A</scp>lzheimer's disease. Neuropathology and Applied Neurobiology, 2015, 41, 497-506.	1.8	78

#	Article	IF	Citations
350	Lyar Is a New Ligand for Retinal Pigment Epithelial Phagocytosis. Journal of Cellular Biochemistry, 2015, 116, 2177-2187.	1.2	2
351	Lack of Genetic Association Between TREM2 and Alzheimerâ€™s Disease in East Asian Population. American Journal of Alzheimer's Disease and Other Dementias, 2015, 30, 541-546.	0.9	21
352	Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease. Circulation, 2015, 131, 2061-2069.	1.6	145
353	The receptor TREML4 amplifies TLR7-mediated signaling during antiviral responses and autoimmunity. Nature Immunology, 2015, 16, 495-504.	7.0	67
354	Microglial Malfunction: The Third Rail in the Development of Alzheimer's Disease. Trends in Neurosciences, 2015, 38, 621-636.	4.2	134
355	CD33 modulates TREM2: convergence of Alzheimer loci. Nature Neuroscience, 2015, 18, 1556-1558.	7.1	134
356	The anti-inflammatory glycoprotein, CD200, restores neurogenesis and enhances amyloid phagocytosis in a mouse model of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2995-3007.	1.5	55
357	Do glia drive synaptic and cognitive impairment in disease?. Nature Neuroscience, 2015, 18, 1539-1545.	7.1	344
358	Review of Amyotrophic Lateral Sclerosis, Parkinsonâ€™s and Alzheimerâ€™s diseases helps further define pathology of the novel paradigm for Alzheimerâ€™s with heavy metals as primary disease cause. Medical Hypotheses, 2015, 85, 779-790.	0.8	25
359	Neurodegenerative Disorders as Systemic Diseases. , 2015, , .		2
360	ATP-binding Cassette Transporter A7 (ABCA7) Loss of Function Alters Alzheimer Amyloid Processing. Journal of Biological Chemistry, 2015, 290, 24152-24165.	1.6	96
361	Myeloid Cells in Alzheimer's Disease: Culprits, Victims or Innocent Bystanders?. Trends in Neurosciences, 2015, 38, 659-668.	4.2	60
362	Decision tree analysis of genetic risk for clinically heterogeneous Alzheimerâ€™s disease. BMC Neurology, 2015, 15, 47.	0.8	25
363	Microglia: Dynamic Mediators of Synapse Development and Plasticity. Trends in Immunology, 2015, 36, 605-613.	2.9	537
364	Replacement of brain-resident myeloid cells does not alter cerebral amyloid-Î² deposition in mouse models of Alzheimerâ€™s disease. Journal of Experimental Medicine, 2015, 212, 1803-1809.	4.2	81
365	Silencing of TREM2 exacerbates tau pathology, neurodegenerative changes, and spatial learning deficits in P301S tau transgenic mice. Neurobiology of Aging, 2015, 36, 3176-3186.	1.5	81
367	Impact of peripheral myeloid cells on amyloid-Î² pathology in Alzheimerâ€™s diseaseâ€“like mice. Journal of Experimental Medicine, 2015, 212, 1811-1818.	4.2	99
368	Alzheimer's disease: rare variants with large effect sizes. Current Opinion in Genetics and Development, 2015, 33, 49-55.	1.5	33

#	Article	IF	Citations
369	Involvement of inflammation in Alzheimerâ€™s disease pathogenesis and therapeutic potential of anti-inflammatory agents. Archives of Pharmacal Research, 2015, 38, 2106-2119.	2.7	114
370	Neuroinflammation: Ways in Which the Immune System Affects the Brain. Neurotherapeutics, 2015, 12, 896-909.	2.1	170
371	GWAS of longitudinal amyloid accumulation on¹⁸F-florbetapir PET in Alzheimerâ€™s disease implicates microglial activation geneIL1RAP. Brain, 2015, 138, 3076-3088.	3.7	117
372	Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer's disease. Molecular Psychiatry, 2015, 20, 1294-1300.	4.1	55
373	The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E. Journal of Biological Chemistry, 2015, 290, 26033-26042.	1.6	218
374	Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). Journal of Biological Chemistry, 2015, 290, 26043-26050.	1.6	395
375	Recent Advances from the Bench Toward the Bedside in Alzheimer's Disease. EBioMedicine, 2015, 2, 94-95.	2.7	5
376	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.4	173
377	Promoting Autophagic Clearance: Viable Therapeutic Targets in Alzheimer's Disease. Neurotherapeutics, 2015, 12, 94-108.	2.1	75
378	Prostaglandin E2 Receptor Subtype 2 Regulation of Scavenger Receptor CD36 Modulates Microglial Aî²42 Phagocytosis. American Journal of Pathology, 2015, 185, 230-239.	1.9	31
379	Mutation analysis of patients with neurodegenerative disorders using NeuroX array. Neurobiology of Aging, 2015, 36, 545.e9-545.e14.	1.5	36
380	TREM2 analysis and increased risk of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 546.e9-546.e13.	1.5	37
381	Triggering receptor expressed on myeloid cellsâ€2 fineâ€tunes inflammatory responses in murine Gramâ€negative sepsis. FASEB Journal, 2015, 29, 1247-1257.	0.2	55
382	What happens to microglial TREM2 in Alzheimerâ€™s disease: Immunoregulatory turned into immunopathogenic?. Neuroscience, 2015, 302, 138-150.	1.1	56
383	The Use of Pharmacological Retromer Chaperones in Alzheimer's Disease and other Endosomal-related Disorders. Neurotherapeutics, 2015, 12, 12-18.	2.1	30
384	Microglial Dynamics and Role in the Healthy and Diseased Brain. Neuroscientist, 2015, 21, 169-184.	2.6	275
385	Alzheimerâ€™s Disease Risk Genes and Mechanisms of Disease Pathogenesis. Biological Psychiatry, 2015, 77, 43-51.	0.7	1,034
386	Temporal-logic analysis of microglial phenotypic conversion with exposure to amyloid-Î². Molecular BioSystems, 2015, 11, 434-453.	2.9	11

#	Article	IF	Citations
387	Glial Asthenia and Functional Paralysis. Neuroscientist, 2015, 21, 552-568.	2.6	87
388	The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive?. Brain Research, 2015, 1617, 155-173.	1.1	78
389	ABCA7 in Alzheimerâ€™s Disease. Molecular Neurobiology, 2015, 51, 1008-1016.	1.9	30
390	PLD3 in Alzheimerâ€™s Disease. Molecular Neurobiology, 2015, 51, 480-486.	1.9	19
391	Transcriptomics and mechanistic elucidation of Alzheimer's disease risk genes in the brain and inÂvitro models. Neurobiology of Aging, 2015, 36, 1221.e15-1221.e28.	1.5	55
392	Is Alzheimer's Associated Amyloid Beta an Innate Immune Protein. , 0, , .		1
393	A Link Between Nerve Growth Factor Metabolic Deregulation and Amyloid-Î²-Driven Inflammation in Down Syndrome. CNS and Neurological Disorders - Drug Targets, 2016, 15, 434-447.	0.8	24
394	Risk Factors for Alzheimerâ€™s Disease. , 2016, , .		1
395	Toward precision medicine in Alzheimerâ€™s disease. Annals of Translational Medicine, 2016, 4, 107-107.	0.7	77
396	Targeted sequencing approach to identify genetic mutations in Nasu-Hakola disease. Intractable and Rare Diseases Research, 2016, 5, 269-274.	0.3	4
397	A Mutation inDAOAModifies the Age of Onset inPSEN1E280A Alzheimerâ€™s Disease. Neural Plasticity, 2016, 2016, 1-7.	1.0	25
398	Modeling Alzheimerâ€™s Disease with Induced Pluripotent Stem Cells: Current Challenges and Future Concerns. Stem Cells International, 2016, 2016, 1-12.	1.2	17
399	Redox Imbalance and Viral Infections in Neurodegenerative Diseases. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-13.	1.9	54
400	Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms. ELife, 2016, 5, .	2.8	145
401	Genes associated with Alzheimer's disease: an overview and current status. Clinical Interventions in Aging, 2016, 11, 665.	1.3	235
402	Targeting neuroinflammation in Alzheimer’s disease. Journal of Inflammation Research, 2016, Volume 9, 199-208.	1.6	198
403	Evidence of Tau Hyperphosphorylation and Dystrophic Microglia in the Common Marmoset. Frontiers in Aging Neuroscience, 2016, 8, 315.	1.7	55
404	AÎ² and Inflammatory Stimulus Activate Diverse Signaling Pathways in Monocytic Cells: Implications in Retaining Phagocytosis in AÎ²-Laden Environment. Frontiers in Cellular Neuroscience, 2016, 10, 279.	1.8	5

#	Article	IF	Citations
405	Tau Protein Hyperphosphorylation and Aggregation in Alzheimerâ€™s Disease and Other Tauopathies, and Possible Neuroprotective Strategies. Biomolecules, 2016, 6, 6.	1.8	503
406	Genetic and Transcriptomic Profiles of Inflammation in Neurodegenerative Diseases: Alzheimer, Parkinson, Creutzfeldt-Jakob and Tauopathies. International Journal of Molecular Sciences, 2016, 17, 206.	1.8	91
407	Checkpoints to the Brain: Directing Myeloid Cell Migration to the Central Nervous System. International Journal of Molecular Sciences, 2016, 17, 2030.	1.8	12
408	microRNA-34a-Mediated Down-Regulation of the Microglial-Enriched Triggering Receptor and Phagocytosis-Sensor TREM2 in Age-Related Macular Degeneration. PLoS ONE, 2016, 11, e0150211.	1.1	107
409	Alzheimerâ€™s Disease Risk Polymorphisms Regulate Gene Expression in the ZCWPW1 and the CELF1 Loci. PLoS ONE, 2016, 11, e0148717.	1.1	99
410	Genomic Modifiers of Natural Killer Cells, Immune Responsiveness and Lymphoid Tissue Remodeling Together Increase Host Resistance to Viral Infection. PLoS Pathogens, 2016, 12, e1005419.	2.1	8
411	The BET-Bromodomain Inhibitor JQ1 Reduces Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of Alzheimer's Disease. Current Alzheimer Research, 2016, 13, 985-995.	0.7	66
412	ZCWPW1 is associated with late-onset Alzheimer's disease in Han Chinese: a replication study and meta-analyses. Oncotarget, 2016, 7, 20305-20311.	0.8	24
413	The amyloid cascade hypothesis: are we poised for success or failure?. Journal of Neurochemistry, 2016, 139, 237-252.	2.1	308
414	Targeting microglia for the treatment of Alzheimer's Disease. Glia, 2016, 64, 1710-1732.	2.5	144
415	Common and Rare Genetic Variants Associated With Alzheimer's Disease. Journal of Cellular Physiology, 2016, 231, 1432-1437.	2.0	12
416	Increased tauopathy drives microglia-mediated clearance of beta-amyloid. Acta Neuropathologica Communications, 2016, 4, 63.	2.4	35
417	Alcohol and Alzheimer's Diseaseâ€”Does Alcohol Dependence Contribute to Beta-Amyloid Deposition, Neuroinflammation and Neurodegeneration in Alzheimer's Disease?. Alcohol and Alcoholism, 2017, 52, 151-158.	0.9	54
418	Performance Metrics for Selecting Single Nucleotide Polymorphisms in Late-onset Alzheimerâ€™s Disease. Scientific Reports, 2016, 6, 36155.	1.6	17
419	Association of Frontotemporal Dementia GWAS Loci with Late-Onset Alzheimerâ€™s Disease in a Northern Han Chinese Population. Journal of Alzheimer's Disease, 2016, 52, 43-50.	1.2	5
420	Depletion of the triggering receptor expressed on myeloid cells 2 inhibits progression of renal cell carcinoma via regulating related protein expression and PTEN-PI3K/Akt pathway. International Journal of Oncology, 2016, 49, 2498-2506.	1.4	22
421	Does the Interplay Between Aging and Neuroinflammation Modulate Alzheimerâ€™s Disease Clinical Phenotypes? A Clinico-Pathological Perspective. Journal of Alzheimer's Disease, 2016, 53, 403-417.	1.2	12
422	<scp>sTREM</scp> 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in earlyâ€stage Alzheimer's disease and associate with neuronal injury markers. EMBO Molecular Medicine, 2016, 8, 466-476.	3.3	392

#	Article	IF	Citations
423	Porphyromonas gingivalissuppresses adaptive immunity in periodontitis, atherosclerosis, and Alzheimerâ€™s disease. Journal of Oral Microbiology, 2016, 8, 33029.	1.2	108
424	LRP1 modulates the microglial immune response via regulation of JNK and NF-ÎºB signaling pathways. Journal of Neuroinflammation, 2016, 13, 304.	3.1	101
425	From Common to Rare Variants: The Genetic Component of Alzheimer Disease. Human Heredity, 2016, 81, 129-141.	0.4	37
426	<scp>CSF sTREM</scp> 2: marking the tipping point between preclinical <scp>AD</scp> and dementia?. EMBO Molecular Medicine, 2016, 8, 437-438.	3.3	3
427	TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. EMBO Molecular Medicine, 2016, 8, 992-1004.	3.3	144
428	Early changes in CSF sTREM2 in dominantly inherited Alzheimerâ€™s disease occur after amyloid deposition and neuronal injury. Science Translational Medicine, 2016, 8, 369ra178.	5.8	211
429	Chronic consumption of a western diet induces robust glial activation in aging mice and in a mouse model of Alzheimerâ€™s disease. Scientific Reports, 2016, 6, 21568.	1.6	82
430	Delayed glial clearance of degenerating axons in aged Drosophila is due to reduced PI3K/Draper activity. Nature Communications, 2016, 7, 12871.	5.8	40
431	Early Evidence of Low Bone Density and Decreased Serotonergic Synthesis in the Dorsal Raphe of aÂTauopathy Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 1605-1619.	1.2	41
432	Brain omega-3 polyunsaturated fatty acids modulate microglia cell number and morphology in response to intracerebroventricular amyloid-Î² 1-40 in mice. Journal of Neuroinflammation, 2016, 13, 257.	3.1	64
433	Genomics implicates adaptive and innate immunity in Alzheimer's and Parkinson's diseases. Annals of Clinical and Translational Neurology, 2016, 3, 924-933.	1.7	84
434	Increased occurrence of protein kinase CK2 in astrocytes in Alzheimerâ€™s disease pathology. Journal of Neuroinflammation, 2016, 13, 4.	3.1	54
435	Portuguese family with the co-occurrence of frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis phenotypes due to progranulin gene mutation. Neurobiology of Aging, 2016, 41, 200.e1-200.e5.	1.5	96
436	ABCA7 Deficiency Accelerates Amyloid-Î² Generation and Alzheimer's Neuronal Pathology. Journal of Neuroscience, 2016, 36, 3848-3859.	1.7	109
437	Untangling the Web: Toxic and Protective Effects of Neuroinflammation and PGE₂ Signaling in Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2016, 7, 454-463.	1.7	45
438	The Immune System and Neuroinflammation as Potential Sources of Blood-Based Biomarkers for Alzheimerâ€™s Disease, Parkinsonâ€™s Disease, and Huntingtonâ€™s Disease. ACS Chemical Neuroscience, 2016, 7, 520-527.	1.7	69
439	Genomeâ€wide linkage analyses of nonâ€Hispanic white families identify novel loci for familial lateâ€onset Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 2-10.	0.4	24
440	A rare coding variant in TREM2 increases risk for Alzheimer's disease in Han Chinese. Neurobiology of Aging, 2016, 42, 217.e1-217.e3.	1.5	71

#	Article	IF	Citations
441	TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy. Neuron, 2016, 90, 724-739.	3.8	528
442	Mosaic Loss of Chromosome Y in Blood Is Associated with Alzheimer Disease. American Journal of Human Genetics, 2016, 98, 1208-1219.	2.6	164
443	Estrogens, Neuroinflammation, and Neurodegeneration. Endocrine Reviews, 2016, 37, 372-402.	8.9	254
444	Elevated TREM2 mRNA expression in leukocytes in schizophrenia but not major depressive disorder. Journal of Neural Transmission, 2016, 123, 637-641.	1.4	13
445	ABCA7 rare variants and Alzheimer disease risk. Neurology, 2016, 86, 2134-2137.	1.5	63
446	Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics. Annual Review of Neuroscience, 2016, 39, 57-79.	5.0	97
447	Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiology of Aging, 2016, 41, 200.e13-200.e20.	1.5	174
448	Mutation analysis of the MS4A and TREM gene clusters inÂaÂcase-control Alzheimer's disease data set. Neurobiology of Aging, 2016, 42, 217.e7-217.e13.	1.5	28
449	FRMD4A-cytohesin signaling modulates cellular release of Tau. Journal of Cell Science, 2016, 129, 2003-15.	1.2	27
450	Crowdsourced estimation of cognitive decline and resilience in Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 645-653.	0.4	72
451	Association Between Genetic Traits for Immune-Mediated Diseases and Alzheimer Disease. JAMA Neurology, 2016, 73, 691.	4.5	151
452	New Genetic Links Between Alzheimer Disease and Immune-Mediated Diseases Revealed by Overlapping Genome-wide Association Study Hits. JAMA Neurology, 2016, 73, 638.	4.5	2
453	Better Utilization of Mouse Models of Neurodegenerative Diseases in Preclinical Studies: From the Bench to the Clinic. Methods in Molecular Biology, 2016, 1438, 311-347.	0.4	3
454	Genomics of Alzheimer Disease. JAMA Neurology, 2016, 73, 867.	4.5	105
455	Genetic and Epigenetic Architecture of Alzheimerâ€™s Dementia. Current Genetic Medicine Reports, 2016, 4, 7-15.	1.9	2
456	Mouse Models for Drug Discovery. Methods in Molecular Biology, 2016, , .	0.4	5
457	Neuroinflammation in Alzheimer's disease: Current evidence and future directions. Alzheimer's and Dementia, 2016, 12, 719-732.	0.4	1,076
458	Mutations modifying sporadic Alzheimer's disease age of onset. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 1116-1130.	1.1	20

#	Article	IF	Citations
459	Lymphatics in Neurological Disorders: A Neuro-Lympho-Vascular Component of Multiple Sclerosis and Alzheimerâ€™s Disease?. Neuron, 2016, 91, 957-973.	3.8	123
460	Soluble phospho-tau from Alzheimerâ€™s disease hippocampus drives microglial degeneration. Acta Neuropathologica, 2016, 132, 897-916.	3.9	124
461	Multitasking Microglia and Alzheimerâ€™s Disease: Diversity, Tools and Therapeutic Targets. Journal of Molecular Neuroscience, 2016, 60, 390-404.	1.1	12
462	TREM1 facilitates microglial phagocytosis of amyloid beta. Acta Neuropathologica, 2016, 132, 667-683.	3.9	79
463	Towards Personalized Intervention for Alzheimerâ€™s Disease. Genomics, Proteomics and Bioinformatics, 2016, 14, 289-297.	3.0	19
464	Vps35â€dependent recycling of Trem2 regulates microglial function. Traffic, 2016, 17, 1286-1296.	1.3	62
465	Microglia contributes to plaque growth by cell death due to uptake of amyloid Î² in the brain of Alzheimer's disease mouse model. Glia, 2016, 64, 2274-2290.	2.5	147
466	Alzheimer Disease and Its Growing Epidemic. Neurologic Clinics, 2016, 34, 941-953.	0.8	114
467	TYROBP genetic variants in early-onset Alzheimer's disease. Neurobiology of Aging, 2016, 48, 222.e9-222.e15.	1.5	69
468	Microglia communication: Parallels between aging and Alzheimer's disease. Clinical and Experimental Neuroimmunology, 2016, 7, 114-125.	0.5	60
469	Genetics in Parkinson disease: Mendelian versus nonâ€Mendelian inheritance. Journal of Neurochemistry, 2016, 139, 59-74.	2.1	390
470	The clinical spectrum of sporadic and familial forms of frontotemporal dementia. Journal of Neurochemistry, 2016, 138, 6-31.	2.1	111
471	Targeting innate immunity for neurodegenerative disorders of the central nervous system. Journal of Neurochemistry, 2016, 138, 653-693.	2.1	106
472	Prostaglandin J2: a potential target for halting inflammationâ€induced neurodegeneration. Annals of the New York Academy of Sciences, 2016, 1363, 125-137.	1.8	33
473	The contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease. Journal of Neurochemistry, 2016, 136, 457-474.	2.1	331
474	The amyloid hypothesis of Alzheimer's disease at 25Âyears. EMBO Molecular Medicine, 2016, 8, 595-608.	3.3	4,226
475	Extracellular Mitochondria and Mitochondrial Components Act as Damage-Associated Molecular Pattern Molecules in the Mouse Brain. Journal of NeuroImmune Pharmacology, 2016, 11, 622-628.	2.1	34
476	Genome research in pre-dementia stages of Alzheimer's disease. Expert Reviews in Molecular Medicine, 2016, 18, e11.	1.6	13

#	Article	IF	Citations
477	The human-specificCASP4gene product contributes to Alzheimer-related synaptic and behavioural deficits. Human Molecular Genetics, 2016, 25, 4315-4327.	1.4	21
478	Increased DNA methylation near TREM2 is consistently seen in the superior temporal gyrus in Alzheimer's disease brain. Neurobiology of Aging, 2016, 47, 35-40.	1.5	79
480	Neurodegenerative Diseases and Dementia. , 2016, , 167-197.		0
481	Effects of Alzheimerâ€™s Disease-Associated Risk Loci on Amyloid-Î² Accumulation in the Brain of Idiopathic Normal Pressure Hydrocephalus Patients. Journal of Alzheimer's Disease, 2016, 55, 995-1003.	1.2	6
483	Genomics of Alzheimer's disease: Value of high-throughput genomic technologies to dissect its etiology. Molecular and Cellular Probes, 2016, 30, 397-403.	0.9	11
484	Interactions between inflammation, sex steroids, and Alzheimerâ€™s disease risk factors. Frontiers in Neuroendocrinology, 2016, 43, 60-82.	2.5	81
485	Tau and tauopathies. Brain Research Bulletin, 2016, 126, 238-292.	1.4	444
486	TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia. Neuron, 2016, 91, 328-340.	3.8	643
487	Inhomogeneous distribution of Iba€‐1 characterizes microglial pathology in Alzheimer's disease. Glia, 2016, 64, 1562-1572.	2.5	81
488	The endocytic pathway in microglia during health, aging and Alzheimerâ€™s disease. Ageing Research Reviews, 2016, 32, 89-103.	5.0	93
489	The Genetic Basis of Alzheimer's Disease. , 2016, , 547-571.		5
490	Innate phagocytosis by peripheral blood monocytes is altered in Alzheimerâ€™s disease. Acta Neuropathologica, 2016, 132, 377-389.	3.9	40
491	Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 1259-1272.	0.4	86
492	Neuroinflammation â€” using big data to inform clinical practice. Nature Reviews Neurology, 2016, 12, 685-698.	4.9	29
493	Ageing, neurodegeneration and brain rejuvenation. Nature, 2016, 539, 180-186.	13.7	787
494	Neurodegeneration: From cellular concepts to clinical applications. Science Translational Medicine, 2016, 8, 364ps18.	5.8	73
495	Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimerâ€™s disease. BMC Medical Genomics, 2016, 9, 30.	0.7	20
496	The neuritic plaque facilitates pathological conversion of tau in an Alzheimerâ€™s disease mouse model. Nature Communications, 2016, 7, 12082.	5.8	56

#	Article	IF	Citations
497	TREM2/DAP12 Signal Elicits Proinflammatory Response in Microglia and Exacerbates Neuropathic Pain. Journal of Neuroscience, 2016, 36, 11138-11150.	1.7	101
498	CNS disease models with human pluripotent stem cells in the CRISPR age. Current Opinion in Cell Biology, 2016, 43, 96-103.	2.6	19
499	TREMs in Alzheimer's disease: Genetic and clinical investigations. Clinica Chimica Acta, 2016, 463, 88-95.	0.5	20
500	Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimerâ€™s disease. Scientific Reports, 2016, 6, 30028.	1.6	469
501	Gain-of-function mutations in protein kinase CÎ± (PKCÎ±) may promote synaptic defects in Alzheimerâ€™s disease. Science Signaling, 2016, 9, ra47.	1.6	84
502	Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimerâ€™s disease. Genome Medicine, 2016, 8, 104.	3.6	224
503	Do Microglia Default on Network Maintenance in Alzheimerâ€™s Disease?. Journal of Alzheimer's Disease, 2016, 51, 657-669.	1.2	17
504	Rare TREM2 variants associated with Alzheimerâ€™s disease display reduced cell surface expression. Acta Neuropathologica Communications, 2016, 4, 98.	2.4	46
505	A novel approach for multi-SNP GWAS and its application in Alzheimerâ€™s disease. BMC Bioinformatics, 2016, 17, 268.	1.2	12
506	Expression and processing analyses of wild type and p.R47H TREM2 variant in Alzheimerâ€™s disease brains. Molecular Neurodegeneration, 2016, 11, 72.	4.4	55
507	Genetic variations underlying Alzheimer's disease: evidence from genome-wide association studies and beyond. Lancet Neurology, The, 2016, 15, 857-868.	4.9	241
508	The Complex Pathways to Mechanism-Based Therapeutics in Alzheimerâ€™s Disease. , 2016, , 1-22.		0
509	The Genetic Basis of Alzheimerâ€™s Disease. , 2016, , 23-37.		5
510	Anti-Amyloid-Î² Immunotherapy for Alzheimerâ€™s Disease. , 2016, , 193-226.		9
511	Fluid Biomarkers and Diagnostics. , 2016, , 565-587.		0
512	Cerebrospinal fluid soluble TREM2 in aging and Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2016, 8, 17.	3.0	105
513	Apolipoprotein E as a Therapeutic Target in Alzheimerâ€™s Disease: A Review of Basic Research and Clinical Evidence. CNS Drugs, 2016, 30, 773-789.	2.7	93
514	Elucidating novel dysfunctional pathways in Alzheimer's disease by integrating loci identified in genetic and epigenetic studies. Neuroepigenetics, 2016, 6, 32-50.	2.8	17

#	Article	IF	Citations
516	ABCA7 p.G215S as potential protective factor for Alzheimer's disease. Neurobiology of Aging, 2016, 46, 235.e1-235.e9.	1.5	37
517	Differential burden of rare protein truncating variants in Alzheimerâ€™s disease patients compared to centenarians. Human Molecular Genetics, 2016, 25, ddw150.	1.4	10
518	Functional involvement of Î³-secretase in signaling of the triggering receptor expressed on myeloid cells-2 (TREM2). Journal of Neuroinflammation, 2016, 13, 17.	3.1	28
519	TREM2 upregulation correlates with 5-hydroxymethycytosine enrichment in Alzheimerâ€™s disease hippocampus. Clinical Epigenetics, 2016, 8, 37.	1.8	68
520	Chronic Toxoplasma gondii infection enhances Î²-amyloid phagocytosis and clearance by recruited monocytes. Acta Neuropathologica Communications, 2016, 4, 25.	2.4	78
521	The Evolution of Genetics: Alzheimerâ€™s and Parkinsonâ€™s Diseases. Neuron, 2016, 90, 1154-1163.	3.8	81
522	Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2016, 11, 3.	4.4	236
523	Microglia and neuroprotection. Journal of Neurochemistry, 2016, 136, 10-17.	2.1	296
524	CLU rs9331888 Polymorphism Contributes to Alzheimerâ€™s Disease Susceptibility in Caucasian But Not East Asian Populations. Molecular Neurobiology, 2016, 53, 1446-1451.	1.9	40
525	Association study of TREM2 polymorphism rs75932628 with leucoaraiosis or Parkinson's disease in the Han Chinese population. BMJ Open, 2016, 6, e009499.	0.8	10
526	Molecular systems evaluation of oligomerogenic APPE693Q and fibrillogenic APPKM670/671NL/PSEN1Î”exon9 mouse models identifies shared features with human Alzheimerâ€™s brain molecular pathology. Molecular Psychiatry, 2016, 21, 1099-1111.	4.1	18
527	Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. Multiple Sclerosis Journal, 2016, 22, 1587-1595.	1.4	73
528	MicroRNA deregulation and chemotaxis and phagocytosis impairment inÂAlzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 7-17.	1.2	51
529	Defining the Genetic Architecture of Alzheimer's Disease: Where Next?. Neurodegenerative Diseases, 2016, 16, 6-11.	0.8	13
530	TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice. Neuropharmacology, 2016, 105, 196-206.	2.0	136
531	Genetic analysis of MC1R variants in Chinese Han patients with sporadic Parkinsonâ€™s disease. Neuroscience Letters, 2016, 611, 101-105.	1.0	12
532	Tau and neurodegenerative disease: the story so far. Nature Reviews Neurology, 2016, 12, 15-27.	4.9	603
533	Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells. Molecular and Cellular Neurosciences, 2016, 73, 13-31.	1.0	100

#	Article	IF	Citations
534	Defective Phagocytic Corpse Processing Results in Neurodegeneration and Can Be Rescued by TORC1 Activation. Journal of Neuroscience, 2016, 36, 3170-3183.	1.7	50
535	Early and protective microglial activation in Alzheimerâ€™s disease: a prospective study using¹⁸F-DPA-714 PET imaging. Brain, 2016, 139, 1252-1264.	3.7	365
536	Next generation transcriptomics and genomics elucidate biological complexity of microglia in health and disease. Glia, 2016, 64, 197-213.	2.5	112
537	Molecular genetics of earlyâ€onset Alzheimer's disease revisited. Alzheimer's and Dementia, 2016, 12, 733-748.	0.4	409
538	Microglia: Architects of the Developing Nervous System. Trends in Cell Biology, 2016, 26, 587-597.	3.6	264
539	Inflammation in central nervous system diseases. Clinical and Experimental Neuroimmunology, 2016, 7, 18-27.	0.5	1
540	Opposing roles of the triggering receptor expressed on myeloid cells 2 and triggering receptor expressed on myeloid cells-like transcript 2 in microglia activation. Neurobiology of Aging, 2016, 42, 132-141.	1.5	89
541	The adaptive immune system restrains Alzheimerâ€™s disease pathogenesis by modulating microglial function. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E1316-25.	3.3	311
542	The Cellular Phase of Alzheimerâ€™s Disease. Cell, 2016, 164, 603-615.	13.5	1,346
543	Parkinsonism, movement disorders and genetics in frontotemporal dementia. Nature Reviews Neurology, 2016, 12, 175-185.	4.9	173
544	TREM2 Function in Alzheimerâ€™s Disease and Neurodegeneration. ACS Chemical Neuroscience, 2016, 7, 420-427.	1.7	100
545	The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume. Neurobiology of Aging, 2016, 40, 68-77.	1.5	115
546	Exome sequencing in dementia with Lewy bodies. Translational Psychiatry, 2016, 6, e728-e728.	2.4	35
547	Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurology, The, 2016, 15, 455-532.	4.9	1,242
548	Alzheimer's disease. Lancet, The, 2016, 388, 505-517.	6.3	2,430
549	TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nature Reviews Neuroscience, 2016, 17, 201-207.	4.9	312
550	New tools for studying microglia in the mouse and human CNS. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E1738-46.	3.3	1,400
551	Eliminating microglia in Alzheimerâ€™s mice prevents neuronal loss without modulating amyloid-Î²2 pathology. Brain, 2016, 139, 1265-1281.	3.7	514

#	Article	IF	Citations
552	Novel PSEN1 mutations (H214N and R220P) associated with familial Alzheimer's disease identified by targeted exome sequencing. Neurobiology of Aging, 2016, 40, 192.e7-192.e11.	1.5	15
553	The Lipoxygenases: Their Regulation and Implication in Alzheimerâ€™s Disease. Neurochemical Research, 2016, 41, 243-257.	1.6	90
554	Accelerating stem cell trials for Alzheimer's disease. Lancet Neurology, The, 2016, 15, 219-230.	4.9	76
555	Stem cell therapy for Alzheimer's disease: hope or hype?. Lancet Neurology, The, 2016, 15, 133-135.	4.9	16
556	Immunotherapies in Alzheimerâ€™s disease: Too much, too little, too late or off-target?. Acta Neuropathologica, 2016, 131, 481-504.	3.9	30
557	Genetic analysis of TREM2 variants in Chinese Han patients with sporadic Parkinsonâ€™s disease. Neuroscience Letters, 2016, 612, 189-192.	1.0	23
558	Plaque-Associated Local Toxicity Increases over the Clinical Course of Alzheimer Disease. American Journal of Pathology, 2016, 186, 375-384.	1.9	73
559	Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathologica, 2016, 131, 925-933.	3.9	262
560	Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimerâ€™s-like pathology. Brain, 2016, 139, 891-907.	3.7	389
561	Toward more predictive genetic mouse models of Alzheimer's disease. Brain Research Bulletin, 2016, 122, 1-11.	1.4	140
562	The Triggering Receptor Expressed on Myeloid Cells 2: A Molecular Link of Neuroinflammation and Neurodegenerative Diseases. Journal of Biological Chemistry, 2016, 291, 4334-4341.	1.6	61
563	Unraveling the mechanistic complexity of Alzheimer's disease through systems biology. Alzheimer's and Dementia, 2016, 12, 708-718.	0.4	22
564	New insights on the role of microglia in synaptic pruning in health and disease. Current Opinion in Neurobiology, 2016, 36, 128-134.	2.0	431
565	Microglial dysfunction connects depression and Alzheimerâ€™s disease. Brain, Behavior, and Immunity, 2016, 55, 151-165.	2.0	100
566	Pro-inflammatory S100A9 Protein as a Robust Biomarker Differentiating Early Stages of Cognitive Impairment in Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2016, 7, 34-39.	1.7	60
567	Review: High-performance computing to detect epistasis in genome scale data sets. Briefings in Bioinformatics, 2016, 17, 368-379.	3.2	39
568	AlzPathway, an Updated Map of Curated Signaling Pathways: Towards Deciphering Alzheimerâ€™s Disease Pathogenesis. Methods in Molecular Biology, 2016, 1303, 423-432.	0.4	17
569	CR1 rs3818361 Polymorphism Contributes to Alzheimerâ€™s Disease Susceptibility in Chinese Population. Molecular Neurobiology, 2016, 53, 4054-4059.	1.9	47

#	Article	IF	Citations
570	Viral gene transfer of APPsÎ± rescues synaptic failure in an Alzheimerâ€™s disease mouse model. Acta Neuropathologica, 2016, 131, 247-266.	3.9	131
571	Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease. Current Opinion in Neurobiology, 2016, 36, 74-81.	2.0	223
572	Potential of tocotrienols in the prevention and therapy of Alzheimer's disease. Journal of Nutritional Biochemistry, 2016, 31, 1-9.	1.9	33
573	Perturbation of the transcriptome: implications of the innate immune system in Alzheimer's disease. Current Opinion in Pharmacology, 2016, 26, 47-53.	1.7	14
574	Next Generation Sequencing in Alzheimerâ€™s Disease. Methods in Molecular Biology, 2016, 1303, 281-297.	0.4	18
575	Application of Systems Theory in Longitudinal Studies on the Origin and Progression of Alzheimerâ€™s Disease. Methods in Molecular Biology, 2016, 1303, 49-67.	0.4	30
576	Pooled-DNA Sequencing for Elucidating New Genomic Risk Factors, Rare Variants Underlying Alzheimerâ€™s Disease. Methods in Molecular Biology, 2016, 1303, 299-314.	0.4	3
577	Dissecting Complex and Multifactorial Nature of Alzheimerâ€™s Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective. Molecular Neurobiology, 2016, 53, 4833-4864.	1.9	52
578	Microglia in Health and Disease. Cold Spring Harbor Perspectives in Biology, 2016, 8, a020560.	2.3	211
579	Network-Based Analysis for Uncovering Mechanisms Underlying Alzheimerâ€™s Disease. Methods in Molecular Biology, 2016, 1303, 479-491.	0.4	3
580	Sex differences in neurodevelopmental and neurodegenerative disorders: Focus on microglial function and neuroinflammation during development. Journal of Steroid Biochemistry and Molecular Biology, 2016, 160, 127-133.	1.2	269
581	Altered Neuroinflammation and Behavior after Traumatic Brain Injury in a Mouse Model of Alzheimer's Disease. Journal of Neurotrauma, 2016, 33, 625-640.	1.7	42
582	Interaction between variants in CLU and MS4A4E modulates Alzheimer's disease risk. Alzheimer's and Dementia, 2016, 12, 121-129.	0.4	18
583	Myeloid cell-based therapies in neurological disorders: How far have we come?. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 323-328.	1.8	13
584	Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: input and lessons. European Journal of Human Genetics, 2016, 24, 710-716.	1.4	77
585	PLD3 in Alzheimerâ€™s Disease: a Modest Effect as Revealed by Updated Association and Expression Analyses. Molecular Neurobiology, 2016, 53, 4034-4045.	1.9	30
586	The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genetics in Medicine, 2016, 18, 421-430.	1.1	695
587	Low Testosterone Level and Risk of Alzheimerâ€™s Disease in the Elderly Men: a Systematic Review and Meta-Analysis. Molecular Neurobiology, 2016, 53, 2679-2684.	1.9	103

#	Article	IF	Citations
588	The Role of Retromer in Alzheimerâ€™s Disease. Molecular Neurobiology, 2016, 53, 4201-4209.	1.9	13
590	Microglia in Alzheimerâ€™s disease: A multifaceted relationship. Brain, Behavior, and Immunity, 2016, 55, 138-150.	2.0	98
591	Dissecting the Contribution of Vascular Alterations and Aging to Alzheimerâ€™s Disease. Molecular Neurobiology, 2016, 53, 3793-3811.	1.9	48
592	Thyrotropin and Alzheimerâ€™s Disease Risk in the Elderly: a Systematic Review and Meta-Analysis. Molecular Neurobiology, 2016, 53, 1229-1236.	1.9	4
593	Genome-wide significant risk factors for Alzheimerâ€™s disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment. Molecular Psychiatry, 2017, 22, 153-160.	4.1	102
594	TREM2 Overexpression has No Improvement on Neuropathology and Cognitive Impairment in Aging APPswe/PS1dE9 Mice. Molecular Neurobiology, 2017, 54, 855-865.	1.9	40
595	A Missense Variant in TREML2 Reduces Risk of Alzheimerâ€™s Disease in a Han Chinese Population. Molecular Neurobiology, 2017, 54, 977-982.	1.9	13
596	Triggering Receptor Expressed on Myeloid Cells 2 Deficiency Alters Acute Macrophage Distribution and Improves Recovery after Traumatic Brain Injury. Journal of Neurotrauma, 2017, 34, 423-435.	1.7	70
597	Induced pluripotent stem cells as a discovery tool for Alzheimer×³s disease. Brain Research, 2017, 1656, 98-106.	1.1	35
598	Monoaminergic neuropathology in Alzheimerâ€™s disease. Progress in Neurobiology, 2017, 151, 101-138.	2.8	206
599	Association of DISC1 Polymorphisms with Late-Onset Alzheimerâ€™s Disease in Northern Han Chinese. Molecular Neurobiology, 2017, 54, 2922-2927.	1.9	4
600	Inflammation in Alzheimerâ€™s disease: Lessons learned from microglia-depletion models. Brain, Behavior, and Immunity, 2017, 61, 1-11.	2.0	266
601	A novel mutation in TREM2 gene causing Nasu-Hakola disease and review of the literature. Neurobiology of Aging, 2017, 53, 194.e13-194.e22.	1.5	61
602	Opposing Functions of Microglial and Macrophagic TNFR2 in the Pathogenesis of Experimental Autoimmune Encephalomyelitis. Cell Reports, 2017, 18, 198-212.	2.9	125
603	The APOE Îµ4 genotype modulates CSF YKLâ€40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 50-59.	1.2	36
604	Quantitative Comparison of Dense-Core Amyloid Plaque Accumulation in Amyloid-Î² Protein Precursor Transgenic Mice. Journal of Alzheimer's Disease, 2017, 56, 743-761.	1.2	39
605	Major Shifts in Glial Regional Identity Are a Transcriptional Hallmark of Human Brain Aging. Cell Reports, 2017, 18, 557-570.	2.9	326
606	Discovery and functional prioritization of Parkinsonâ€™s disease candidate genes from large-scale whole exome sequencing. Genome Biology, 2017, 18, 22.	3.8	96

#	Article	IF	Citations
607	TREM2 Promotes Microglial Survival by Activating Wnt/Î²-Catenin Pathway. Journal of Neuroscience, 2017, 37, 1772-1784.	1.7	242
608	Infectious immunity in the central nervous system and brain function. Nature Immunology, 2017, 18, 132-141.	7.0	163
609	A Common Variant of IL-6R is Associated with Elevated IL-6 Pathway Activity in Alzheimerâ€™s Disease Brains. Journal of Alzheimer's Disease, 2017, 56, 1037-1054.	1.2	44
610	InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines. American Journal of Human Genetics, 2017, 100, 267-280.	2.6	717
611	Clearance of cerebral AÎ² in Alzheimerâ€™s disease: reassessing the role of microglia and monocytes. Cellular and Molecular Life Sciences, 2017, 74, 2167-2201.	2.4	199
612	Soluble TREM2 induces inflammatory responses and enhances microglial survival. Journal of Experimental Medicine, 2017, 214, 597-607.	4.2	258
613	Recent Progress in Alzheimerâ€™s Disease Research, Part 1: Pathology. Journal of Alzheimer's Disease, 2017, 57, 1-28.	1.2	75
614	Future Directions in Imaging Neurodegeneration. Current Neurology and Neuroscience Reports, 2017, 17, 9.	2.0	13
615	Neocortical and hippocampal TREM2 protein levels during the progression of Alzheimer's disease. Neurobiology of Aging, 2017, 54, 133-143.	1.5	33
616	Genome-wide association study identifies four novel loci associated with Alzheimerâ€™s endophenotypes and disease modifiers. Acta Neuropathologica, 2017, 133, 839-856.	3.9	199
617	Psychosocial stress on neuroinflammation and cognitive dysfunctions in Alzheimer's disease: the emerging role for microglia?. Neuroscience and Biobehavioral Reviews, 2017, 77, 148-164.	2.9	101
618	Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-Î² and other amyloidogenic proteins. Journal of Lipid Research, 2017, 58, 824-836.	2.0	159
619	NLRP3 inflammasome-driven pathways in depression: Clinical and preclinical findings. Brain, Behavior, and Immunity, 2017, 64, 367-383.	2.0	295
620	A Precision Medicine Initiative for Alzheimerâ€™s disease: the road ahead to biomarker-guided integrative disease modeling. Climacteric, 2017, 20, 107-118.	1.1	112
621	Microglia Function in the Central Nervous System During Health and Neurodegeneration. Annual Review of Immunology, 2017, 35, 441-468.	9.5	1,450
622	EFAD transgenic mice as a human APOE relevant preclinical model of AlzheimerÅ‰s disease. Journal of Lipid Research, 2017, 58, 1733-1755.	2.0	56
623	Tau Spread, Apolipoprotein E, Inflammation, and More. Neurologic Clinics, 2017, 35, 175-190.	0.8	18
624	DNA methylation changes at TREM2 intron 1 and TREM2 mRNA expression in patients with Alzheimer's disease. Journal of Psychiatric Research, 2017, 92, 74-80.	1.5	70

#	Article	IF	Citations
625	Neuroinflammation as a therapeutic target in neurodegenerative diseases. , 2017, , 49-80.		7
626	Applying fluid biomarkers to Alzheimer's disease. American Journal of Physiology - Cell Physiology, 2017, 313, C3-C10.	2.1	46
628	TREM2-Ligand Interactions in Health and Disease. Journal of Molecular Biology, 2017, 429, 1607-1629.	2.0	173
629	TREM2, Microglia, and Neurodegenerative Diseases. Trends in Molecular Medicine, 2017, 23, 512-533.	3.5	327
630	Recent Progress in Alzheimerâ€™s Disease Research, Part 2: Genetics and Epidemiology. Journal of Alzheimer's Disease, 2017, 57, 317-330.	1.2	131
631	Membrane damage is at the core of Alzheimer's disease. Lancet Neurology, The, 2017, 16, 342.	4.9	15
632	Elucidating the Role of TREM2 in Alzheimerâ€™s Disease. Neuron, 2017, 94, 237-248.	3.8	255
633	A split-luciferase complementation, real-time reporting assay enables monitoring of the disease-associated transmembrane protein TREM2 in live cells. Journal of Biological Chemistry, 2017, 292, 10651-10663.	1.6	16
634	<scp>TREM</scp>2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Reports, 2017, 18, 1186-1198.	2.0	240
635	Systems biology in the central nervous system: A brief perspective on essential recent advancements. Current Opinion in Systems Biology, 2017, 3, 67-76.	1.3	8
636	N -glycan and Alzheimer's disease. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 2447-2454.	1.1	94
637	Higher Peripheral TREM2 mRNA Levels Relate to Cognitive Deficits and Hippocampal Atrophy in Alzheimerâ€™s Disease and Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2017, 58, 413-423.	1.2	38
638	The vicious circle of hypometabolism in neurodegenerative diseases: Ways and mechanisms of metabolic correction. Journal of Neuroscience Research, 2017, 95, 2217-2235.	1.3	149
639	A novel presenilin 1 mutation (F388L) identified in a Chinese family with early-onset Alzheimer's disease. Neurobiology of Aging, 2017, 50, 168.e1-168.e4.	1.5	9
640	Deciphering microglial diversity in Alzheimer's disease. Science, 2017, 356, 1123-1124.	6.0	15
641	Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimerâ€™s pathology. Acta Neuropathologica, 2017, 134, 769-788.	3.9	85
642	Multiple variants in families with amyotrophic lateral sclerosis and frontotemporal dementia related to C9orf72 repeat expansion: further observations on their oligogenic nature. Journal of Neurology, 2017, 264, 1426-1433.	1.8	27
643	A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease. Nature Neuroscience, 2017, 20, 1052-1061.	7.1	330

#	Article	IF	Citations
644	Diverse Requirements for Microglial Survival, Specification, and Function Revealed by Defined-Medium Cultures. Neuron, 2017, 94, 759-773.e8.	3.8	457
646	Alzheimerâ€™s Disease and ncRNAs. Advances in Experimental Medicine and Biology, 2017, 978, 337-361.	0.8	64
647	DNA Modifications and Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2017, 978, 303-319.	0.8	14
648	OH MYeloid! Immune cells wreaking havoc on brain homeostasis. EMBO Journal, 2017, 36, 1803-1805.	3.5	0
649	Cholinergic neuron gene expression differences captured by translational profiling in a mouse model of Alzheimer's disease. Neurobiology of Aging, 2017, 57, 104-119.	1.5	24
650	Parkinson Disease and Autoimmune Disordersâ€"What Can We Learn From Genome-wide Pleiotropy?. JAMA Neurology, 2017, 74, 769.	4.5	2
652	Microglial Interferon Signaling and White Matter. Neurochemical Research, 2017, 42, 2625-2638.	1.6	42
653	A Unique Microglia Type Associated with Restricting Development of Alzheimerâ€™s Disease. Cell, 2017, 169, 1276-1290.e17.	13.5	3,282
654	Triggering Receptor Expressed on Myeloid Cells 2, a Novel Regulator of Immunocyte Phenotypes, Confers Neuroprotection by Relieving Neuroinflammation. Anesthesiology, 2017, 127, 98-110.	1.3	68
655	The <scp>FTD</scp>â€like syndrome causing <scp>TREM</scp>2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism. EMBO Journal, 2017, 36, 1837-1853.	3.5	152
656	Autophagy in neuroinflammatory diseases. Autoimmunity Reviews, 2017, 16, 856-874.	2.5	50
657	Stem cell models of Alzheimerâ€™s disease: progress and challenges. Alzheimer's Research and Therapy, 2017, 9, 42.	3.0	112
658	Polysaccharides from Ganoderma lucidum attenuate microglia-mediated neuroinflammation and modulate microglial phagocytosis and behavioural response. Journal of Neuroinflammation, 2017, 14, 63.	3.1	91
659	The Gut Microbiota and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 1-15.	1.2	624
660	HÃ©tÃ©rogÃ©nÃ©itÃ© gÃ©nÃ©tique de la maladie dâ€™AlzheimerÂ: des mutations causales aux facteurs de risque gÃ©nÃ©tiques rares et frÃ©quents. Pratique Neurologique - FMC, 2017, 8, 96-105.	0.1	0
661	Neuroinflammation, Mast Cells, and Glia: Dangerous Liaisons. Neuroscientist, 2017, 23, 478-498.	2.6	87
662	The Birth of the Modern Era of Parkinsonâ€™s Disease Genetics. Journal of Parkinson's Disease, 2017, 7, S87-S93.	1.5	13
663	Identification of a rare coding variant in TREM2 in a Chinese individual with Alzheimerâ€™s disease. Neurocase, 2017, 23, 65-69.	0.2	8

#	Article	IF	Citations
664	Enhanced susceptibility of triple transgenic Alzheimerâ€™s disease (3xTg-AD) mice to acute infection. Journal of Neuroinflammation, 2017, 14, 50.	3.1	36
665	Microglial complement receptor 3 regulates brain AÎ² levels through secreted proteolytic activity. Journal of Experimental Medicine, 2017, 214, 1081-1092.	4.2	100
666	Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimerâ€™s disease: An integrative review. Progress in Neurobiology, 2017, 156, 1-68.	2.8	112
667	The Correlation between Inflammatory Biomarkers and Polygenic Risk Score inÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 56, 25-36.	1.2	51
668	Inflammasomes as therapeutic targets for <scp>A</scp>lzheimer's disease. Brain Pathology, 2017, 27, 223-234.	2.1	110
669	Young microglia restore amyloid plaque clearance of aged microglia. EMBO Journal, 2017, 36, 583-603.	3.5	124
671	Opening up the DNA methylome of dementia. Molecular Psychiatry, 2017, 22, 485-496.	4.1	59
673	Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2017, 37, 637-647.	1.7	329
674	A candidate regulatory variant at the TREM gene cluster associates with decreased Alzheimer's disease risk and increased TREML1 and TREM2 brain gene expression. Alzheimer's and Dementia, 2017, 13, 663-673.	0.4	48
675	Genomic variants, genes, and pathways of Alzheimer's disease: An overview. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 5-26.	1.1	147
676	17q21.31 duplication causes prominent tau-related dementia with increased MAPT expression. Molecular Psychiatry, 2017, 22, 1119-1125.	4.1	57
677	Exploring genome-wide DNA methylation patterns in Aicardi syndrome. Epigenomics, 2017, 9, 1373-1386.	1.0	8
679	TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 11524-11529.	3.3	328
680	Î³â€Secretase in microglia â€“ implications for neurodegeneration and neuroinflammation. Journal of Neurochemistry, 2017, 143, 445-454.	2.1	15
681	The role of the immune system in Alzheimer disease: Etiology and treatment. Ageing Research Reviews, 2017, 40, 84-94.	5.0	167
682	Using induced pluripotent stem cells to explore genetic and epigenetic variation associated with Alzheimer's disease. Epigenomics, 2017, 9, 1455-1468.	1.0	13
683	Neuron-specific methylome analysis reveals epigenetic regulation and tau-related dysfunction of BRCA1 in Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9645-E9654.	3.3	72
684	Central and peripheral circadian clocks and their role in Alzheimer's disease. DMM Disease Models and Mechanisms, 2017, 10, 1187-1199.	1.2	44

#	Article	IF	Citations
685	Siglecâ€H is a microgliaâ€specific marker that discriminates microglia from CNSâ€associated macrophages and CNSâ€infiltrating monocytes. Glia, 2017, 65, 1927-1943.	2.5	123
686	Genetics of Alzheimerâ€™s Disease: the Importance of Polygenic and Epistatic Components. Current Neurology and Neuroscience Reports, 2017, 17, 78.	2.0	49
687	A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. Nature, 2017, 549, 389-393.	13.7	144
688	TREM-2 negatively regulates LPS-mediated inflammatory response in rat bone marrow-derived MSCs. Molecular Medicine Reports, 2017, 16, 4777-4783.	1.1	5
689	Ultra-rare mutations in SRCAP segregate in Caribbean Hispanic families with Alzheimer disease. Neurology: Genetics, 2017, 3, e178.	0.9	8
690	Genetics of Alzheimerâ€™s disease: From pathogenesis to clinical usage. Journal of Clinical Neuroscience, 2017, 45, 1-8.	0.8	33
691	The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity, 2017, 47, 566-581.e9.	6.6	1,741
692	A Tale of Two Genes: Microglial Apoe and Trem2. Immunity, 2017, 47, 398-400.	6.6	43
693	Combination of AÎ² Suppression and Innate Immune Activation in the Brain Significantly Attenuates Amyloid Plaque Deposition. American Journal of Pathology, 2017, 187, 2886-2894.	1.9	7
694	Microglia emerge as central players in brain disease. Nature Medicine, 2017, 23, 1018-1027.	15.2	1,208
695	The lipid-sensor TREM2 aggravates disease in a model of LCMV-induced hepatitis. Scientific Reports, 2017, 7, 11289.	1.6	12
696	An Alzheimerâ€associated TREM2 variant occurs at the <scp>ADAM</scp> cleavage site and affects shedding and phagocytic function. EMBO Molecular Medicine, 2017, 9, 1356-1365.	3.3	164
697	<scp>TREM</scp> 2 shedding by cleavage at the H157â€S158 bond is accelerated for the Alzheimer's diseaseâ€associated H157Y variant. EMBO Molecular Medicine, 2017, 9, 1366-1378.	3.3	120
698	Vaccination strategies in tauopathies and synucleinopathies. Journal of Neurochemistry, 2017, 143, 467-488.	2.1	30
699	Antibiotic-induced perturbations in microbial diversity during post-natal development alters amyloid pathology in an aged APPSWE/PS1Î”E9 murine model of Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 10411.	1.6	206
700	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
701	Mutations in TYROBP are not a common cause of dementia in a Turkish cohort. Neurobiology of Aging, 2017, 58, 240.e1-240.e3.	1.5	6
702	Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. Neurobiology of Aging, 2017, 59, 220.e1-220.e9.	1.5	116

#	Article	IF	Citations
703	Î²-Catenin Pathway Is Involved in TREM2-Mediated Microglial Survival. Journal of Neuroscience, 2017, 37, 7073-7075.	1.7	2
704	<scp>HDAC</scp>3 negatively regulates spatial memory in a mouse model of Alzheimer's disease. Aging Cell, 2017, 16, 1073-1082.	3.0	71
705	Modulation of Hematopoietic Lineage Specification Impacts TREM2 Expression in Microglia-Like Cells Derived From Human Stem Cells. ASN Neuro, 2017, 9, 175909141771661.	1.5	22
706	Unraveling the genes implicated in Alzheimer's disease. Biomedical Reports, 2017, 7, 105-114.	0.9	22
707	Amyloid in Alzheimerâ€™s Disease: Guilty Beyond Reasonable Doubt?. Trends in Pharmacological Sciences, 2017, 38, 849-851.	4.0	22
708	<scp>APP</scp> mouse models for Alzheimer's disease preclinical studies. EMBO Journal, 2017, 36, 2473-2487.	3.5	530
709	Neurodegeneration-associated mutant TREM2 proteins abortively cycle between the ER and ERâ€“Golgi intermediate compartment. Molecular Biology of the Cell, 2017, 28, 2723-2733.	0.9	28
710	A new approach for ratiometric in vivo calcium imaging of microglia. Scientific Reports, 2017, 7, 6030.	1.6	55
711	Four Decades of Research in Alzheimerâ€™s Disease (1975â€“2014): A Bibliometric and Scientometric Analysis. Journal of Alzheimer's Disease, 2017, 59, 763-783.	1.2	33
712	Evidence of CNS Î²-amyloid deposition in Nasu-Hakola disease due to the TREM2 Q33X mutation. Neurology, 2017, 89, 2503-2505.	1.5	26
713	Genetics of Alzheimer's disease: an update. Future Neurology, 2017, 12, 237-247.	0.9	0
714	Glial Draper Rescues AÎ² Toxicity in aDrosophilaModel of Alzheimer's Disease. Journal of Neuroscience, 2017, 37, 11881-11893.	1.7	56
715	Gene Linkage and Systems Biology. Advances in Neurobiology, 2017, 15, 479-489.	1.3	0
716	Microglia contribute to normal myelinogenesis and to oligodendrocyte progenitor maintenance during adulthood. Acta Neuropathologica, 2017, 134, 441-458.	3.9	375
717	Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimerâ€™s disease. BMC Medical Genomics, 2017, 10, 29.	0.7	28
718	Glial contributions to neurodegeneration in tauopathies. Molecular Neurodegeneration, 2017, 12, 50.	4.4	283
719	Knowledge-driven binning approach for rare variant association analysis: application to neuroimaging biomarkers in Alzheimerâ€™s disease. BMC Medical Informatics and Decision Making, 2017, 17, 61.	1.5	16
720	The Alzheimerâ€™s disease risk factors apolipoprotein E and TREM2 are linked in a receptor signaling pathway. Journal of Neuroinflammation, 2017, 14, 59.	3.1	59

#	Article	IF	Citations
721	YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimerâ€™s disease and other tauopathies. Journal of Neuroinflammation, 2017, 14, 118.	3.1	99
722	Late onset Alzheimerâ€™s disease genetics implicates microglial pathways in disease risk. Molecular Neurodegeneration, 2017, 12, 43.	4.4	407
723	Effect of high fat diet on phenotype, brain transcriptome and lipidome in Alzheimerâ€™s model mice. Scientific Reports, 2017, 7, 4307.	1.6	69
724	Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. Brain, 2017, 140, 184-200.	3.7	184
725	Alzheimer's diseaseâ€associated TREM2 variants exhibit either decreased or increased ligandâ€dependent activation. Alzheimer's and Dementia, 2017, 13, 381-387.	0.4	192
726	Polygenic score prediction captures nearly all common genetic risk for Alzheimer's disease. Neurobiology of Aging, 2017, 49, 214.e7-214.e11.	1.5	164
727	Molecular Imaging and Precision Medicine in Dementia and Movement Disorders. PET Clinics, 2017, 12, 119-136.	1.5	1
728	Genetic variation associated with the occurrence and progression of neurological disorders. NeuroToxicology, 2017, 61, 243-264.	1.4	18
729	Contributions of triggering-receptor-expressed-on-myeloid-cells-2 to neurological diseases. International Journal of Neuroscience, 2017, 127, 368-375.	0.8	21
730	Relative Incidence of Seizures and Myoclonus in Alzheimerâ€™s Disease, Dementia with Lewy Bodies, and Frontotemporal Dementia. Journal of Alzheimer's Disease, 2017, 60, 211-223.	1.2	109
732	A human microglia-like cellular model for assessing the effects of neurodegenerative disease gene variants. Science Translational Medicine, 2017, 9, .	5.8	106
733	47th Annual Meeting of the German Society for Immunology, 12â€“15 September, 2017, Erlangen, Germany. European Journal of Immunology, 2017, 47, 1-333.	1.6	2
734	Genetic approaches to neurodegenerative disease. , 0, , 57-76.		0
735	Intracellular trafficking of TREM2 is regulated by presenilin 1. Experimental and Molecular Medicine, 2017, 49, e405-e405.	3.2	17
736	A Novel TREM2-Mediated Link between Diabetes and Cognitive Impairment: Recent Findings and Future Perspectives. , 2017, 7, .		3
737	Similarity and Differences in Inflammation-Related Characteristics of the Peripheral Immune System of Patients with Parkinsonâ€™s and Alzheimerâ€™s Diseases. International Journal of Molecular Sciences, 2017, 18, 2633.	1.8	39
738	Molecular mechanisms of the genetic risk factors in pathogenesis of Alzheimer disease. Frontiers in Bioscience - Landmark, 2017, 22, 180-192.	3.0	14
739	Autophagy and Proteostasis: A Unifying Theory of Â Neurodegenerative Disease. Journal of Restorative Medicine, 2017, 6, 3-18.	0.7	0

#	Article	IF	Citations
740	Stem cells in neurodegeneration: mind the gap. , 2017, , 81-100.		0
741	Cellular Regulation of Amyloid Formation in Aging and Disease. Frontiers in Neuroscience, 2017, 11, 64.	1.4	70
742	Neurodegenerative Disorders. , 2017, , 1-16.		18
743	Epigenomics of Alzheimerâ€™s Disease. , 2017, , 227-278.		2
744	Neuroinflammation and Infection: Molecular Mechanisms Associated with Dysfunction of Neurovascular Unit. Frontiers in Cellular and Infection Microbiology, 2017, 7, 276.	1.8	112
745	Mitochondria-Derived Damage-Associated Molecular Patterns in Neurodegeneration. Frontiers in Immunology, 2017, 8, 508.	2.2	84
746	Editorial: Danger Signals Triggering Immune Response and Inflammation. Frontiers in Immunology, 2017, 8, 979.	2.2	23
747	Increase of TREM2 during Aging of an Alzheimerâ€™s Disease Mouse Model Is Paralleled by Microglial Activation and Amyloidosis. Frontiers in Aging Neuroscience, 2017, 9, 8.	1.7	60
748	Nutritional and Pharmacological Strategies to Regulate Microglial Polarization in Cognitive Aging and Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2017, 9, 175.	1.7	37
749	TREM2/DAP12 Complex Regulates Inflammatory Responses in Microglia via the JNK Signaling Pathway. Frontiers in Aging Neuroscience, 2017, 9, 204.	1.7	53
750	The Role of Microglia in Prion Diseases: A Paradigm of Functional Diversity. Frontiers in Aging Neuroscience, 2017, 9, 207.	1.7	51
751	Lessons Learned about Neurodegeneration from Microglia and Monocyte Depletion Studies. Frontiers in Aging Neuroscience, 2017, 9, 234.	1.7	22
752	Key Aging-Associated Alterations in Primary Microglia Response to Beta-Amyloid Stimulation. Frontiers in Aging Neuroscience, 2017, 9, 277.	1.7	86
753	Divergent Neuroinflammatory Regulation of Microglial TREM Expression and Involvement of NF-Î¹B. Frontiers in Cellular Neuroscience, 2017, 11, 56.	1.8	51
754	Genetics of Tinnitus: Still in its Infancy. Frontiers in Neuroscience, 2017, 11, 236.	1.4	42
755	DNA Methylation Changes in Intron 1 of Triggering Receptor Expressed on Myeloid Cell 2 in Japanese Schizophrenia Subjects. Frontiers in Neuroscience, 2017, 11, 275.	1.4	19
756	Alzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy. Frontiers in Neuroscience, 2017, 11, 680.	1.4	108
757	Alzheimerâ€™s Disease: From Genetic Variants to the Distinct Pathological Mechanisms. Frontiers in Molecular Neuroscience, 2017, 10, 319.	1.4	35

#	Article	IF	Citations
758	Risk Factors for Alzheimerâ€™s Disease. , 2017, , 47-91.		0
759	Microglia-Synapse Pathways: Promising Therapeutic Strategy for Alzheimerâ€™s Disease. BioMed Research International, 2017, 2017, 1-11.	0.9	22
760	Molecular Imaging of Neuroinflammation in Neurodegenerative Dementias: The Role of In Vivo PET Imaging. International Journal of Molecular Sciences, 2017, 18, 993.	1.8	64
761	Caspase-8, association with Alzheimerâ€™s Disease and functional analysis of rare variants. PLoS ONE, 2017, 12, e0185777.	1.1	38
762	Neurochemical Aspects of Î²-Amyloid Cascade Hypothesis for Alzheimerâ€™s Disease. , 2017, , 1-46.		0
763	Contribution of Neuroinflammation in the Pathogenesis of Alzheimerâ€™s Disease. , 2017, , 201-245.		0
764	Systematic tissue-specific functional annotation of the human genome highlights immune-related DNA elements for late-onset Alzheimerâ€™s disease. PLoS Genetics, 2017, 13, e1006933.	1.5	96
765	TREM2 in Neurodegenerative Diseases. Molecular Neurodegeneration, 2017, 12, 56.	4.4	270
766	TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Molecular Neurodegeneration, 2017, 12, 74.	4.4	208
767	Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2017, 12, 82.	4.4	100
768	Practical considerations for choosing a mouse model of Alzheimerâ€™s disease. Molecular Neurodegeneration, 2017, 12, 89.	4.4	305
769	Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimerâ€™s disease resilience. Genome Medicine, 2017, 9, 100.	3.6	67
770	Absence of CX3CR1 impairs the internalization of Tau by microglia. Molecular Neurodegeneration, 2017, 12, 59.	4.4	144
771	TREM2 and the Progression of Alzheimerâ€™s Disease. Current Neurovascular Research, 2017, 14, 177-183.	0.4	8
772	Receptors for Interleukins and Tumor Necrosis Factor are Important in Assessing their Roles in CNS Disorders. Journal of Clinical & Cellular Immunology, 2017, 08, .	1.5	0
773	Exome Sequencing of Extended Families with Alzheimerâ€™s Disease Identifies Novel Genes Implicated in Cell Immunity and Neuronal Function. , 2017, 07, .		13
774	Neuroimaging Feature Terminology: A Controlled Terminology for the Annotation of Brain Imaging Features. Journal of Alzheimer's Disease, 2017, 59, 1153-1169.	1.2	11
775	Comprehensive Overview of Alzheimerâ€™s Disease Neurodegeneration, from Amyloid-Î² to Neuroinflammatory Modulation. , 0, , .		0

#	Article	IF	Citations
776	INPP5D mRNA Expression and Cognitive Decline in Japanese Alzheimerâ€™s Disease Subjects. Journal of Alzheimer's Disease, 2017, 58, 687-694.	1.2	35
777	Different Roles of Microglia/Macrophage in Ischemic Stroke and Alzheimer's Disease. , 2017, 7, .		0
778	CNS inflammation and neurodegeneration. Journal of Clinical Investigation, 2017, 127, 3577-3587.	3.9	351
779	Microglia in prion diseases. Journal of Clinical Investigation, 2017, 127, 3230-3239.	3.9	89
780	Alzheimer risk loci and associated neuropathology in a population-based study (Vantaa 85+). Neurology: Genetics, 2018, 4, e211.	0.9	16
781	Convergent molecular defects underpin diverse neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 962-969.	0.9	19
782	TREM2 Is a Receptor for Î²-Amyloid that Mediates Microglial Function. Neuron, 2018, 97, 1023-1031.e7.	3.8	462
783	Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimerâ€™s Disease Models. Neuron, 2018, 97, 1032-1048.e5.	3.8	246
784	TREM2 and Amyloid Beta: A Love-Hate Relationship. Neuron, 2018, 97, 991-993.	3.8	18
785	The genetic landscape of Alzheimer disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 148, 395-408.	1.0	86
786	Frontotemporal dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 148, 409-430.	1.0	51
787	ApoE facilitates the microglial response to amyloid plaque pathology. Journal of Experimental Medicine, 2018, 215, 1047-1058.	4.2	194
788	Biomarkers for Preclinical Alzheimerâ€™s Disease. Neuromethods, 2018, , .	0.2	5
789	A Bayesian Framework for Generalized Linear Mixed Modeling Identifies New Candidate Loci for Late-Onset Alzheimerâ€™s Disease. Genetics, 2018, 209, 51-64.	1.2	12
790	Biallelic Loss of Function of SORL1 in an Early Onset Alzheimerâ€™s Disease Patient. Journal of Alzheimer's Disease, 2018, 62, 821-831.	1.2	18
791	Assessment of the Genetic Architecture of Alzheimerâ€™s Disease Risk in Rate of Memory Decline. Journal of Alzheimer's Disease, 2018, 62, 745-756.	1.2	45
792	The rs75932628 and rs2234253 polymorphisms of the TREM2 gene were associated with susceptibility to frontotemporal lobar degeneration in Caucasian populations. Annals of Human Genetics, 2018, 82, 177-185.	0.3	14
793	Prospects for strain-specific immunotherapy in Alzheimerâ€™s disease and tauopathies. Npj Vaccines, 2018, 3, 9.	2.9	45

#	Article	IF	Citations
794	Disentangling the biological pathways involved in early features of Alzheimer's disease in the Rotterdam Study. , 2018, 14, 848-857.		36
795	Etiology of type 2 diabetes and Alzheimer's disease: Exploring the mitochondria. Mitochondrion, 2018, 43, 16-24.	1.6	40
796	Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage ofÂAlzheimerâ€™s Disease Pathogenesis. Journal of Alzheimer's Disease, 2018, 63, 577-590.	1.2	31
797	Whole genome sequencing of Caribbean Hispanic families with lateâ€onset Alzheimer's disease. Annals of Clinical and Translational Neurology, 2018, 5, 406-417.	1.7	42
798	Evidence of Wnt/Î²-catenin alterations in brain and bone of aÂtauopathy mouse model of Alzheimer's disease. Neurobiology of Aging, 2018, 67, 148-158.	1.5	36
799	Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics. Nature Reviews Neuroscience, 2018, 19, 283-301.	4.9	302
800	TREM2 modulates microglia phenotypes in the neuroinflammation of Parkinson's disease. Biochemical and Biophysical Research Communications, 2018, 499, 797-802.	1.0	102
801	The Past and the Future of Alzheimerâ€™s Disease Fluid Biomarkers. Journal of Alzheimer's Disease, 2018, 62, 1125-1140.	1.2	106
802	TREM2-activating antibodies abrogate the negative pleiotropic effects of the Alzheimer's disease variant Trem2R47H on murine myeloid cell function. Journal of Biological Chemistry, 2018, 293, 12620-12633.	1.6	75
803	Precision pharmacology for Alzheimerâ€™s disease. Pharmacological Research, 2018, 130, 331-365.	3.1	79
804	Systemic inflammation as a predictor of brain aging: Contributions of physical activity, metabolic risk, and genetic risk. NeuroImage, 2018, 172, 118-129.	2.1	82
805	Novel targets in Alzheimerâ€™s disease: A special focus on microglia. Pharmacological Research, 2018, 130, 402-413.	3.1	46
806	Identification of genetic risk factors in the Chinese population implicates a role of immune system in Alzheimerâ€™s disease pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1697-1706.	3.3	71
807	Identification of rare genetic variants in Italian patients with dementia by targeted gene sequencing. Neurobiology of Aging, 2018, 66, 180.e23-180.e31.	1.5	18
808	Concussion, microvascular injury, and early tauopathy in young athletes after impact head injury and an impact concussion mouse model. Brain, 2018, 141, 422-458.	3.7	315
809	TREM2 overexpression attenuates neuroinflammation and protects dopaminergic neurons in experimental models of Parkinson's disease. Experimental Neurology, 2018, 302, 205-213.	2.0	83
810	Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimerâ€™s Disease Not Evident in Mouse Models. Cell Reports, 2018, 22, 832-847.	2.9	499
811	TREM2 Ameliorates Neuronal Tau Pathology Through Suppression of Microglial Inflammatory Response. Inflammation, 2018, 41, 811-823.	1.7	39

#	Article	IF	Citations
812	Neuroinflammatory responses in Alzheimerâ€™s disease. Journal of Neural Transmission, 2018, 125, 771-779.	1.4	109
813	The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 130-142.	1.2	169
814	The effect of rare variants in TREM2 and PLD3 on longitudinal cognitive function in the Wisconsin Registry for Alzheimer's Prevention. Neurobiology of Aging, 2018, 66, 177.e1-177.e5.	1.5	18
815	Using imputed genotype data in the joint score tests for genetic association and geneâ€“environment interactions in caseâ€control studies. Genetic Epidemiology, 2018, 42, 146-155.	0.6	8
816	Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. Journal of Experimental Medicine, 2018, 215, 745-760.	4.2	182
817	Cracking novel shared targets between epilepsy and Alzheimerâ€™s disease: need of the hour. Reviews in the Neurosciences, 2018, 29, 425-442.	1.4	16
818	Oligogenic genetic variation of neurodegenerative disease genes in 980 postmortem human brains. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 813-816.	0.9	17
819	Emerging Mechanisms in Alzheimerâ€™s Disease and Their Therapeutic Implications. Biological Psychiatry, 2018, 83, 298-299.	0.7	3
820	An APOE -independent cis -eSNP on chromosome 19q13.32 influences tau levels and late-onset Alzheimer's disease risk. Neurobiology of Aging, 2018, 66, 178.e1-178.e8.	1.5	12
821	Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimerâ€™s disease. Critical Reviews in Biochemistry and Molecular Biology, 2018, 53, 279-310.	2.3	95
822	Genetic Analysis of <i>TREM2</i> Variants in Tunisian Patients with Alzheimer's Disease. Medical Principles and Practice, 2018, 27, 317-322.	1.1	6
823	Integrated biology approach reveals molecular and pathological interactions among Alzheimerâ€™s Aβ42, Tau, TREM2, and TYROBP in Drosophila models. Genome Medicine, 2018, 10, 26.	3.6	23
824	Amyloid-beta modulates microglial responses by binding to the triggering receptor expressed on myeloid cells 2 (TREM2). Molecular Neurodegeneration, 2018, 13, 15.	4.4	124
825	Sexual dimorphism in predisposition to Alzheimer's disease. Neurobiology of Aging, 2018, 70, 308-324.	1.5	165
826	Genetics and Epigenetics in the Neurodegenerative Disorders of the Central Nervous System. , 2018, , 1-20.		1
827	Genetic Risk Factors for Complex Forms of Alzheimerâ€™s Disease. , 2018, , 51-76.		0
828	Cellular players that shape evolving pathology and neurodegeneration following traumatic brain injury. Brain, Behavior, and Immunity, 2018, 71, 9-17.	2.0	51
829	Functional Studies of Missense TREM2 Mutations in Human Stem Cell-Derived Microglia. Stem Cell Reports, 2018, 10, 1294-1307.	2.3	124

#	Article	IF	Citations
830	Toward a New Concept of Alzheimerâ€™s Disease Models: A Perspective from Neuroinflammation. Journal of Alzheimer's Disease, 2018, 64, S329-S338.	1.2	22
831	Role of Genetics and Epigenetics in the Pathogenesis of Alzheimerâ€™s Disease and Frontotemporal Dementia. Journal of Alzheimer's Disease, 2018, 62, 913-932.	1.2	54
832	Complex role of chemokine mediators in animal models of Alzheimer's Disease. Biomedical Journal, 2018, 41, 34-40.	1.4	26
833	Frontotemporal Dementia and Chorea Associated with a Compound Heterozygous TREM2 Mutation. Journal of Alzheimer's Disease, 2018, 63, 195-201.	1.2	11
834	The role of Alu-derived RNAs in Alzheimerâ€™s and other neurodegenerative conditions. Medical Hypotheses, 2018, 115, 29-34.	0.8	15
835	Mendelian adult-onset leukodystrophy genes in Alzheimer's disease: critical influence of CSF1R and NOTCH3. Neurobiology of Aging, 2018, 66, 179.e17-179.e29.	1.5	32
836	TREM2 variants in neurodegenerative disorders in the Polish population. Homozygosity and compound heterozygosity in FTD patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 407-412.	1.1	10
837	Understanding Alzheimer Disease at the Interface between Genetics and Transcriptomics. Trends in Genetics, 2018, 34, 434-447.	2.9	148
838	Mitochondria and Alzheimerâ€™s Disease: the Role of Mitochondrial Genetic Variation. Current Genetic Medicine Reports, 2018, 6, 1-10.	1.9	45
839	Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease. Journal of Neuroimmunology, 2018, 319, 19-27.	1.1	68
840	Alzheimerâ€™s Disease, Oligomers, and Inflammation. Journal of Alzheimer's Disease, 2018, 62, 1261-1276.	1.2	141
841	Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. Journal of Alzheimer's Disease, 2018, 64, S47-S105.	1.2	122
842	Lymphoblast-derived integration-free iPSC line AD-TREM2-1 from a 67 year-old Alzheimer's disease patient expressing the TREM2 p.R47H variant. Stem Cell Research, 2018, 29, 60-63.	0.3	0
843	Metabolic Dysfunction in Alzheimerâ€™s Disease: From Basic Neurobiology to Clinical Approaches. Journal of Alzheimer's Disease, 2018, 64, S405-S426.	1.2	66
844	Genetic Complexity of Early-Onset Alzheimerâ€™s Disease. , 2018, , 29-50.		7
845	The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study. Lancet Neurology, The, 2018, 17, 434-444.	4.9	177
846	Histone Deacetylases 1 and 2 Regulate Microglia Function during Development, Homeostasis, and Neurodegeneration in a Context-Dependent Manner. Immunity, 2018, 48, 514-529.e6.	6.6	144
847	Association of the CX3CR1-V249I Variant with Neurofibrillary Pathology Progression in Late-Onset Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 2340-2349.	1.9	22

#	Article	IF	Citations
848	AÎ² propagation and strains: Implications for the phenotypic diversity in Alzheimer's disease. Neurobiology of Disease, 2018, 109, 191-200.	2.1	57
849	Innate immunity in Alzheimerâ€™s disease: the relevance of animal models?. Journal of Neural Transmission, 2018, 125, 827-846.	1.4	16
850	Untangling Genetic Risk for Alzheimerâ€™s Disease. Biological Psychiatry, 2018, 83, 300-310.	0.7	160
851	Integrated approach reveals diet, APOE genotype and sex affect immune response in APP mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 152-161.	1.8	23
852	Behavioral and transcriptomic analysis of Trem2-null mice: not all knockout mice are created equal. Human Molecular Genetics, 2018, 27, 211-223.	1.4	50
853	Differential contribution of microglia and monocytes in neurodegenerative diseases. Journal of Neural Transmission, 2018, 125, 809-826.	1.4	84
854	Microglia-Mediated Neuroprotection, TREM2 , and Alzheimerâ€™s Disease: Evidence From OpticalÂImaging. Biological Psychiatry, 2018, 83, 377-387.	0.7	84
855	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
856	Polygenic risk score of sporadic lateâ€onset Alzheimer's disease reveals a shared architecture with the familial and earlyâ€onset forms. Alzheimer's and Dementia, 2018, 14, 205-214.	0.4	109
857	Letâ€™s make microglia great again in neurodegenerative disorders. Journal of Neural Transmission, 2018, 125, 751-770.	1.4	19
858	TREM2 expression in the human brain: a marker of monocyte recruitment?. Brain Pathology, 2018, 28, 595-602.	2.1	55
859	Lymphatic drainage system of the brain: A novel target for intervention of neurological diseases. Progress in Neurobiology, 2018, 163-164, 118-143.	2.8	158
860	Polygenic risk score in postmortem diagnosed sporadic early-onset Alzheimer's disease. Neurobiology of Aging, 2018, 62, 244.e1-244.e8.	1.5	30
861	Wholeâ€exome sequencing of the <scp>BDR</scp> cohort: evidence to support the role of the <scp>PILRA</scp> gene in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2018, 44, 506-521.	1.8	35
862	Cerebrospinal fluid in the dementias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 146, 85-97.	1.0	9
863	Markers of microglia in post-mortem brain samples from patients with Alzheimerâ€™s disease: a systematic review. Molecular Psychiatry, 2018, 23, 177-198.	4.1	331
864	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	4.9	195
865	Microglia in Alzheimerâ€™s disease. Journal of Cell Biology, 2018, 217, 459-472.	2.3	1,188

#	Article	IF	Citations
866	Fish oil feeding attenuates neuroinflammatory gene expression without concomitant changes in brain eicosanoids and docosanoids in a mouse model of Alzheimerâ€™s disease. Brain, Behavior, and Immunity, 2018, 69, 74-90.	2.0	27
867	Genetics of neurodegenerative diseases: an overview. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 309-323.	1.0	69
868	Rare genetic variation implicated in non-Hispanic white families with Alzheimer disease. Neurology: Genetics, 2018, 4, e286.	0.9	27
869	The p.R47H Variant of TREM2 Gene is Associated With Late-onset Alzheimer Disease in Colombian Population. Alzheimer Disease and Associated Disorders, 2018, 32, 305-308.	0.6	7
870	A Network Explanation of Alzheimer's Regional Vulnerability. Cold Spring Harbor Symposia on Quantitative Biology, 2018, 83, 193-200.	2.0	11
871	The Correlation between Genotype and Phenotype of Alzheimer's Disease. , 2018, 08, .		0
872	3 .Neuropathologie und molekulare Mechanismen. , 2018, , 35-122.		1
873	Utility of an Alzheimerâ€™s Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimerâ€™s Disease: A Prospective Longitudinal Study. Journal of Alzheimer's Disease, 2018, 66, 1193-1211.	1.2	27
874	Linkage analysis of multiplex Caribbean Hispanic families loaded for unexplained earlyâ€onset cases identifies novel Alzheimer's disease loci. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 554-562.	1.2	8
875	Developmental roles of microglia: A window into mechanisms of disease. Developmental Dynamics, 2019, 248, 98-117.	0.8	28
876	A Brief Synopsis on the Genetics of Alzheimerâ€™s Disease. Current Genetic Medicine Reports, 2018, 6, 133-135.	1.9	19
877	Toxic Protein Spread in Neurodegeneration: Reality versus Fantasy. Trends in Molecular Medicine, 2018, 24, 1007-1020.	3.5	26
878	Subchronic Pathobiological Response Following Chronic Repetitive Mild Traumatic Brain Injury in an Aged Preclinical Model of Amyloid Pathogenesis. Journal of Neuropathology and Experimental Neurology, 2018, 77, 1144-1162.	0.9	2
879	Functional alterations of myeloid cells during the course of Alzheimerâ€™s disease. Molecular Neurodegeneration, 2018, 13, 61.	4.4	44
880	CSF sTREM2 in deliriumâ€”relation to Alzheimerâ€™s disease CSF biomarkers AÎ²42, t-tau and p-tau. Journal of Neuroinflammation, 2018, 15, 304.	3.1	36
881	The Role of Glial Cells and Synapse Loss in Mouse Models of Alzheimerâ€™s Disease. Frontiers in Cellular Neuroscience, 2018, 12, 473.	1.8	24
882	RAB10: an Alzheimer’s disease resilience locus and potential drug target. Clinical Interventions in Aging, 2019, Volume 14, 73-79.	1.3	37
883	Neuroinflammation in Preclinical Alzheimer's Disease: A Review of Current Evidence. , 2018, 08, .		2

#	Article	IF	Citations
884	Genome-wide RNAseq study of the molecular mechanisms underlying microglia activation in response to pathological tau perturbation in the rTg4510 tau transgenic animal model. Molecular Neurodegeneration, 2018, 13, 65.	4.4	62
885	Bioinformatics Analysis Reveals Potential Candidate Genes for Different Glioma Subtypes (Astrocytoma, Ependymoma, and Oligodendroglioma). Cancer Biotherapy and Radiopharmaceuticals, 2018, 33, 478-490.	0.7	0
886	Meta-analysis of Alzheimerâ€™s disease on 9,751 samples from Norway and IGAP study identifies four risk loci. Scientific Reports, 2018, 8, 18088.	1.6	47
887	New insights into the role of TREM2 in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2018, 13, 66.	4.4	286
888	Are Porphyromonas gingivalis Outer Membrane Vesicles Microbullets for Sporadic Alzheimerâ€™s Disease Manifestation?. Journal of Alzheimer's Disease Reports, 2018, 2, 219-228.	1.2	55
889	THE TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-2 (TREM-2) AS EXPRESSION OF THE RELATIONSHIP BETWEEN MICROGLIA AND ALZHEIMERâ€™S DISEASE: A NOVEL MARKER FOR A PROMISING PATHWAY TO EXPLORE. Journal of Frailty & Aging,the, 2019, 8, 1-3.	0.8	4
890	The Receptor for Advanced Glycation Endproducts (RAGE) and Mediation of Inflammatory Neurodegeneration. , 2018, 08, .		41
891	The Genetic Diagnosis of Neurodegenerative Diseases and Therapeutic Perspectives. Brain Sciences, 2018, 8, 222.	1.1	23
892	TREM2 in Alzheimerâ€™s Disease: Microglial Survival and Energy Metabolism. Frontiers in Aging Neuroscience, 2018, 10, 395.	1.7	64
893	TREM2 triggers microglial density and ageâ€related neuronal loss. Glia, 2019, 67, 539-550.	2.5	84
894	Innate Immunity Cells and the Neurovascular Unit. International Journal of Molecular Sciences, 2018, 19, 3856.	1.8	38
895	Improving the Gene Ontology Resource to Facilitate More Informative Analysis and Interpretation of Alzheimerâ€™s Disease Data. Genes, 2018, 9, 593.	1.0	15
896	Brain Iron Homeostasis: A Focus on Microglial Iron. Pharmaceuticals, 2018, 11, 129.	1.7	80
897	Current state of Alzheimerâ€™s fluid biomarkers. Acta Neuropathologica, 2018, 136, 821-853.	3.9	370
898	Microglia in Alzheimer's Disease: Risk Factors and Inflammation. Frontiers in Neurology, 2018, 9, 978.	1.1	96
899	microRNAs in Neurodegeneration: Current Findings and Potential Impacts. , 2018, 08, .		37
900	Genomics: New Light on Alzheimerâ€™s Disease Research. International Journal of Molecular Sciences, 2018, 19, 3771.	1.8	14
901	The Gut-Microglia Connection: Implications for Central Nervous System Diseases. Frontiers in Immunology, 2018, 9, 2325.	2.2	89

#	Article	IF	Citations
902	Inflammation: the link between comorbidities, genetics, and Alzheimerâ€™s disease. Journal of Neuroinflammation, 2018, 15, 276.	3.1	353
903	TREM2 â€" a key player in microglial biology and Alzheimer disease. Nature Reviews Neurology, 2018, 14, 667-675.	4.9	396
904	Imaging the evolution and pathophysiology of Alzheimer disease. Nature Reviews Neuroscience, 2018, 19, 687-700.	4.9	372
905	Differential effects of partial and complete loss of TREM2 on microglial injury response and tauopathy. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10172-10177.	3.3	118
906	White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimerâ€™s disease. Brain, 2018, 141, 3065-3080.	3.7	116
907	Alzheimerâ€™s Disease: Beyond the Neuron. , 0, , .		1
908	Microglia prevent peripheral immune cell invasion and promote an anti-inflammatory environment in the brain of APP-PS1 transgenic mice. Journal of Neuroinflammation, 2018, 15, 274.	3.1	89
909	Caspases orchestrate microglia instrumental functions. Progress in Neurobiology, 2018, 171, 50-71.	2.8	27
910	The identity and function of microglia in neurodegeneration. Nature Immunology, 2018, 19, 1048-1058.	7.0	241
911	Converging pathways in neurodegeneration, from genetics to mechanisms. Nature Neuroscience, 2018, 21, 1300-1309.	7.1	325
912	Modelling Sporadic Alzheimerâ€™s Disease Using Induced Pluripotent Stem Cells. Neurochemical Research, 2018, 43, 2179-2198.	1.6	27
913	Paired Immunoglobulin-like Type 2 Receptor Alpha G78R variant alters ligand binding and confers protection to Alzheimer's disease. PLoS Genetics, 2018, 14, e1007427.	1.5	56
914	The Early Events That Initiate Î²-Amyloid Aggregation in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 359.	1.7	85
915	Role of triggering receptor expressed on myeloid cells 2 in neuroinflammation and neurodegeneration of the central nervous system. Clinical and Experimental Neuroimmunology, 2018, 9, 219-224.	0.5	1
916	Microglia in Alzheimer's Disease: A Role for Ion Channels. Frontiers in Neuroscience, 2018, 12, 676.	1.4	31
917	ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans. Molecular Neurodegeneration, 2018, 13, 53.	4.4	75
918	Unravelling the glial response in the pathogenesis of Alzheimer's disease. FASEB Journal, 2018, 32, 5766-5777.	0.2	30
919	Glycoprotein NMB: a novel Alzheimerâ€™s disease associated marker expressed in a subset of activated microglia. Acta Neuropathologica Communications, 2018, 6, 108.	2.4	107

#	Article	IF	Citations
920	Rodent models for Alzheimer disease. Nature Reviews Neuroscience, 2018, 19, 583-598.	4.9	240
921	Inflammation as a central mechanism in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 575-590.	1.8	1,254
922	Rare variants in the splicing regulatory elements of EXOC3L4 are associated with brain glucose metabolism in Alzheimerâ€™s disease. BMC Medical Genomics, 2018, 11, 76.	0.7	12
923	Microglial signatures and their role in health and disease. Nature Reviews Neuroscience, 2018, 19, 622-635.	4.9	599
924	The Trem2 R47H Alzheimerâ€™s risk variant impairs splicing and reduces Trem2 mRNA and protein in mice but not in humans. Molecular Neurodegeneration, 2018, 13, 49.	4.4	91
925	Human Alzheimerâ€™s disease gene expression signatures and immune profile in APP mouse models: a discrete transcriptomic view of Aî² plaque pathology. Journal of Neuroinflammation, 2018, 15, 256.	3.1	35
927	Microglia TREM2 is required for electroacupuncture to attenuate neuroinflammation in focal cerebral ischemia/reperfusion rats. Biochemical and Biophysical Research Communications, 2018, 503, 3225-3234.	1.0	20
928	Human Induced Pluripotent Stem Cell-Derived Microglia-Like Cells Harboring TREM2 Missense Mutations Show Specific Deficits in Phagocytosis. Cell Reports, 2018, 24, 2300-2311.	2.9	118
929	Mitochondria at the Base of Neuronal Innate Immunity in Alzheimerâ€™s and Parkinsonâ€™s Diseases. , 2018, , .		1
930	Lack of association between triggering receptor expressed on myeloid cells 2 polymorphism rs75932628 and late-onset Alzheimerâ€™s disease in a Chinese Han population. Psychiatric Genetics, 2018, 28, 16-18.	0.6	14
931	Role of TREM-1 in pulmonary tuberculosis patients- analysis of serum soluble TREM-1 levels. Scientific Reports, 2018, 8, 8223.	1.6	14
932	Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration. Cell, 2018, 173, 1073-1081.	13.5	765
933	From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 64, S271-S279.	1.2	66
934	Chronic stress as a risk factor for Alzheimer's disease: Roles of microglia-mediated synaptic remodeling, inflammation, and oxidative stress. Neurobiology of Stress, 2018, 9, 9-21.	1.9	255
935	Pyk2 is a Novel Tau Tyrosine Kinase thatÂisÂRegulated by the Tyrosine Kinase Fyn. Journal of Alzheimer's Disease, 2018, 64, 205-221.	1.2	36
936	Microglia and macrophages in brain homeostasis and disease. Nature Reviews Immunology, 2018, 18, 225-242.	10.6	1,263
937	TREMendous 2 Be Social. Immunity, 2018, 48, 842-843.	6.6	3
938	Is Targeting the Inflammasome a Way Forward for Neuroscience Drug Discovery?. SLAS Discovery, 2018, 23, 991-1017.	1.4	17

#	Article	IF	Citations
939	One for all and all for One: Improving replication of genetic studies through network diffusion. PLoS Genetics, 2018, 14, e1007306.	1.5	22
940	Alzheimerâ€™s Disease and Frontotemporal Dementia: The Current State of Genetics and Genetic Testing Since the Advent of Next-Generation Sequencing. Molecular Diagnosis and Therapy, 2018, 22, 505-513.	1.6	41
941	Embryonic Microglia Derive from Primitive Macrophages and Are Replaced by cmyb-Dependent Definitive Microglia in Zebrafish. Cell Reports, 2018, 24, 130-141.	2.9	81
942	Modelling microglial function with induced pluripotent stem cells: an update. Nature Reviews Neuroscience, 2018, 19, 445-452.	4.9	41
943	A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimerâ€™s disease. Nature Neuroscience, 2018, 21, 941-951.	7.1	458
944	The Transcriptional Regulatory Properties of Amyloid Beta 1â€“42 may Include Regulation of Genes Related to Neurodegeneration. NeuroMolecular Medicine, 2018, 20, 363-375.	1.8	16
945	Current Concepts of Neurodegenerative Mechanisms in Alzheimerâ€™s Disease. BioMed Research International, 2018, 2018, 1-12.	0.9	113
946	The Microglial Response to Neurodegenerative Disease. Advances in Immunology, 2018, 139, 1-50.	1.1	22
947	Aging and Alzheimerâ€™s disease: Comparison and associations from molecular to system level. Aging Cell, 2018, 17, e12802.	3.0	180
948	Bone-Marrow-Derived Microglia-Like Cells Ameliorate Brain Amyloid Pathology and Cognitive Impairment in a Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 64, 563-585.	1.2	32
949	Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau. Journal of Experimental Medicine, 2018, 215, 2235-2245.	4.2	167
950	Cerebrospinal fluid tau, Aî², and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration. Alzheimer's and Dementia, 2018, 14, 1159-1170.	0.4	96
951	TREM2-Dependent Effects on Microglia in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 202.	1.7	60
952	Minimotifs dysfunction is pervasive in neurodegenerative disorders. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 414-432.	1.8	2
953	Microglia changes associated to Alzheimer's disease pathology in aged chimpanzees. Journal of Comparative Neurology, 2018, 526, 2921-2936.	0.9	30
954	Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines. Frontiers in Immunology, 2018, 9, 586.	2.2	756
955	The Inflammatory Continuum of Traumatic Brain Injury and Alzheimerâ€™s Disease. Frontiers in Immunology, 2018, 9, 672.	2.2	99
956	The Role of Genetics in Advancing Precision Medicine for Alzheimerâ€™s Diseaseâ€”A Narrative Review. Frontiers in Medicine, 2018, 5, 108.	1.2	61

#	Article	IF	Citations
957	Use of Eflornithine (DFMO) in the Treatment of Early Alzheimer's Disease: A Compassionate Use, Single-Case Study. Frontiers in Aging Neuroscience, 2018, 10, 60.	1.7	14
958	The Retromer Complex and Sorting Nexins in Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 2018, 10, 79.	1.7	55
959	Microglia in Alzheimerâ€™s Disease: Activated, Dysfunctional or Degenerative. Frontiers in Aging Neuroscience, 2018, 10, 140.	1.7	160
960	Integrative Analysis of Hippocampus Gene Expression Profiles Identifies Network Alterations in Aging and Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 153.	1.7	58
961	Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. Frontiers in Neuroscience, 2018, 12, 37.	1.4	132
962	Microglia Gone Rogue: Impacts on Psychiatric Disorders across the Lifespan. Frontiers in Molecular Neuroscience, 2017, 10, 421.	1.4	151
963	Emerging Biosensing Technologies for Neuroinflammatory and Neurodegenerative Disease Diagnostics. Frontiers in Molecular Neuroscience, 2018, 11, 164.	1.4	25
964	Neuroepigenetics and Alzheimerâ€™s Disease: An Update. Journal of Alzheimer's Disease, 2018, 64, 671-688.	1.2	20
965	Diaphanous 1 (DIAPH1) is Highly Expressed in the Aged Human Medial Temporal Cortex and Upregulated in Myeloid Cells During Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 64, 995-1007.	1.2	18
966	Is â€˜friendly fireâ€™ in the brain provoking Alzheimerâ€™s disease?. Nature, 2018, 556, 426-428.	13.7	38
967	Genetic variants associated with Alzheimerâ€™s disease confer different cerebral cortex cell-type population structure. Genome Medicine, 2018, 10, 43.	3.6	62
968	Alzheimer's disease pathology in Nasu-Hakola disease brains. Intractable and Rare Diseases Research, 2018, 7, 32-36.	0.3	20
969	The role of TREM2 in Alzheimer's disease and other neurodegenerative disorders. Lancet Neurology, The, 2018, 17, 721-730.	4.9	161
970	The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2018, 13, 29.	4.4	147
971	Dietary arachidonic acid: a Janus face actor in brain and Alzheimerâ€™s disease?. OCL - Oilseeds and Fats, Crops and Lipids, 2018, 25, D406.	0.6	4
972	Motor neuron-derived microRNAs cause astrocyte dysfunction in amyotrophic lateral sclerosis. Brain, 2018, 141, 2561-2575.	3.7	50
973	Impact of the biological definition of Alzheimerâ€™s disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology?. Translational Neurodegeneration, 2018, 7, 12.	3.6	27
974	The Microglial Innate Immune Receptor TREM2 Is Required for Synapse Elimination and Normal Brain Connectivity. Immunity, 2018, 48, 979-991.e8.	6.6	436

#	Article	IF	Citations
975	CD200-, CX3CL1-, and TREM2-mediated neuron-microglia interactions and their involvements in Alzheimerâ€™s disease. Reviews in the Neurosciences, 2018, 29, 837-848.	1.4	28
976	The polymorphism rs6918289 located in the downstream region of the TREM2 gene is associated with TNF-Î± levels and IMT-F. Scientific Reports, 2018, 8, 7160.	1.6	3
977	Alzheimerâ€™s disease hypothesis and related therapies. Translational Neurodegeneration, 2018, 7, 2.	3.6	385
978	TREM2 regulates innate immunity in Alzheimerâ€™s disease. Journal of Neuroinflammation, 2018, 15, 107.	3.1	63
979	Molecular biomarkers of Alzheimer's disease: progress and prospects. DMM Disease Models and Mechanisms, 2018, 11, .	1.2	163
980	Targeted exome sequencing reveals homozygous TREM2 R47C mutation presenting with behavioral variant frontotemporal dementia without bone involvement. Neurobiology of Aging, 2018, 68, 160.e15-160.e19.	1.5	14
981	Small nuclear RNA-mediated modulation of splicing reveals a therapeutic strategy for a TREM2 mutation and its post-transcriptional regulation. Scientific Reports, 2018, 8, 6937.	1.6	20
982	Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases. Molecular Neurodegeneration, 2018, 13, 41.	4.4	77
983	In Vivo Imaging of Microglia With Multiphoton Microscopy. Frontiers in Aging Neuroscience, 2018, 10, 218.	1.7	29
984	Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nature Reviews Immunology, 2018, 18, 759-772.	10.6	394
985	Recent progress in therapeutic strategies for microglia-mediated neuroinflammation in neuropathologies. Expert Opinion on Therapeutic Targets, 2018, 22, 765-781.	1.5	47
986	Roles of Microglial and Monocyte Chemokines and Their Receptors in Regulating Alzheimer's Disease-Associated Amyloid-Î² and Tau Pathologies. Frontiers in Neurology, 2018, 9, 549.	1.1	86
987	Stem Cells as Potential Targets of Polyphenols in Multiple Sclerosis and Alzheimerâ€™s Disease. BioMed Research International, 2018, 2018, 1-30.	0.9	21
988	PD-1 deficiency is not sufficient to induce myeloid mobilization to the brain or alter the inflammatory profile during chronic neurodegeneration. Brain, Behavior, and Immunity, 2018, 73, 708-716.	2.0	18
989	An exTREMe disruption in Alzheimer's cleanup. Journal of Biological Chemistry, 2018, 293, 12647-12648.	1.6	0
990	PU.1 regulates Alzheimerâ€™s disease-associated genes in primary human microglia. Molecular Neurodegeneration, 2018, 13, 44.	4.4	111
991	Microglial TREM2/DAP12 Signaling: A Double-Edged Sword in Neural Diseases. Frontiers in Cellular Neuroscience, 2018, 12, 206.	1.8	186
992	AnIn VitroBone Model to Investigate the Role of Triggering Receptor Expressed on Myeloid Cells-2 in Bone Homeostasis. Tissue Engineering - Part C: Methods, 2018, 24, 391-398.	1.1	9

#	Article	IF	Citations
993	Lymphoblast-derived integration-free iPSC line AD-TREM2-3 from a 74â€¯year-old Alzheimer's disease patient expressing the TREM2 p.R47H variant. Stem Cell Research, 2018, 30, 141-144.	0.3	1
994	Loss of Trem2 in microglia leads to widespread disruption of cell coexpression networks in mouse brain. Neurobiology of Aging, 2018, 69, 151-166.	1.5	25
995	Neuroinflammation, Type 2 Diabetes, and Dementia. , 2018, , 195-209.		4
996	Neuroinflammation in Age-Related Neurodegenerative Diseases. , 2018, , 477-507.		0
997	Sex and the Aging Immune System. , 2018, , 803-830.		1
998	Evolving views of human genetic variation and its relationship to neurologic and psychiatric disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 147, 37-42.	1.0	3
999	Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?. Expert Opinion on Therapeutic Targets, 2018, 22, 587-598.	1.5	27
1000	EIF2AK3 variants in Dutch patients with Alzheimer's disease. Neurobiology of Aging, 2019, 73, 229.e11-229.e18.	1.5	25
1001	Cytosolic Phospholipase A2 Facilitates Oligomeric Amyloid-Î² Peptide Association with Microglia via Regulation of Membrane-Cytoskeleton Connectivity. Molecular Neurobiology, 2019, 56, 3222-3234.	1.9	12
1002	Whole-Exome Sequencing of an Exceptional Longevity Cohort. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 1386-1390.	1.7	14
1003	Microglia in Neurodegenerative Disorders. Methods in Molecular Biology, 2019, 2034, 57-67.	0.4	39
1004	The basis of cellular and regional vulnerability in Alzheimerâ€™s disease. Acta Neuropathologica, 2019, 138, 729-749.	3.9	73
1005	Cell Type Specific Expression of Toll-Like Receptors in Human Brains and Implications in Alzheimerâ€™s Disease. BioMed Research International, 2019, 2019, 1-18.	0.9	42
1006	HENA, heterogeneous network-based data set for Alzheimerâ€™s disease. Scientific Data, 2019, 6, 151.	2.4	34
1007	Microglia. Methods in Molecular Biology, 2019, , .	0.4	1
1008	The role of Locus Coeruleus in neuroinflammation occurring in Alzheimerâ€™s disease. Brain Research Bulletin, 2019, 153, 47-58.	1.4	35
1009	Assessing costâ€effectiveness of early intervention in Alzheimer's disease: An openâ€source modeling framework. Alzheimer's and Dementia, 2019, 15, 1309-1321.	0.4	38
1010	The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimerâ€™s disease risk. Science Translational Medicine, 2019, 11, .	5.8	170

#	Article	IF	Citations
1011	Evaluation of the Common Molecular Basis in Alzheimerâ€™s and Parkinsonâ€™s Diseases. International Journal of Molecular Sciences, 2019, 20, 3730.	1.8	12
1012	Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nature Reviews Neurology, 2019, 15, 501-518.	4.9	734
1013	TREM2 deficiency aggravates Î±â€synucleinâ€“induced neurodegeneration and neuroinflammation in Parkinson's disease models. FASEB Journal, 2019, 33, 12164-12174.	0.2	50
1014	Targeting the Synapse in Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2019, 13, 735.	1.4	163
1015	Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimerâ€™s disease model. Nature Communications, 2019, 10, 3758.	5.8	478
1016	Loss of Ataxin-1 Potentiates Alzheimerâ€™s Pathogenesis by Elevating Cerebral BACE1 Transcription. Cell, 2019, 178, 1159-1175.e17.	13.5	49
1017	Blood-brain barrier and innate immunity in the pathogenesis of Alzheimer's disease. Progress in Molecular Biology and Translational Science, 2019, 168, 99-145.	0.9	23
1018	The Emerging Role of Triggering Receptor Expressed on Myeloid Cells 2 as a Target for Immunomodulation in Ischemic Stroke. Frontiers in Immunology, 2019, 10, 1668.	2.2	46
1019	Neuron-Glia Signaling in Synapse Elimination. Annual Review of Neuroscience, 2019, 42, 107-127.	5.0	224
1020	Overexpression of TIPE2, a Negative Regulator of Innate and Adaptive Immunity, Attenuates Cognitive Deficits in APP/PS1 Mice. Journal of NeuroImmune Pharmacology, 2019, 14, 519-529.	2.1	11
1021	Efficacy and mechanism of cGAMP to suppress Alzheimerâ€™s disease by elevating TREM2. Brain, Behavior, and Immunity, 2019, 81, 495-508.	2.0	39
1022	TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimerâ€™s Disease. Neuron, 2019, 103, 820-835.e7.	3.8	222
1023	Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimerâ€™s disease. PLoS ONE, 2019, 14, e0218111.	1.1	23
1024	5xFAD Mice Display Sex-Dependent Inflammatory Gene Induction During the Prodromal Stage of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 70, 1259-1274.	1.2	30
1025	Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk. Journal of Neuroscience, 2019, 39, 7408-7427.	1.7	85
1026	Neuroinflammation and Functional Connectivity in Alzheimer's Disease: Interactive Influences on Cognitive Performance. Journal of Neuroscience, 2019, 39, 7218-7226.	1.7	145
1027	Impact of TREM2 risk variants on brain region-specific immune activation and plaque microenvironment in Alzheimerâ€™s disease patient brain samples. Acta Neuropathologica, 2019, 138, 613-630.	3.9	68
1028	Genes, pathways and risk prediction in Alzheimerâ€™s disease. Human Molecular Genetics, 2019, 28, R235-R240.	1.4	16

#	Article	IF	Citations
1029	TREM2 R47H (rs75932628) variant is unlikely to contribute to Multiple Sclerosis susceptibility and severity in a large Greek MS cohort. Multiple Sclerosis and Related Disorders, 2019, 35, 116-118.	0.9	8
1030	Systemic inflammation impairs microglial AÎ² clearance through <scp>NLRP</scp> 3 inflammasome. EMBO Journal, 2019, 38, e101064.	3.5	226
1031	TREM2 is required for microglial instruction of astrocytic synaptic engulfment in neurodevelopment. Glia, 2019, 67, 1873-1892.	2.5	54
1032	Lipid-Associated Macrophages Control Metabolic Homeostasis in a Trem2-Dependent Manner. Cell, 2019, 178, 686-698.e14.	13.5	718
1033	A Breakdown in Metabolic Reprogramming Causes Microglia Dysfunction in Alzheimer's Disease. Cell Metabolism, 2019, 30, 493-507.e6.	7.2	374
1034	The Post-amyloid Era in Alzheimer's Disease: Trust Your Gut Feeling. Frontiers in Aging Neuroscience, 2019, 11, 143.	1.7	41
1035	Interleukin 9 alterations linked to alzheimer disease in african americans. Annals of Neurology, 2019, 86, 407-418.	2.8	42
1036	Genetic variability in response to amyloid beta deposition influences Alzheimerâ€™s disease risk. Brain Communications, 2019, 1, fcz022.	1.5	67
1037	Reformulating Pro-Oxidant Microglia in Neurodegeneration. Journal of Clinical Medicine, 2019, 8, 1719.	1.0	47
1038	Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment. Human Brain Mapping, 2019, 40, 5424-5442.	1.9	127
1039	Molecular Basis of Neurodegeneration: Lessons from Alzheimerâ€™s and Parkinsonâ€™s Diseases. , 2019, , .		2
1040	Transcriptional Networks of Microglia in Alzheimerâ€™s Disease and Insights into Pathogenesis. Genes, 2019, 10, 798.	1.0	19
1041	Liver X Receptors Regulate Cholesterol Metabolism and Immunity in Hepatic Nonparenchymal Cells. International Journal of Molecular Sciences, 2019, 20, 5045.	1.8	38
1042	Distinct Signaling Pathways Regulate TREM2 Phagocytic and NFÎºB Antagonistic Activities. Frontiers in Cellular Neuroscience, 2019, 13, 457.	1.8	61
1043	A single systemic inflammatory insult causes acute motor deficits and accelerates disease progression in a mouse model of human tauopathy. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 579-591.	1.8	15
1044	Microglia as Dynamic Cellular Mediators of Brain Function. Trends in Molecular Medicine, 2019, 25, 967-979.	3.5	107
1045	Microglial P2Y12 receptor regulates ventral hippocampal CA1 neuronal excitability and innate fear in mice. Molecular Brain, 2019, 12, 71.	1.3	88
1046	Gut microbiota mediated allostasis prevents stress-induced neuroinflammatory risk factors of Alzheimer's disease. Progress in Molecular Biology and Translational Science, 2019, 168, 147-181.	0.9	21

#	Article	IF	Citations
1047	Genome-Wide Association Studies for Cerebrospinal Fluid Soluble TREM2 in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2019, 11, 297.	1.7	24
1048	Entanglement of CCR5 and Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2019, 11, 209.	1.7	21
1049	Overview of Transgenic Mouse Models for Alzheimer's Disease. Current Protocols in Neuroscience, 2019, 89, e81.	2.6	78
1050	In Vivo Phagocytosis Analysis of Amyloid Beta. Methods in Molecular Biology, 2019, 2034, 287-292.	0.4	10
1052	Developing Effective Alzheimerâ€™s Disease Therapies: Clinical Experience and Future Directions. Journal of Alzheimer's Disease, 2019, 71, 715-732.	1.2	89
1053	Bringing Order out of Chaos: Establishing an Epistatic Relationship between CD33 and TREM2. Neuron, 2019, 103, 747-749.	3.8	2
1054	Whole solid tumour volume histogram analysis of the apparent diffusion coefficient for differentiating high-grade from low-grade serous ovarian carcinoma: correlation with Ki-67 proliferation status. Clinical Radiology, 2019, 74, 918-925.	0.5	17
1055	Alterations in Alzheimerâ€™s Disease-Associated Gene Expression in Severe Obstructive Sleep Apnea Patients. Journal of Clinical Medicine, 2019, 8, 1361.	1.0	6
1056	Microglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and Development. Frontiers in Pharmacology, 2019, 10, 840.	1.6	25
1057	Neurosteroids as regulators of neuroinflammation. Frontiers in Neuroendocrinology, 2019, 55, 100788.	2.5	133
1058	Modeling of Alzheimerâ€™s Disease and Outlooks for its Therapy Using Induced Pluripotent Stem Cells. Neurochemical Journal, 2019, 13, 215-228.	0.2	0
1059	Stress granules and neurodegeneration. Nature Reviews Neuroscience, 2019, 20, 649-666.	4.9	452
1060	Is Alzheimerâ€™s disease an inflammasomopathy?. Ageing Research Reviews, 2019, 56, 100966.	5.0	67
1061	Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities. Frontiers in Aging Neuroscience, 2019, 11, 233.	1.7	228
1062	PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model. Nature Communications, 2019, 10, 465.	5.8	112
1063	Editorial: The Role of Glia in Alzheimer's Disease. Frontiers in Neurology, 2018, 9, 1161.	1.1	6
1064	Drug Development for Alzheimerâ€™s Disease: Microglia Induced Neuroinflammation as a Target?. International Journal of Molecular Sciences, 2019, 20, 558.	1.8	99
1065	Inflammatory mechanisms in neurodegeneration. Journal of Neurochemistry, 2019, 149, 562-581.	2.1	85

#	Article	IF	Citations
1066	Genetic screen in a large series of patients with primary progressive aphasia. Alzheimer's and Dementia, 2019, 15, 553-560.	0.4	30
1067	Genetic Analysis of PICK1 Gene in Alzheimer's Disease: A Study for Finding a New Gene Target. Frontiers in Neurology, 2019, 9, 1169.	1.1	4
1068	APOE Genotype Specific Effects on the Early Neurodegenerative Sequelae Following Chronic Repeated Mild Traumatic Brain Injury. Neuroscience, 2019, 404, 297-313.	1.1	25
1069	Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimerâ€™s disease. Scientific Reports, 2019, 9, 7803.	1.6	33
1070	Modeling Alzheimerâ€™s disease with human iPS cells: advancements, lessons, and applications. Neurobiology of Disease, 2019, 130, 104503.	2.1	24
1071	Cortisol and IgA are Involved in the Progression of Alzheimerâ€™s Disease. A Pilot Study. Cellular and Molecular Neurobiology, 2019, 39, 1061-1065.	1.7	12
1072	Genome-wide association study identifies Alzheimer's risk variant in MS4A6A influencing cerebrospinal fluid sTREM2 levels. Neurobiology of Aging, 2019, 84, 241.e13-241.e20.	1.5	35
1073	A rare functional variant of SHARPIN attenuates the inflammatory response and associates with increased risk of late-onset Alzheimerâ€™s disease. Molecular Medicine, 2019, 25, 20.	1.9	33
1074	Proteomic signatures of neuroinflammation in Alzheimerâ€™s disease, multiple sclerosis and ischemic stroke. Expert Review of Proteomics, 2019, 16, 601-611.	1.3	14
1075	Microglial Trem2 induces synaptic impairment at early stage and prevents amyloidosis at late stage in APP/PS1 mice. FASEB Journal, 2019, 33, 10425-10442.	0.2	42
1076	Clusterin accumulates in synapses in Alzheimerâ€™s disease and is increased in apolipoprotein E4 carriers. Brain Communications, 2019, 1, fcz003.	1.5	42
1077	Functions of â€˜A disintegrin and metalloproteases (ADAMs)â€™ in the mammalian nervous system. Cellular and Molecular Life Sciences, 2019, 76, 3055-3081.	2.4	82
1078	Do Microglial Sex Differences Contribute to Sex Differences in Neurodegenerative Diseases?. Trends in Molecular Medicine, 2019, 25, 741-749.	3.5	84
1079	Role of brain imaging in disorders of brainâ€“gut interaction: a Rome Working Team Report. Gut, 2019, 68, 1701-1715.	6.1	91
1080	Analysis of Whole-Exome Sequencing Data for Alzheimer Disease Stratified by APOE Genotype. JAMA Neurology, 2019, 76, 1099.	4.5	32
1081	Genetic analyses of early-onset Alzheimerâ€™s disease using next generation sequencing. Scientific Reports, 2019, 9, 8368.	1.6	91
1082	Peripheral versus central nervous system APOE in Alzheimerâ€™s disease: Interplay across the blood-brain barrier. Neuroscience Letters, 2019, 708, 134306.	1.0	38
1083	The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration. Movement Disorders, 2019, 34, 959-969.	2.2	68

#	Article	IF	Citations
1084	Alzheimerâ€™s disease polygenic risk score as a predictor of conversion from mild-cognitive impairment. Translational Psychiatry, 2019, 9, 154.	2.4	69
1085	Adiponectin suppresses amyloid-Î² oligomer (AÎ²O)-induced inflammatory response of microglia via AdipoR1-AMPK-NF-ÎºB signaling pathway. Journal of Neuroinflammation, 2019, 16, 110.	3.1	78
1086	TREM2 Attenuates AÎ²1-42-Mediated Neuroinflammation in BV-2 Cells by Downregulating TLR Signaling. Neurochemical Research, 2019, 44, 1830-1839.	1.6	35
1087	CpGâ€related SNPs in the MS4A region have a doseâ€dependent effect on risk of lateâ€“onset Alzheimer disease. Aging Cell, 2019, 18, e12964.	3.0	8
1088	Epigenetic processes in Alzheimer's disease. , 2019, , 153-180.		5
1089	The Transcriptional Landscape of Microglial Genes in Aging and Neurodegenerative Disease. Frontiers in Immunology, 2019, 10, 1170.	2.2	51
1090	Cellular Specificity of NF-ÎºB Function in the Nervous System. Frontiers in Immunology, 2019, 10, 1043.	2.2	201
1091	Endo-lysosomal dysregulations and late-onset Alzheimerâ€™s disease: impact of genetic risk factors. Molecular Neurodegeneration, 2019, 14, 20.	4.4	144
1092	Updating Neuroimmune Targets in Central Nervous System Dysfunction. Trends in Pharmacological Sciences, 2019, 40, 482-494.	4.0	19
1093	Targeting Apolipoprotein E for Alzheimerâ€™s Disease: An Industry Perspective. International Journal of Molecular Sciences, 2019, 20, 2161.	1.8	27
1094	Association of Variants in PINX1 and TREM2 With Late-Onset Alzheimer Disease. JAMA Neurology, 2019, 76, 942.	4.5	20
1095	TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers. Molecular Neurodegeneration, 2019, 14, 18.	4.4	58
1097	Alzheimerâ€™s disease: risk factors and potentially protective measures. Journal of Biomedical Science, 2019, 26, 33.	2.6	415
1098	Mathematical Modeling and Docking of Medicinal Plants and Synthetic Drugs to Determine Their Effects on Abnormal Expression of Cholinesterase and Acetyl Cholinesterase Proteins in Alzheimer. Lecture Notes in Computer Science, 2019, , 111-127.	1.0	0
1099	Sex-specific effects of microbiome perturbations on cerebral AÎ² amyloidosis and microglia phenotypes. Journal of Experimental Medicine, 2019, 216, 1542-1560.	4.2	165
1100	Aminophospholipids are signal-transducing TREM2 ligands on apoptotic cells. Scientific Reports, 2019, 9, 7508.	1.6	61
1101	The Major Risk Factors for Alzheimerâ€™s Disease: Age, Sex, and Genes Modulate the Microglia Response to AÎ² Plaques. Cell Reports, 2019, 27, 1293-1306.e6.	2.9	527
1102	An update on the interactions between Alzheimer's disease, autophagy and inflammation. Gene, 2019, 705, 157-166.	1.0	62

#	Article	IF	Citations
1103	A Unifying Hypothesis for Alzheimerâ€™s Disease: From Plaques to Neurodegeneration. Trends in Neurosciences, 2019, 42, 310-322.	4.2	99
1104	Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimerâ€™s disease. Acta Neuropathologica, 2019, 138, 251-273.	3.9	187
1105	Phagocytosis in the Brain: Homeostasis and Disease. Frontiers in Immunology, 2019, 10, 790.	2.2	206
1106	Immune Signaling in Neurodegeneration. Immunity, 2019, 50, 955-974.	6.6	217
1107	Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice. Acta Neuropathologica Communications, 2019, 7, 46.	2.4	31
1108	The Receptor for Advanced Glycation End Products (RAGE) and DIAPH1: Implications for vascular and neuroinflammatory dysfunction in disorders of the central nervous system. Neurochemistry International, 2019, 126, 154-164.	1.9	44
1109	TREM2 Variants and Neurodegenerative Diseases: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2019, 68, 1171-1184.	1.2	42
1110	Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders. Neuron, 2019, 101, 1003-1015.	3.8	29
1111	Integrated Analysis of Whole Exome Sequencing and Copy Number Evaluation in Parkinsonâ€™s Disease. Scientific Reports, 2019, 9, 3344.	1.6	31
1112	Polygenic Risk Scores in Neurodegenerative Diseases: a Review. Current Genetic Medicine Reports, 2019, 7, 22-29.	1.9	23
1113	Antiâ€PrP^C antibody rescues cognition and synapses in transgenic alzheimer mice. Annals of Clinical and Translational Neurology, 2019, 6, 554-574.	1.7	24
1114	SORL1 genetic variants and Alzheimer disease risk: a literature review and meta-analysis of sequencing data. Acta Neuropathologica, 2019, 138, 173-186.	3.9	77
1115	Endo-lysosomal pathway and ubiquitin-proteasome system dysfunction in Alzheimer's disease pathogenesis. Neuroscience Letters, 2019, 703, 68-78.	1.0	56
1116	Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimerâ€™s disease model. Nature Communications, 2019, 10, 1365.	5.8	217
1117	Analysis of 50 Neurodegenerative Genes in Clinically Diagnosed Early-Onset Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2019, 20, 1514.	1.8	57
1118	Alzheimerâ€™s disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph. Alzheimer's Research and Therapy, 2019, 11, 16.	3.0	100
1119	Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine. , 2019, 199, 173-187.		90
1120	Shared genes between Alzheimerâ€™s disease and ischemic stroke. CNS Neuroscience and Therapeutics, 2019, 25, 855-864.	1.9	36

#	Article	IF	Citations
1121	Relative risk for Alzheimer disease based on complete family history. Neurology, 2019, 92, e1745-e1753.	1.5	45
1122	Clusterin in Alzheimerâ€™s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies. Frontiers in Neuroscience, 2019, 13, 164.	1.4	221
1123	The new genetic landscape of Alzheimerâ€™s disease: from amyloid cascade to genetically driven synaptic failure hypothesis?. Acta Neuropathologica, 2019, 138, 221-236.	3.9	122
1124	Association of Rare Coding Mutations With Alzheimer Disease and Other Dementias Among Adults of European Ancestry. JAMA Network Open, 2019, 2, e191350.	2.8	58
1125	Curcumin restores innate immune Alzheimer's disease risk gene expression to ameliorate Alzheimer pathogenesis. Neurobiology of Disease, 2019, 127, 432-448.	2.1	70
1126	Glial activation and inflammation along the Alzheimerâ€™s disease continuum. Journal of Neuroinflammation, 2019, 16, 46.	3.1	175
1127	Up-regulation of TREM2 accelerates the reduction of amyloid deposits and promotes neuronal regeneration in the hippocampus of amyloid beta1-42 injected mice. Journal of Chemical Neuroanatomy, 2019, 97, 71-79.	1.0	22
1128	Microglia in Alzheimerâ€™s disease: A target for immunotherapy. Journal of Leukocyte Biology, 2019, 106, 219-227.	1.5	78
1129	Effects of Microglial Cytokines on Alzheimerâ€™s Disease-Related Phenomena. Journal of Alzheimer's Disease, 2019, 67, 1021-1034.	1.2	7
1130	The Role of APOE4 in Disrupting the Homeostatic Functions of Astrocytes and Microglia in Aging and Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2019, 11, 14.	1.7	174
1131	Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimerâ€™s disease pathogenesis. Cellular and Molecular Life Sciences, 2019, 76, 1833-1863.	2.4	75
1132	Microglial inflammation and phagocytosis in Alzheimer's disease: Potential therapeutic targets. British Journal of Pharmacology, 2019, 176, 3515-3532.	2.7	85
1133	Glial Contribution to Excitatory and Inhibitory Synapse Loss in Neurodegeneration. Frontiers in Cellular Neuroscience, 2019, 13, 63.	1.8	99
1134	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
1135	CD14 and Toll-Like Receptor 4 Promote Fibrillar AÎ²42 Uptake by Microglia Through A Clathrin-Mediated Pathway. Journal of Alzheimer's Disease, 2019, 68, 323-337.	1.2	20
1136	Genetic Risk Factors for Alzheimer Disease: Emerging Roles of Microglia in Disease Pathomechanisms. Advances in Experimental Medicine and Biology, 2019, 1118, 83-116.	0.8	34
1137	Imbalance of Microglial TLR4/TREM2 in LPS-Treated APP/PS1 Transgenic Mice: A Potential Link Between Alzheimerâ€™s Disease and Systemic Inflammation. Neurochemical Research, 2019, 44, 1138-1151.	1.6	82
1138	Benefits and Challenges of Rare Genetic Variation in Alzheimerâ€™s Disease. Current Genetic Medicine Reports, 2019, 7, 53-62.	1.9	9

#	Article	IF	Citations
1139	Î³-Secretase and its modulators: Twenty years and beyond. Neuroscience Letters, 2019, 701, 162-169.	1.0	46
1140	rAAV-based brain slice culture models of Alzheimerâ€™s and Parkinsonâ€™s disease inclusion pathologies. Journal of Experimental Medicine, 2019, 216, 539-555.	4.2	48
1141	Metabolic Syndrome and Its Biomarkers in the Development and Progression of Alzheimerâ€™s Disease and Other Dementias. , 2019, , .		0
1142	Neuropathology-driven Whole-genome Sequencing Study Points to Novel Candidate Genes for Healthy Brain Aging. Alzheimer Disease and Associated Disorders, 2019, 33, 7-14.	0.6	1
1143	Neuroimmune interactions in Alzheimer's diseaseâ€"New frontier with old challenges?. Progress in Molecular Biology and Translational Science, 2019, 168, 183-201.	0.9	12
1144	Isolation of Region-specific Microglia from One Adult Mouse Brain Hemisphere for Deep Single-cell RNA Sequencing. Journal of Visualized Experiments, 2019, , .	0.2	6
1145	The Radiogenomics of Late-onset Alzheimer Disease. Topics in Magnetic Resonance Imaging, 2019, 28, 325-334.	0.7	2
1146	The Emerging Roles and Therapeutic Potential of Soluble TREM2 in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2019, 11, 328.	1.7	34
1147	Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. Alzheimer's Research and Therapy, 2019, 11, 94.	3.0	20
1148	Pan-SHIP1/2 inhibitors promote microglia effector functions essential for CNS homeostasis. Journal of Cell Science, 2020, 133, .	1.2	41
1149	Immunological signatures in frontotemporal lobar degeneration. Current Opinion in Neurology, 2019, 32, 272-278.	1.8	6
1150	Neurodegenerative Diseaseâ€“Associated Variants in TREM2 Destabilize the Apical Ligand-Binding Region of the Immunoglobulin Domain. Frontiers in Neurology, 2019, 10, 1252.	1.1	20
1151	Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimerâ€™s disease. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641988881.	1.5	46
1152	Genetic perturbations of disease risk genes in mice capture transcriptomic signatures of late-onset Alzheimerâ€™s disease. Molecular Neurodegeneration, 2019, 14, 50.	4.4	31
1153	Genome sequencing for early-onset or atypical dementia: high diagnostic yield and frequent observation of multiple contributory alleles. Journal of Physical Education and Sports Management, 2019, 5, a003491.	0.5	25
1154	Frequency of the TREM2 R47H Variant in Various Neurodegenerative Disorders. Alzheimer Disease and Associated Disorders, 2019, 33, 327-330.	0.6	6
1155	Friend, Foe or Both? Immune Activity in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2019, 11, 337.	1.7	63
1156	Curcuminoid Analogs Differentially Modulate Nuclear Factor Kappa-Light-Chain-Enhancer, P65 Serine276, Mitogen- and Stress-activated Protein Kinase 1 And MicroRNA 148a Status. Progress in Preventive Medicine (New York, N Y), 2019, 4, e0024.	0.7	2

#	Article	IF	Citations
1157	Behavioral Variant Frontotemporal Dementia-like Syndrome With Novel Heterozygous TREM2 Frameshift Mutation. Alzheimer Disease and Associated Disorders, 2019, 33, 75-76.	0.6	1
1158	Two Gene Variants Modulate Risk for Alzheimer's Disease, Providing Potential New Target. Neurology Today: an Official Publication of the American Academy of Neurology, 2019, 19, 35-36.	0.0	1
1159	The leukotriene signaling pathway: a druggable target in Alzheimerâ€™s disease. Drug Discovery Today, 2019, 24, 505-516.	3.2	48
1160	The Role of APOE and TREM2 in Alzheimerâ€²s Diseaseâ€"Current Understanding and Perspectives. International Journal of Molecular Sciences, 2019, 20, 81.	1.8	123
1161	Effects of rising amyloidÎ² levels on hippocampal synaptic transmission, microglial response and cognition in APPSwe/PSEN1M146V transgenic mice. EBioMedicine, 2019, 39, 422-435.	2.7	16
1162	Rescue of Transgenic Alzheimerâ€™s Pathophysiology by Polymeric Cellular Prion Protein Antagonists. Cell Reports, 2019, 26, 145-158.e8.	2.9	27
1163	Molecular Imaging of Dementia With Lewy Bodies. International Review of Neurobiology, 2019, 144, 59-93.	0.9	10
1164	Frontotemporal dementia spectrum: first genetic screen in a Greek cohort. Neurobiology of Aging, 2019, 75, 224.e1-224.e8.	1.5	16
1165	Sexual differentiation of microglia. Frontiers in Neuroendocrinology, 2019, 52, 156-164.	2.5	97
1166	Human stem cellâ€“derived monocytes and microgliaâ€like cells reveal impaired amyloid plaque clearance upon heterozygous or homozygous loss of TREM2. Alzheimer's and Dementia, 2019, 15, 453-464.	0.4	55
1167	Complement C7is a novel risk gene for Alzheimer's disease in Han Chinese. National Science Review, 2019, 6, 257-274.	4.6	55
1168	Practical approach to the diagnosis of adult-onset leukodystrophies: an updated guide in the genomic era. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 543-555.	0.9	87
1169	Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimerâ€™s disease risk. Nature Genetics, 2019, 51, 404-413.	9.4	1,625
1170	Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nature Neuroscience, 2019, 22, 191-204.	7.1	358
1171	A rare missense variant of CASP7 is associated with familial lateâ€onset Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 441-452.	0.4	39
1172	Beyond the neuronâ€“cellular interactions early in Alzheimer disease pathogenesis. Nature Reviews Neuroscience, 2019, 20, 94-108.	4.9	237
1173	Early increase of CSF sTREM2 in Alzheimerâ€™s disease is associated with tau related-neurodegeneration but not with amyloid-Î² pathology. Molecular Neurodegeneration, 2019, 14, 1.	4.4	253
1174	Genetic Study of Alzheimerâ€™s Disease in Saudi Population. Journal of Alzheimer's Disease, 2019, 67, 231-242.	1.2	10

#	Article	IF	Citations
1175	Blood-Brain Barrier: From Physiology to Disease and Back. Physiological Reviews, 2019, 99, 21-78.	13.1	1,232
1176	CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum. Neurobiology of Aging, 2019, 74, 182-190.	1.5	45
1177	Review: Neuropathology of nonâ€tau frontotemporal lobar degeneration. Neuropathology and Applied Neurobiology, 2019, 45, 19-40.	1.8	93
1178	Nanotherapeutic strategies for the treatment of neurodegenerative diseases. , 2019, , 321-356.		14
1179	Next Generation Sequencing Analysis in Early Onset Dementia Patients. Journal of Alzheimer's Disease, 2019, 67, 243-256.	1.2	29
1180	TLR4 (toll-like receptor 4) activation suppresses autophagy through inhibition of FOXO3 and impairs phagocytic capacity of microglia. Autophagy, 2019, 15, 753-770.	4.3	144
1181	Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid-Î²-Induced Synaptic Dysfunction and Loss. Journal of Neuroscience, 2019, 39, 758-772.	1.7	61
1182	Alzheimerâ€™s Disease and Dementia. , 2019, , 25-82.		2
1183	Serum Soluble Triggering Receptor Expressed on Myeloid Cells 2 as a Biomarker for Incident Dementia: The Hisayama Study. Annals of Neurology, 2019, 85, 47-58.	2.8	45
1184	Fluidâ€based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases. Journal of Neurochemistry, 2019, 151, 417-434.	2.1	15
1185	Role of Rab GTPases in Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2019, 10, 828-838.	1.7	27
1186	Centenarian controls increase variant effect sizes by an average twofold in an extreme caseâ€“extreme control analysis of Alzheimerâ€™s disease. European Journal of Human Genetics, 2019, 27, 244-253.	1.4	46
1187	Integrative approach to sporadic Alzheimerâ€™s disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau. Molecular Psychiatry, 2019, 24, 1383-1397.	4.1	46
1188	<scp>APOE</scp> Îµ4 is also required in <scp>TREM</scp>2 R47H variant carriers for Alzheimer's disease to develop. Neuropathology and Applied Neurobiology, 2019, 45, 183-186.	1.8	12
1189	Could Alzheimerâ€™s Disease Originate in the Periphery and If So How So?. Molecular Neurobiology, 2019, 56, 406-434.	1.9	71
1190	Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series. Molecular Psychiatry, 2020, 25, 3399-3412.	4.1	34
1191	A novel homozygous mutation in TREM2 found in a Chinese early-onset dementia family with mild bone involvement. Neurobiology of Aging, 2020, 86, 201.e1-201.e7.	1.5	5
1192	Mechanistic complexities of bone loss in Alzheimerâ€™s disease: a review. Connective Tissue Research, 2020, 61, 4-18.	1.1	22

#	Article	IF	Citations
1193	Whole exome sequencing study identifies novel rare and common Alzheimerâ€™s-Associated variants involved in immune response and transcriptional regulation. Molecular Psychiatry, 2020, 25, 1859-1875.	4.1	191
1194	The Role of Sex and Sex Hormones in Neurodegenerative Diseases. Endocrine Reviews, 2020, 41, 273-319.	8.9	118
1195	Modeling Alzheimerâ€™s disease with iPSC-derived brain cells. Molecular Psychiatry, 2020, 25, 148-167.	4.1	263
1196	Functional connectivity among brain regions affected in Alzheimer's disease is associated with CSF TNF-Î± in APOE4 carriers. Neurobiology of Aging, 2020, 86, 112-122.	1.5	22
1197	Genomics of Alzheimerâ€™s disease. , 2020, , 275-283.		5
1198	Effects of Docosahexaenoic Acid and Its Peroxidation Product on Amyloid-Î² Peptide-Stimulated Microglia. Molecular Neurobiology, 2020, 57, 1085-1098.	1.9	18
1199	A 20-Year Journey from Axonal Injury to Neurodegenerative Diseases and the Prospect of Immunotherapy for Combating Alzheimerâ€™s Disease. Journal of Immunology, 2020, 204, 243-250.	0.4	26
1200	A locked immunometabolic switch underlies TREM2 R47H loss of function in human iPSCâ€derived microglia. FASEB Journal, 2020, 34, 2436-2450.	0.2	82
1201	TREM2 Regulates Microglial Cholesterol Metabolism upon Chronic Phagocytic Challenge. Neuron, 2020, 105, 837-854.e9.	3.8	391
1202	Genetics of Alzheimerâ€™s disease: where we are, and where we are going. Current Opinion in Neurobiology, 2020, 61, 40-48.	2.0	144
1203	Microglial microRNAs mediate sex-specific responses to tau pathology. Nature Neuroscience, 2020, 23, 167-171.	7.1	79
1204	Inverse Relationship Between Alzheimerâ€™s Disease and Cancer: How Immune Checkpoints Might Explain the Mechanisms Underlying Age-Related Diseases. Journal of Alzheimer's Disease, 2020, 73, 443-454.	1.2	14
1205	Association Between Tollâ€Like Receptor 4 (TLR4) and Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) Genetic Variants and Clinical Progression of Huntington's Disease. Movement Disorders, 2020, 35, 401-408.	2.2	15
1206	Neuroimaging of Diseases Causing Dementia. Neurologic Clinics, 2020, 38, 65-94.	0.8	9
1207	Increased levels of AÎ²42 decrease the lifespan of ob/ob mice with dysregulation of microglia and astrocytes. FASEB Journal, 2020, 34, 2425-2435.	0.2	15
1208	Microglia, Lifestyle Stress, and Neurodegeneration. Immunity, 2020, 52, 222-240.	6.6	174
1209	Systematic review of genetic association studies in people with Lewy body dementia. International Journal of Geriatric Psychiatry, 2020, 35, 436-448.	1.3	17
1210	Analysis of Cerebrospinal Fluid Soluble TREM2 and Polymorphisms in Sporadic Parkinsonâ€™s Disease in a Chinese Population. Journal of Molecular Neuroscience, 2020, 70, 294-301.	1.1	14

#	Article	IF	Citations
1211	CSF sTREM2 and Tau Work Together in Predicting Increased Temporal Lobe Atrophy in Older Adults. Cerebral Cortex, 2020, 30, 2295-2306.	1.6	15
1212	The influence of environment and origin on brain resident macrophages and implications for therapy. Nature Neuroscience, 2020, 23, 157-166.	7.1	74
1213	Peripheral Blood-Derived Microglia-Like Cells Decrease Amyloid-Î² Burden and Ameliorate Cognitive Impairment in a Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 73, 413-429.	1.2	10
1214	Triggering Receptor Expressed on Myeloid Cell 2 R47H Exacerbates Immune Response in Alzheimerâ€™s Disease Brain. Frontiers in Immunology, 2020, 11, 559342.	2.2	19
1215	Epigenome-wide association study of Alzheimerâ€™s disease replicates 22 differentially methylated positions and 30 differentially methylated regions. Clinical Epigenetics, 2020, 12, 149.	1.8	43
1216	Microglia and Astrocytes in Disease: Dynamic Duo or Partners in Crime?. Trends in Immunology, 2020, 41, 820-835.	2.9	146
1217	Obstructive Sleep Apnea and Its Treatment in Aging: Effects on Alzheimerâ€™s disease Biomarkers, Cognition, Brain Structure and Neurophysiology. Neurobiology of Disease, 2020, 145, 105054.	2.1	57
1218	Immune response and endocytosis pathways are associated with the resilience against Alzheimerâ€™s disease. Translational Psychiatry, 2020, 10, 332.	2.4	33
1219	Research on Cognition Disorders. , 2020, , .		0
1220	Microglial Immunometabolism in Alzheimerâ€™s Disease. Frontiers in Cellular Neuroscience, 2020, 14, 563446.	1.8	27
1221	Identification of a dysfunctional microglial population in human Alzheimerâ€™s disease cortex using novel single-cell histology image analysis. Acta Neuropathologica Communications, 2020, 8, 170.	2.4	47
1222	Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimerâ€™s Disease. Neuron, 2020, 108, 801-821.	3.8	132
1223	The effect of amyloid on microglia-neuron interactions before plaque onset occurs independently of TREM2 in a mouse model of Alzheimer's disease. Neurobiology of Disease, 2020, 145, 105072.	2.1	12
1224	Non-pathological roles of microglial TREM2/DAP12: TREM2/DAP12 regulates the physiological functions of microglia from development to aging. Neurochemistry International, 2020, 141, 104878.	1.9	17
1225	Diagnostic and Prognostic Laboratory Testing for Alzheimer Disease. Clinics in Laboratory Medicine, 2020, 40, 289-303.	0.7	2
1226	MFSD7C switches mitochondrial ATP synthesis to thermogenesis in response to heme. Nature Communications, 2020, 11, 4837.	5.8	21
1227	The role of glia in protein aggregation. Neurobiology of Disease, 2020, 143, 105015.	2.1	28
1228	Peripheral TREM2 mRNA levels in early and late-onset Alzheimer diseaseâ€™s patients. Molecular Biology Reports, 2020, 47, 5903-5909.	1.0	8

#	Article	IF	Citations
1229	Crosstalk Between Astrocytes and Microglia: An Overview. Frontiers in Immunology, 2020, 11, 1416.	2.2	224
1230	From beta amyloid to altered proteostasis in Alzheimerâ€™s disease. Ageing Research Reviews, 2020, 64, 101126.	5.0	31
1231	Passive immunotherapies targeting AÎ² and tau in Alzheimer's disease. Neurobiology of Disease, 2020, 144, 105010.	2.1	81
1232	The Molecular Etiology of Alzheimerâ€™s disease. Brain Pathology, 2020, 30, 964-965.	2.1	11
1233	Compound AD16 Reduces Amyloid Plaque Deposition and Modifies Microglia in a Transgenic Mouse Model of Alzheimerâ€™s Disease. ACS Pharmacology and Translational Science, 2020, 3, 1100-1110.	2.5	4
1234	Effects of Neurological Disorders on Bone Health. Frontiers in Psychology, 2020, 11, 612366.	1.1	35
1235	Locus Coeruleus Modulates Neuroinflammation in Parkinsonism and Dementia. International Journal of Molecular Sciences, 2020, 21, 8630.	1.8	32
1236	Matrix Metalloproteinase 14 Mediates APP Proteolysis and Lysosomal Alterations Induced by Oxidative Stress in Human Neuronal Cells. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-13.	1.9	2
1237	Diesel exhaust impairs TREM2 to dysregulate neuroinflammation. Journal of Neuroinflammation, 2020, 17, 351.	3.1	13
1238	The good, the bad, and the opportunities of the complement system in neurodegenerative disease. Journal of Neuroinflammation, 2020, 17, 354.	3.1	133
1239	Potential caveats of putative microglia-specific markers for assessment of age-related cerebrovascular neuroinflammation. Journal of Neuroinflammation, 2020, 17, 366.	3.1	45
1240	Dysregulated Wnt Signalling in the Alzheimerâ€™s Brain. Brain Sciences, 2020, 10, 902.	1.1	28
1241	Neuron Loss in Alzheimerâ€™s Disease: Translation in Transgenic Mouse Models. International Journal of Molecular Sciences, 2020, 21, 8144.	1.8	39
1242	Phosphonamidate Compounds for Butyrylcholinesterase Selective Inhibitors. Bulletin of the Korean Chemical Society, 2020, 41, 1153-1160.	1.0	3
1243	Roles of microglial membranes in Alzheimer's disease. Current Topics in Membranes, 2020, 86, 301-314.	0.5	2
1244	TREM2 Alzheimerâ€™s variant R47H causes similar transcriptional dysregulation to knockout, yet only subtle functional phenotypes in human iPSC-derived macrophages. Alzheimer's Research and Therapy, 2020, 12, 151.	3.0	35
1245	Interleukinâ€12/23 deficiency differentially affects pathology in male and female Alzheimer's diseaseâ€like mice. EMBO Reports, 2020, 21, e48530.	2.0	24
1246	Genetic and polygenic risk score analysis for Alzheimer's disease in the Chinese population. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12074.	1.2	14

#	Article	IF	Citations
1247	TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis. Acta Neuropathologica, 2020, 140, 513-534.	3.9	186
1248	Microglial burden, activation and dystrophy patterns in frontotemporal lobar degeneration. Journal of Neuroinflammation, 2020, 17, 234.	3.1	29
1249	Efficient Strategies for Microglia Replacement in the Central Nervous System. Cell Reports, 2020, 32, 108041.	2.9	68
1250	Trem2 deficiency differentially affects phenotype and transcriptome of human APOE3 and APOE4 mice. Molecular Neurodegeneration, 2020, 15, 41.	4.4	43
1251	Microglia: Agents of the CNS Pro-Inflammatory Response. Cells, 2020, 9, 1717.	1.8	174
1252	Single Cell Transcriptome Analysis of Niemannâ€“Pick Disease, Type C1 Cerebella. International Journal of Molecular Sciences, 2020, 21, 5368.	1.8	20
1253	Genetics of Chronic Traumatic Encephalopathy. Seminars in Neurology, 2020, 40, 420-429.	0.5	8
1254	Invited Review â€“ A 5â€year update on epigenomeâ€wide association studies of DNA modifications in Alzheimerâ€™s disease: progress, practicalities and promise. Neuropathology and Applied Neurobiology, 2020, 46, 641-653.	1.8	10
1255	Activation of FAK/Rac1/Cdc42â€GTPase signaling ameliorates impaired microglial migration response to AÎ²₄₂in triggering receptor expressed on myeloid cells 2 lossâ€ofâ€function murine models. FASEB Journal, 2020, 34, 10984-10997.	0.2	24
1256	Control of Innate Immunity by Sialic Acids in the Nervous Tissue. International Journal of Molecular Sciences, 2020, 21, 5494.	1.8	18
1257	Understanding microglial diversity and implications for neuronal function in health and disease. Developmental Neurobiology, 2021, 81, 507-523.	1.5	29
1258	Imaging Alzheimer's genetic risk using diffusion MRI: A systematic review. NeuroImage: Clinical, 2020, 27, 102359.	1.4	24
1259	Immunological Features of Non-neuronal Brain Cells: Implications for Alzheimerâ€™s Disease Immunotherapy. Trends in Immunology, 2020, 41, 794-804.	2.9	36
1260	Higher CSF sTREM2 and microglia activation are associated with slower rates of betaâ€amyloid accumulation. EMBO Molecular Medicine, 2020, 12, e12308.	3.3	73
1261	HighÂGlucose and Hypoxia-Mediated Damage to Human Brain Microvessel Endothelial Cells Induces an Altered, Pro-Inflammatory Phenotype in BV-2 Microglia In Vitro. Cellular and Molecular Neurobiology, 2022, 42, 985-996.	1.7	11
1262	Loss of TREM2 Confers Resilience to Synaptic and Cognitive Impairment in Aged Mice. Journal of Neuroscience, 2020, 40, 9552-9563.	1.7	32
1263	Cerebrospinal fluid sTREM2 in Alzheimerâ€™s disease: comparisons between clinical presentation and AT classification. Scientific Reports, 2020, 10, 15886.	1.6	23
1264	Trem2 Y38C mutation and loss of Trem2 impairs neuronal synapses in adult mice. Molecular Neurodegeneration, 2020, 15, 62.	4.4	26

#	Article	IF	Citations
1265	CELF2 regulates the species-specific alternative splicing of TREM2. Scientific Reports, 2020, 10, 17995.	1.6	14
1266	Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimerâ€™s disease model. Journal of Experimental Medicine, 2020, 217, .	4.2	223
1267	Relation between FCGRIIB rs1050501 and HSV-1 specific IgG antibodies in Alzheimerâ€™s disease. Journal of Translational Medicine, 2020, 18, 325.	1.8	7
1268	The APOE Îµ4 exerts differential effects on familial and other subtypes of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 1613-1623.	0.4	30
1269	The innate immunity protein IFITM3 modulates Î³-secretase in Alzheimerâ€™s disease. Nature, 2020, 586, 735-740.	13.7	219
1270	Both Amyloid-Î² Peptide and Tau Protein Are Affected by an Anti-Amyloid-Î² Antibody Fragment in Elderly 3xTg-AD Mice. International Journal of Molecular Sciences, 2020, 21, 6630.	1.8	10
1271	Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions. Human Molecular Genetics, 2020, 29, 3224-3248.	1.4	76
1272	Human Pluripotent Stem Cell-Derived Neural Cells as a Relevant Platform for Drug Screening in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 6867.	1.8	26
1273	Immune-Related Hub Genes and the Competitive Endogenous RNA Network in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 77, 1255-1265.	1.2	17
1274	Tau-Mediated Dysregulation of Neuroplasticity and Glial Plasticity. Frontiers in Molecular Neuroscience, 2020, 13, 151.	1.4	11
1275	Gut Microbiota and Dysbiosis in Alzheimerâ€™s Disease: Implications for Pathogenesis and Treatment. Molecular Neurobiology, 2020, 57, 5026-5043.	1.9	191
1276	APOE and TREM2 regulate amyloid-responsive microglia in Alzheimerâ€™s disease. Acta Neuropathologica, 2020, 140, 477-493.	3.9	117
1277	Nicotinamide, a Poly [ADP-Ribose] Polymerase 1 (PARP-1) Inhibitor, as an Adjunctive Therapy for the Treatment of Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2020, 12, 255.	1.7	47
1278	Examination of the Effect of Rare Variants in TREM2, ABI3, and PLCG2 in LOAD Through Multiple Phenotypes. Journal of Alzheimer's Disease, 2020, 77, 1469-1482.	1.2	18
1279	Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimerâ€™s Disease: Sensitivity, Specificity and Potential for Clinical Use. Journal of Personalized Medicine, 2020, 10, 116.	1.1	26
1280	Toward refining Alzheimer's disease into overlapping subgroups. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12070.	1.8	7
1281	The Role of HDL and HDL Mimetic Peptides as Potential Therapeutics for Alzheimerâ€™s Disease. Biomolecules, 2020, 10, 1276.	1.8	12
1282	Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition. Journal of Neuroinflammation, 2020, 17, 238.	3.1	60

#	Article	IF	Citations
1284	TMEM59 interacts with TREM2 and modulates TREM2-dependent microglial activities. Cell Death and Disease, 2020, 11, 678.	2.7	27
1285	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. Brain Communications, 2020, 2, .	1.5	20
1286	Î³-Secretase Modulatory Proteins: The Guiding Hand Behind the Running Scissors. Frontiers in Aging Neuroscience, 2020, 12, 614690.	1.7	12
1287	Non-genetic Heterogeneity of Macrophages in Diseasesâ€"A Medical Perspective. Frontiers in Cell and Developmental Biology, 2020, 8, 613116.	1.8	10
1288	Therapeutic Targeting Strategies for Early- to Late-Staged Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 9591.	1.8	24
1289	A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12128.	1.2	16
1290	TLR4 Targeting as a Promising Therapeutic Strategy for Alzheimer Disease Treatment. Frontiers in Neuroscience, 2020, 14, 602508.	1.4	46
1291	Model organism development and evaluation for lateâ€onset Alzheimer's disease: MODELâ€AD. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12110.	1.8	63
1292	Cerebral sterile inflammation in neurodegenerative diseases. Inflammation and Regeneration, 2020, 40, 28.	1.5	24
1293	The Novel Omega-6 Fatty Acid Docosapentaenoic Acid Positively Modulates Brain Innate Immune Response for Resolving Neuroinflammation at Early and Late Stages of Humanized APOE-Based Alzheimer's Disease Models. Frontiers in Immunology, 2020, 11, 558036.	2.2	14
1294	Whole-Exome Sequencing Analysis of Alzheimerâ€™s Disease in Non-APOE*4 Carriers. Journal of Alzheimer's Disease, 2020, 76, 1553-1565.	1.2	18
1295	Functional consequences of a close encounter between microglia and brain-infiltrating monocytes during CNS pathology and repair. Journal of Leukocyte Biology, 2021, 110, 89-106.	1.5	6
1296	Multi-omic comparison of Alzheimerâ€™s variants in human ESCâ€"derived microglia reveals convergence at APOE. Journal of Experimental Medicine, 2020, 217, .	4.2	41
1297	Surgery-induced cognitive dysfunction is alleviated through triggering receptor expressed on myeloid cells 2. Acta Histochemica, 2020, 122, 151553.	0.9	2
1298	Triggering receptor expressed on myeloid cells 2 activation downregulates tollâ€like receptor 4 expression and ameliorates cognitive impairment in the Aî²_{1â€42}â€induced Alzheimer's disease mouse model. Synapse, 2020, 74, e22161.	0.6	6
1299	Gene Ontology Curation of Neuroinflammation Biology Improves the Interpretation of Alzheimerâ€™s Disease Gene Expression Data. Journal of Alzheimer's Disease, 2020, 75, 1417-1435.	1.2	18
1300	Cognitive Decline in Alzheimerâ€™s Disease: Limited Clinical Utility for GWAS or Polygenic Risk Scores in a Clinical Trial Setting. Genes, 2020, 11, 501.	1.0	2
1301	Proteomic Profiling of Plasma and Brain Tissue from Alzheimerâ€™s Disease Patients Reveals Candidate Network of Plasma Biomarkers. Journal of Alzheimer's Disease, 2020, 76, 349-368.	1.2	31

#	Article	IF	Citations
1302	Dysregulated Brain Cholesterol Metabolism Is Linked to Neuroinflammation in Huntington's Disease. Movement Disorders, 2020, 35, 1113-1127.	2.2	27
1303	Meprin Î² cleaves TREM2 and controls its phagocytic activity on macrophages. FASEB Journal, 2020, 34, 6675-6687.	0.2	21
1305	Ocular hypertension suppresses homeostatic gene expression in optic nerve head microglia of DBA/2â€‰J mice. Molecular Brain, 2020, 13, 81.	1.3	31
1306	Sleep Disturbances in MCI and AD: Neuroinflammation as a Possible Mediating Pathway. Frontiers in Aging Neuroscience, 2020, 12, 69.	1.7	23
1307	Hippocampal overexpression of TREM2 ameliorates high fat diet induced cognitive impairment and modulates phenotypic polarization of the microglia. Genes and Diseases, 2022, 9, 401-414.	1.5	26
1308	GABAergic dysfunction in excitatory and inhibitory (E/I) imbalance drives the pathogenesis of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 1312-1329.	0.4	97
1309	Exploratory analysis of mtDNA haplogroups in two Alzheimer's longitudinal cohorts. Alzheimer's and Dementia, 2020, 16, 1164-1172.	0.4	25
1310	Selective neuronal vulnerability in Alzheimerâ€™s disease. Ageing Research Reviews, 2020, 62, 101114.	5.0	9
1311	Genetic architecture of Alzheimer's disease. Neurobiology of Disease, 2020, 143, 104976.	2.1	73
1312	Differential regulation of TREM2 and CSF1R in CNS macrophages in an SIV/macaque model of HIV CNS disease. Journal of NeuroVirology, 2020, 26, 511-519.	1.0	6
1313	Macrophage phagocytosis assay with reconstituted target particles. Nature Protocols, 2020, 15, 2230-2246.	5.5	33
1314	Glia in neurodegeneration: Drivers of disease or along for the ride?. Neurobiology of Disease, 2020, 142, 104957.	2.1	56
1315	Alzheimerâ€™s-associated PLCÎ³2 is a signaling node required for both TREM2 function and the inflammatory response in human microglia. Nature Neuroscience, 2020, 23, 927-938.	7.1	142
1316	Microglia. , 2020, , 995-1020.		3
1317	Targeting Microglial Population Dynamics in Alzheimerâ€™s Disease: Are We Ready for a Potential Impact on Immune Function?. Frontiers in Cellular Neuroscience, 2020, 14, 149.	1.8	19
1318	Expedition into Taurine Biology: Structural Insights and Therapeutic Perspective of Taurine in Neurodegenerative Diseases. Biomolecules, 2020, 10, 863.	1.8	18
1319	Î²-Amyloid Clustering around ASC Fibrils Boosts Its Toxicity in Microglia. Cell Reports, 2020, 30, 3743-3754.e6.	2.9	109
1320	d-Serine, the Shape-Shifting NMDA Receptor Co-agonist. Neurochemical Research, 2020, 45, 1344-1353.	1.6	33

#	Article	IF	Citations
1321	Alzheimerâ€™s Risk Factors Age, APOE Genotype, and Sex Drive Distinct Molecular Pathways. Neuron, 2020, 106, 727-742.e6.	3.8	152
1322	High-intensity interval training and moderate-intensity continuous training alleviate Î²-amyloid deposition by inhibiting NLRP3 inflammasome activation in APPswe/PS1dE9 mice. NeuroReport, 2020, 31, 425-432.	0.6	21
1323	Metabolic Reprograming of Microglia in the Regulation of the Innate Inflammatory Response. Frontiers in Immunology, 2020, 11, 493.	2.2	152
1324	Characterization of the chromatin accessibility in an Alzheimerâ€™s disease (AD) mouse model. Alzheimer's Research and Therapy, 2020, 12, 29.	3.0	29
1325	Molecular Pathogenesis and Interventional Strategies for Alzheimerâ€™s Disease: Promises and Pitfalls. ACS Pharmacology and Translational Science, 2020, 3, 472-488.	2.5	21
1326	Murine Gut Microbiome Association With APOE Alleles. Frontiers in Immunology, 2020, 11, 200.	2.2	37
1327	Robust neuroinflammation and perivascular pathology in rTg-DI rats, a novel model of microvascular cerebral amyloid angiopathy. Journal of Neuroinflammation, 2020, 17, 78.	3.1	19
1328	Peripheral cytokine and fatty acid associations with neuroinflammation in AD and aMCI patients: An exploratory study. Brain, Behavior, and Immunity, 2020, 87, 679-688.	2.0	19
1329	Trem2 Splicing and Expression are Preserved in a Human AÎ²-producing, Rat Knock-in Model of Trem2-R47H Alzheimerâ€™s Risk Variant. Scientific Reports, 2020, 10, 4122.	1.6	16
1330	Current clinical approaches in neurodegenerative diseases. , 2020, , 79-124.		1
1331	Immunogenetics of neurological disease. , 2020, , 71-80.		0
1332	Association of APOE With Primary Open-Angle Glaucoma Suggests a Protective Effect for APOE Îµ4. , 2020, 61, 3.		23
1333	Low-Dose Ionizing Radiation Modulates Microglia Phenotypes in the Models of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 4532.	1.8	35
1334	Extracellular proteostasis prevents aggregation during pathogenic attack. Nature, 2020, 584, 410-414.	13.7	39
1335	IPSC-Derived Neuronal Cultures Carrying the Alzheimerâ€™s Disease Associated TREM2 R47H Variant Enables the Construction of an AÎ²-Induced Gene Regulatory Network. International Journal of Molecular Sciences, 2020, 21, 4516.	1.8	9
1336	Invited Review â€“ Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials. Neuropathology and Applied Neurobiology, 2020, 46, 623-640.	1.8	20
1337	TREM2 ectodomain and its soluble form in Alzheimerâ€™s disease. Journal of Neuroinflammation, 2020, 17, 204.	3.1	55
1338	Blood and cerebrospinal fluid biomarkers for Alzheimerâ€™s disease. Journal of Laboratory and Precision Medicine, 0, 5, 15-15.	1.1	5

#	Article	IF	Citations
1339	The role of innate immunity in Alzheimer's disease. Immunological Reviews, 2020, 297, 225-246.	2.8	70
1340	Astrocytes and microglia play orchestrated roles and respect phagocytic territories during neuronal corpse removal in vivo. Science Advances, 2020, 6, eaba3239.	4.7	176
1341	Microglia heterogeneity and neurodegeneration: The emerging paradigm of the role of immunity in Alzheimer's disease. Journal of Neuroimmunology, 2020, 341, 577185.	1.1	58
1342	Amyloid-beta (1-42) lesion of CA1 rat dorsal hippocampus reduces contextual fear memory and increases expression of microglial genes regulating neuroinflammation. Behavioural Brain Research, 2020, 393, 112795.	1.2	7
1343	SLC2A3 rs12842 polymorphism and risk for Alzheimerâ€™s disease. Neurological Research, 2020, 42, 853-861.	0.6	9
1344	Potential Bidirectional Relationship Between Periodontitis and Alzheimerâ€™s Disease. Frontiers in Physiology, 2020, 11, 683.	1.3	49
1345	Genetic Dissection of Alzheimerâ€™s Disease Using Drosophila Models. International Journal of Molecular Sciences, 2020, 21, 884.	1.8	27
1346	Applications of Functional Genomics for Drug Discovery. SLAS Discovery, 2020, 25, 823-842.	1.4	6
1347	Microgliaâ€Related Gene Triggering Receptor Expressed in Myeloid Cells 2 (TREM2) Is Upregulated in the Substantia Nigra of Progressive Supranuclear Palsy. Movement Disorders, 2020, 35, 885-890.	2.2	11
1348	Increased oxidative stress, hyperphosphorylation of tau, and dystrophic microglia in the hippocampus of aged <scp>Tupaia belangeri</scp>. Glia, 2020, 68, 1775-1793.	2.5	23
1349	ABCA7â€”A Member of the ABC Transporter Family in Healthy and Ailing Brain. Brain Sciences, 2020, 10, 121.	1.1	2
1350	The multiplex model of the genetics of Alzheimerâ€™s disease. Nature Neuroscience, 2020, 23, 311-322.	7.1	291
1351	Mechanistic insights into the deleterious roles of Nasu-Hakola disease associated TREM2 variants. Scientific Reports, 2020, 10, 3663.	1.6	24
1352	Genetic architecture of neurodegenerative dementias. Neuropharmacology, 2020, 168, 108014.	2.0	5
1353	Soluble TREM2 is elevated in Parkinsonâ€™s disease subgroups with increased CSF tau. Brain, 2020, 143, 932-943.	3.7	49
1354	A TREML2 missense variant influences specific hippocampal subfield volumes in cognitively normal elderly subjects. Brain and Behavior, 2020, 10, e01573.	1.0	10
1355	Activated Bone Marrow-Derived Macrophages Eradicate Alzheimer's-Related Aî²42 Oligomers and Protect Synapses. Frontiers in Immunology, 2020, 11, 49.	2.2	32
1356	Alzheimer's disease pathology in APOE transgenic mouse models: The Who, What, When, Where, Why, and How. Neurobiology of Disease, 2020, 139, 104811.	2.1	44

#	Article	IF	Citations
1357	Central and Peripheral Metabolic Defects Contribute to the Pathogenesis of Alzheimer's Disease: Targeting Mitochondria for Diagnosis and Prevention. Antioxidants and Redox Signaling, 2020, 32, 1188-1236.	2.5	61
1358	Soluble TREM2 and Inflammatory Proteins in Alzheimerâ€™s Disease Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2020, 73, 1615-1626.	1.2	29
1359	Nrf2 Suppresses Oxidative Stress and Inflammation in App Knock-In Alzheimerâ€™s Disease Model Mice. Molecular and Cellular Biology, 2020, 40, .	1.1	98
1360	Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases. Alzheimer's and Dementia, 2020, 16, 118-130.	0.4	43
1361	Disruption of a RAC1-centred network is associated with Alzheimerâ€™s disease pathology and causes age-dependent neurodegeneration. Human Molecular Genetics, 2020, 29, 817-833.	1.4	29
1362	Trem2 Deletion Reduces Late-Stage Amyloid Plaque Accumulation, Elevates the AÎ²42:AÎ²40 Ratio, and Exacerbates Axonal Dystrophy and Dendritic Spine Loss in the PS2APP Alzheimer's Mouse Model. Journal of Neuroscience, 2020, 40, 1956-1974.	1.7	114
1363	Lifestyle Modifications and Nutritional Interventions in Aging-Associated Cognitive Decline and Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2019, 11, 369.	1.7	77
1364	Human iPSCâ€derived microglia: A growing toolset to study the brain's innate immune cells. Glia, 2020, 68, 721-739.	2.5	77
1365	Alzheimerâ€™s Disease Genetics: Review of Novel Loci Associated with Disease. Current Genetic Medicine Reports, 2020, 8, 1-16.	1.9	20
1366	The age-related microglial transformation in Alzheimer's disease pathogenesis. Neurobiology of Aging, 2020, 92, 82-91.	1.5	20
1367	Dynamic changes of CSF sTREM2 in preclinical Alzheimerâ€™s disease: the CABLE study. Molecular Neurodegeneration, 2020, 15, 25.	4.4	50
1368	Investigation of pathology, expression and proteomic profiles in human TREM2 variant postmortem brains with and without Alzheimerâ€™s disease. Brain Pathology, 2020, 30, 794-810.	2.1	10
1369	Reduction of the RNA Binding Protein TIA1 Exacerbates Neuroinflammation in Tauopathy. Frontiers in Neuroscience, 2020, 14, 285.	1.4	24
1370	New Insights into the Molecular Bases of Familial Alzheimerâ€™s Disease. Journal of Personalized Medicine, 2020, 10, 26.	1.1	19
1371	Screening of dementia genes by whole-exome sequencing in Spanish patients with early-onset dementia: likely pathogenic, uncertain significance and risk variants. Neurobiology of Aging, 2020, 93, e1-e9.	1.5	11
1372	Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimerâ€™s Disease. Current Alzheimer Research, 2020, 17, 112-125.	0.7	40
1373	The Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimerâ€™s Disease. Frontiers in Immunology, 2020, 11, 754.	2.2	100
1374	Regulation of microglia by glutamate and its signal pathway in neurodegenerative diseases. Drug Discovery Today, 2020, 25, 1074-1085.	3.2	18

#	Article	IF	Citations
1375	New fluid biomarkers tracking non-amyloid-Î² and non-tau pathology in Alzheimerâ€™s disease. Experimental and Molecular Medicine, 2020, 52, 556-568.	3.2	57
1376	Key role of MIF-related neuroinflammation in neurodegeneration and cognitive impairment in Alzheimerâ€™s disease. Molecular Medicine, 2020, 26, 34.	1.9	46
1377	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. Frontiers in Immunology, 2020, 11, 456.	2.2	201
1378	The Genetics of Alzheimerâ€™s Disease in the Chinese Population. International Journal of Molecular Sciences, 2020, 21, 2381.	1.8	10
1379	Assessment of TREM2 rs75932628 variantâ€™s association with Parkinsonâ€™s disease in a Greek population and Meta-analysis of current data. International Journal of Neuroscience, 2021, 131, 544-548.	0.8	12
1380	Apolipoprotein E4 and meningeal lymphatics in Alzheimer disease: a conceptual framework. Molecular Psychiatry, 2021, 26, 1075-1097.	4.1	42
1381	Role of Microglia in Regulating Cholesterol and Tau Pathology in Alzheimerâ€™s Disease. Cellular and Molecular Neurobiology, 2021, 41, 651-668.	1.7	10
1382	Genetic testing in dementia â€” utility and clinical strategies. Nature Reviews Neurology, 2021, 17, 23-36.	4.9	26
1383	Knockdown of astrocytic TREM2 in the hippocampus relieves cognitive decline in elderly male mice. Behavioural Brain Research, 2021, 397, 112939.	1.2	3
1384	Functional insights from biophysical study of TREM2 interactions with apoE and AÎ²_{1â€42}. Alzheimer's and Dementia, 2021, 17, 475-488.	0.4	31
1385	Dissecting Alzheimer's disease pathogenesis in human 2D and 3D models. Molecular and Cellular Neurosciences, 2021, 110, 103568.	1.0	30
1386	Prediction of Alzheimer's disease using multi-variants from a Chinese genome-wide association study. Brain, 2021, 144, 924-937.	3.7	30
1387	Development of a robust crystallization platform for immune receptor TREM2 using a crystallization chaperone strategy. Protein Expression and Purification, 2021, 179, 105796.	0.6	4
1388	Early detection and personalized medicine: Future strategies against Alzheimer's disease. Progress in Molecular Biology and Translational Science, 2021, 177, 157-173.	0.9	9
1389	Miniâ€review: Role of the PI3K/Akt pathway and tyrosine phosphatases in Alzheimer's disease susceptibility. Annals of Human Genetics, 2021, 85, 1-6.	0.3	19
1390	TNF-Î±â€“mediated reduction in inhibitory neurotransmission precedes sporadic Alzheimerâ€™s disease pathology in young Trem2 rats. Journal of Biological Chemistry, 2021, 296, 100089.	1.6	23
1391	Harnessing the paradoxical phenotypes of APOE É›2 and APOE É›4 to identify genetic modifiers in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 831-846.	0.4	14
1392	Microglial innate memory and epigenetic reprogramming in neurological disorders. Progress in Neurobiology, 2021, 200, 101971.	2.8	21

#	Article	IF	Citations
1393	Genetic variants in glutamate-, AÎ²â^', and tau-related pathways determine polygenic risk for Alzheimer's disease. Neurobiology of Aging, 2021, 101, 299.e13-299.e21.	1.5	7
1394	Reactive or transgenic increase in microglial TYROBP reveals a TREM2â€'independent TYROBPâ€"APOE link in wildâ€'type and Alzheimer'sâ€'related mice. Alzheimer's and Dementia, 2021, 17, 149-163.	0.4	30
1395	A reporter cell system for the triggering receptor expressed on myeloid cells 2 reveals differential effects of diseaseâ€'associated variants on receptor signaling and activation by antibodies against the stalk region. Glia, 2021, 69, 1126-1139.	2.5	5
1396	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. JAMA Neurology, 2021, 78, 102.	4.5	144
1397	Singular cases of Alzheimerâ€™s disease disclose new and old genetic â€œacquaintancesâ€• Neurological Sciences, 2021, 42, 2021-2029.	0.9	4
1398	Receptor for Advanced Glycation End Products (RAGE) Mediates Cognitive Impairment Triggered by Pneumococcal Meningitis. Neurotherapeutics, 2021, 18, 640-653.	2.1	16
1399	Systems-based proteomics to resolve the biology of Alzheimerâ€™s disease beyond amyloid and tau. Neuropsychopharmacology, 2021, 46, 98-115.	2.8	70
1400	Genetic Insights into Alzheimer's Disease. Annual Review of Pathology: Mechanisms of Disease, 2021, 16, 351-376.	9.6	11
1401	Microglia in neurodegenerative diseases. Neural Regeneration Research, 2021, 16, 270.	1.6	59
1402	Wild-type sTREM2 blocks AÎ² aggregation and neurotoxicity, but the Alzheimer's R47H mutant increases AÎ² aggregation. Journal of Biological Chemistry, 2021, 296, 100631.	1.6	33
1403	Amyloidogenic and anti-amyloidogenic properties of presenilin 1. Advances in Pharmacology, 2021, 90, 239-251.	1.2	4
1405	Network propagation of rare variants in Alzheimerâ€™s disease reveals tissue-specific hub genes and communities. PLoS Computational Biology, 2021, 17, e1008517.	1.5	1
1406	Insight into the genetic etiology of Alzheimer's disease: A comprehensive review of the role of rare variants. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12155.	1.2	33
1407	Engagement of TREM2 by a novel monoclonal antibody induces activation of microglia and improves cognitive function in Alzheimerâ€™s disease models. Journal of Neuroinflammation, 2021, 18, 19.	3.1	51
1408	Microglial Cell Dysregulation in the Aged Brain and Neurodegeneration. , 2021, , 1-13.		0
1409	The biological pathways of Alzheimer disease: a review. AIMS Neuroscience, 2021, 8, 86-132.	1.0	111
1410	The Involvement of Cellular Glycans in Alzheimer's Disease. , 2021, , 287-293.		0
1411	Caloric restriction ameliorates high-fat diet induced cognitive deficits through attenuating neuroinflammationviathe TREM2-PI3K/AKT signaling pathway. Food and Function, 2021, 12, 6464-6478.	2.1	10

#	Article	IF	Citations
1412	Positive Feedback Regulation of Microglial Glucose Metabolism by Histone H4 Lysine 12 Lactylation in Alzheimer's Disease. SSRN Electronic Journal, 0, , .	0.4	49
1413	Implications of Glycosylation in Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2020, 14, 625348.	1.4	50
1414	GenoRisk: A polygenic risk score for Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12211.	1.8	7
1415	cGAS- Stimulator of Interferon Genes Signaling in Central Nervous System Disorders. , 2021, 12, 1658.		12
1416	Role of Adaptive Immune and Impacts of Risk Factors on Adaptive Immune in Alzheimerâ€™s Disease: Are Immunotherapies Effective or Off-Target?. Neuroscientist, 2022, 28, 254-270.	2.6	9
1417	Exome-wide age-of-onset analysis reveals exonic variants in ERN1 and SPPL2C associated with Alzheimerâ€™s disease. Translational Psychiatry, 2021, 11, 146.	2.4	13
1418	Genetics of Alzheimerâ€™s disease. Wiener Medizinische Wochenschrift, 2021, 171, 249-256.	0.5	11
1419	Mitochondriaâ€associated endoplasmic reticulum membranes: At the crossroad between familiar and sporadic Alzheimer's disease. Synapse, 2021, 75, e22196.	0.6	8
1420	TREM2 Mediates Microglial Anti-Inflammatory Activations in Alzheimerâ€™s Disease: Lessons Learned from Transcriptomics. Cells, 2021, 10, 321.	1.8	25
1422	Alzheimerâ€™s Risk Gene TREM2 Determines Functional Properties of New Type of Human iPSC-Derived Microglia. Frontiers in Immunology, 2020, 11, 617860.	2.2	32
1423	Targeting Microglia-Synapse Interactions in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 2342.	1.8	36
1424	Exploring Potential of Alkaloidal Phytochemicals Targeting Neuroinflammatory Signaling of Alzheimer's Disease. Current Pharmaceutical Design, 2021, 27, 357-366.	0.9	11
1425	Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease: Current Evidence and Future Perspectives. Brain Sciences, 2021, 11, 215.	1.1	58
1426	Microglia Fighting for Neurological and Mental Health: On the Central Nervous System Frontline of COVID-19 Pandemic. Frontiers in Cellular Neuroscience, 2021, 15, 647378.	1.8	27
1427	Metabolic disorder in Alzheimerâ€™s disease. Metabolic Brain Disease, 2021, 36, 781-813.	1.4	23
1428	The most prevalent rare coding variants of TREM2 conferring risk of Alzheimer's disease: A systematic review and metaâ€‘analysis. Experimental and Therapeutic Medicine, 2021, 21, 347.	0.8	15
1429	The Immune System's Role in the Consequences of Mild Traumatic Brain Injury (Concussion). Frontiers in Immunology, 2021, 12, 620698.	2.2	23
1430	The influence of the R47H triggering receptor expressed on myeloid cells 2 variant on microglial exosome profiles. Brain Communications, 2021, 3, fcab009.	1.5	7

#	Article	IF	Citations
1431	Scopoletin Ameliorates Lipopolysaccharide Induced Neuroinflammation, Oxidative Stress and Cognitive Dysfunction in Mice: A Mechanistic Study. Journal of Pharmaceutical Research International, 0, , 74-90.	1.0	0
1432	Defective Lysosomal Lipid Catabolism as a Common Pathogenic Mechanism for Dementia. NeuroMolecular Medicine, 2021, 23, 1-24.	1.8	9
1433	Stem Cell Therapies in Alzheimerâ€™s Disease: Applications for Disease Modeling. Journal of Pharmacology and Experimental Therapeutics, 2021, 377, 207-217.	1.3	22
1434	Insight into the role of phosphatidylserine in complement-mediated synapse loss in Alzheimerâ€™s disease. Faculty Reviews, 2021, 10, 19.	1.7	17
1435	Neuroinflammation in Prion Disease. International Journal of Molecular Sciences, 2021, 22, 2196.	1.8	20
1436	Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker. Frontiers in Immunology, 2021, 12, 646523.	2.2	67
1437	Beneficial Metabolic Effects of TREM2 in Obesity Are Uncoupled From Its Expression on Macrophages. Diabetes, 2021, 70, 2042-2057.	0.3	26
1438	The role of innate immune genes in Alzheimer's disease. Current Opinion in Neurology, 2021, 34, 228-236.	1.8	95
1439	Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimerâ€™s disease risk genes. Nature Genetics, 2021, 53, 392-402.	9.4	258
1440	The role of macrophage scavenger receptor 1 (Msr1) in prion pathogenesis. Journal of Molecular Medicine, 2021, 99, 877-887.	1.7	4
1441	Late-in-life neurodegeneration after chronic sleep loss in young adult mice. Sleep, 2021, 44, .	0.6	28
1442	The Impact of Complement Genes on the Risk of Late-Onset Alzheimerâ€™s Disease. Genes, 2021, 12, 443.	1.0	18
1445	Searching the Dark Genome for Alzheimerâ€™s Disease Risk Variants. Brain Sciences, 2021, 11, 332.	1.1	10
1446	Neuroimmunology in neurological and psychiatric disorders. Clinical and Experimental Neuroimmunology, 2021, 12, 92-100.	0.5	0
1447	Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) Interacts With Colony-Stimulating Factor 1 Receptor (CSF1R) but Is Not Necessary for CSF1/CSF1R-Mediated Microglial Survival. Frontiers in Immunology, 2021, 12, 633796.	2.2	13
1448	The Role of Microglia in Inherited White-Matter Disorders and Connections to Frontotemporal Dementia. The Application of Clinical Genetics, 2021, Volume 14, 195-207.	1.4	12
1449	Animal and Cellular Models of Alzheimerâ€™s Disease: Progress, Promise, and Future Approaches. Neuroscientist, 2022, 28, 572-593.	2.6	11
1451	Upregulated expression of a subset of genes inAPP;ob/obmice: Evidence of an interaction between diabetesâ€linked obesity and Alzheimerâ€™s disease. FASEB BioAdvances, 2021, 3, 323-333.	1.3	8

#	Article	IF	Citations
1452	TREM2 alters the phagocytic, apoptotic and inflammatory response to AÎ²42 in HMC3 cells. Molecular Immunology, 2021, 131, 171-179.	1.0	24
1453	Evaluation of the Clinical Features Accompanied by the Gene Mutations. Alzheimer Disease and Associated Disorders, 2021, 35, 214-222.	0.6	4
1454	Microglia regulate synaptic development and plasticity. Developmental Neurobiology, 2021, 81, 568-590.	1.5	81
1455	Set-Based Rare Variant Expression Quantitative Trait Loci in Blood and Brain from Alzheimer Disease Study Participants. Genes, 2021, 12, 419.	1.0	6
1456	African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. Neurology: Genetics, 2021, 7, e571.	0.9	27
1457	Alzheimerâ€™s Disease Pathogenesis: Role of Autophagy and Mitophagy Focusing in Microglia. International Journal of Molecular Sciences, 2021, 22, 3330.	1.8	71
1458	An Analysis of the Neurological and Molecular Alterations Underlying the Pathogenesis of Alzheimerâ€™s Disease. Cells, 2021, 10, 546.	1.8	11
1459	Heritability Enrichment Implicates Microglia in Parkinson's Disease Pathogenesis. Annals of Neurology, 2021, 89, 942-951.	2.8	35
1460	Origins, Biology, and Diseases of Tissue Macrophages. Annual Review of Immunology, 2021, 39, 313-344.	9.5	88
1461	Trem2 restrains the enhancement of tau accumulation and neurodegeneration by Î²-amyloid pathology. Neuron, 2021, 109, 1283-1301.e6.	3.8	137
1462	Protective genes and pathways in Alzheimerâ€™s disease: moving towards precision interventions. Molecular Neurodegeneration, 2021, 16, 29.	4.4	58
1463	TREM2/PLCÎ³2 signalling in immune cells: function, structural insight, and potential therapeutic modulation. Molecular Neurodegeneration, 2021, 16, 22.	4.4	27
1464	COVID-19 and Alzheimerâ€™s disease: how one crisis worsens the other. Translational Neurodegeneration, 2021, 10, 15.	3.6	74
1465	Quantitative endophenotypes as an alternative approach to understanding genetic risk in neurodegenerative diseases. Neurobiology of Disease, 2021, 151, 105247.	2.1	3
1466	Role of triggering receptor expressed on myeloid cells 2 (TREM2) in neurodegenerative dementias. European Journal of Neuroscience, 2021, 53, 3294-3310.	1.2	10
1467	TREM2 expression in the brain and biological fluids in prion diseases. Acta Neuropathologica, 2021, 141, 841-859.	3.9	18
1468	Decoding Cell Death: From a Veritable Library of Babel toVade Mecum?. Annual Review of Immunology, 2021, 39, 791-817.	9.5	7
1469	Alternative Targets to Fight Alzheimerâ€™s Disease: Focus on Astrocytes. Biomolecules, 2021, 11, 600.	1.8	16

#	Article	IF	Citations
1470	TREM2 is a receptor for non-glycosylated mycolic acids of mycobacteria that limits anti-mycobacterial macrophage activation. Nature Communications, 2021, 12, 2299.	5.8	32
1471	Cell-Type-Specific Gene Modules Related to the Regional Homogeneity of Spontaneous Brain Activity and Their Associations With Common Brain Disorders. Frontiers in Neuroscience, 2021, 15, 639527.	1.4	6
1472	Alzheimerâ€™s Disease: New Concepts on the Role of Autoimmunity and NLRP3 Inflammasome in the Pathogenesis of the Disease. Current Neuropharmacology, 2021, 19, 498-512.	1.4	16
1473	White matter aging drives microglial diversity. Neuron, 2021, 109, 1100-1117.e10.	3.8	208
1474	Microglial Function and Regulation during Development, Homeostasis and Alzheimerâ€™s Disease. Cells, 2021, 10, 957.	1.8	24
1475	Microglia and Central Nervous Systemâ€“Associated Macrophagesâ€”From Origin to Disease Modulation. Annual Review of Immunology, 2021, 39, 251-277.	9.5	228
1476	Alzheimer's disease. Lancet, The, 2021, 397, 1577-1590.	6.3	1,530
1477	ABCA7 Regulates Brain Fatty Acid Metabolism During LPS-Induced Acute Inflammation. Frontiers in Neuroscience, 2021, 15, 647974.	1.4	12
1478	Wholeâ€genome sequencing reveals new Alzheimer's diseaseâ€“associated rare variants in loci related to synaptic function and neuronal development. Alzheimer's and Dementia, 2021, 17, 1509-1527.	0.4	50
1479	Bridging heterogeneous mutation data to enhance disease gene discovery. Briefings in Bioinformatics, 2021, 22, .	3.2	4
1480	How understudied populations have contributed to our understanding of Alzheimerâ€™s disease genetics. Brain, 2021, 144, 1067-1081.	3.7	10
1481	TREM2, microglia, and Alzheimerâ€™s disease. Mechanisms of Ageing and Development, 2021, 195, 111438.	2.2	74
1482	Beyond association: successes and challenges in linking non-coding genetic variation to functional consequences that modulate Alzheimerâ€™s disease risk. Molecular Neurodegeneration, 2021, 16, 27.	4.4	20
1483	Neuroinflammation in Alzheimerâ€™s Disease. Biomedicines, 2021, 9, 524.	1.4	120
1484	Aging-associated deficit in CCR7 is linked to worsened glymphatic function, cognition, neuroinflammation, and Î²-amyloid pathology. Science Advances, 2021, 7, .	4.7	73
1485	Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2021, 13, 94.	3.0	12
1486	Microglia and modifiable life factors: Potential contributions to cognitive resilience in aging. Behavioural Brain Research, 2021, 405, 113207.	1.2	24
1487	Transcriptional signature in microglia associated with AÎ² plaque phagocytosis. Nature Communications, 2021, 12, 3015.	5.8	142

#	Article	IF	Citations
1488	Multi-tissue neocortical transcriptome-wide association study implicates 8 genes across 6 genomic loci in Alzheimerâ€™s disease. Genome Medicine, 2021, 13, 76.	3.6	19
1489	Differentially expressed genes in Alzheimerâ€™s disease highlighting the roles of microglia genes including OLR1 and astrocyte gene CDK2AP1. Brain, Behavior, & Immunity - Health, 2021, 13, 100227.	1.3	28
1490	Personalizing the Care and Treatment of Alzheimerâ€™s Disease: An Overview. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 631-653.	0.4	3
1491	NEBULA is a fast negative binomial mixed model for differential or co-expression analysis of large-scale multi-subject single-cell data. Communications Biology, 2021, 4, 629.	2.0	50
1492	Exploiting formyl peptide receptor 2 to promote microglial resolution: a new approach to Alzheimerâ€™s disease treatment. FEBS Journal, 2022, 289, 1801-1822.	2.2	6
1493	Established Beta Amyloid Pathology Is Unaffected by TREM2 Elevation in Reactive Microglia in an Alzheimerâ€™s Disease Mouse Model. Molecules, 2021, 26, 2685.	1.7	2
1494	Genetic profiles of familial late-onset Alzheimer's disease in China: The Shanghai FLOAD study. Genes and Diseases, 2022, 9, 1639-1649.	1.5	4
1495	Vitamin K2 Holds Promise for Alzheimerâ€™s Prevention and Treatment. Nutrients, 2021, 13, 2206.	1.7	21
1496	Acute Trem2 reduction triggers increased microglial phagocytosis, slowing amyloid deposition in mice. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	40
1497	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	5.8	140
1498	A map of transcriptional heterogeneity and regulatory variation in human microglia. Nature Genetics, 2021, 53, 861-868.	9.4	115
1499	Alzheimerâ€™s Disease Genetics: A Dampened Microglial Response?. Neuroscientist, 2023, 29, 245-263.	2.6	11
1500	Modulation of microglial phenotypes by dexmedetomidine through TREM2 reduces neuroinflammation in heatstroke. Scientific Reports, 2021, 11, 13345.	1.6	8
1501	Tau Seeding Mouse Models with Patient Brain-Derived Aggregates. International Journal of Molecular Sciences, 2021, 22, 6132.	1.8	14
1502	Temporal Ordering of Inflammatory Analytes sTNFR2 and sTREM2 in Relation to Alzheimer's Disease Biomarkers and Clinical Outcomes. Frontiers in Aging Neuroscience, 2021, 13, 676744.	1.7	11
1503	Neurodegenerative Disease Risk in Carriers of Autosomal Recessive Disease. Frontiers in Neurology, 2021, 12, 679927.	1.1	6
1504	Reassessment of Pioglitazone for Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2021, 15, 666958.	1.4	30
1505	The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimerâ€™s Disease. Medical Science Monitor, 2021, 27, e933084.	0.5	10

#	Article	IF	Citations
1506	Role of Neuron and Glia in Alzheimerâ€™s Disease and Associated Vascular Dysfunction. Frontiers in Aging Neuroscience, 2021, 13, 653334.	1.7	28
1507	Regulation of microglia population dynamics throughout development, health, and disease. Glia, 2021, 69, 2771-2797.	2.5	29
1508	NLRP3 and Infections: Î²-Amyloid in Inflammasome beyond Neurodegeneration. International Journal of Molecular Sciences, 2021, 22, 6984.	1.8	21
1509	Toxoplasma gondii: A possible etiologic agent for Alzheimer's disease. Heliyon, 2021, 7, e07151.	1.4	13
1510	Reporter cell assay for human CD33 validated by specific antibodies and human iPSC-derived microglia. Scientific Reports, 2021, 11, 13462.	1.6	8
1511	TREM2 Deficiency Disrupts Network Oscillations Leading to Epileptic Activity and Aggravates Amyloid-Î²-Related Hippocampal Pathophysiology in Mice. Journal of Alzheimer's Disease, 2022, 88, 837-847.	1.2	7
1512	Higher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimerâ€™s disease. Nature Communications, 2021, 12, 4001.	5.8	19
1513	Age-Dependent Hippocampal Proteomics in the APP/PS1 Alzheimer Mouse Model: A Comparative Analysis with Classical SWATH/DIA and directDIA Approaches. Cells, 2021, 10, 1588.	1.8	11
1514	Role of Withaferin A and Its Derivatives in the Management of Alzheimerâ€™s Disease: Recent Trends and Future Perspectives. Molecules, 2021, 26, 3696.	1.7	22
1515	Microglia show differential transcriptomic response to AÎ² peptide aggregates ex vivo and in vivo. Life Science Alliance, 2021, 4, e202101108.	1.3	17
1516	Activated microglia mitigate AÎ²-associated tau seeding and spreading. Journal of Experimental Medicine, 2021, 218, .	4.2	94
1517	Human Monocytes Plasticity in Neurodegeneration. Biomedicines, 2021, 9, 717.	1.4	5
1518	Novel TREM2 splicing isoform that lacks the V-set immunoglobulin domain is abundant in the human brain. Journal of Leukocyte Biology, 2021, 110, 829-837.	1.5	15
1519	PIP2 depletion and altered endocytosis caused by expression of Alzheimer's diseaseâ€protective variant PLCÎ³2 R522. EMBO Journal, 2021, 40, e105603.	3.5	21
1522	Inflammatory pathways in Alzheimerâ€™s disease mediated by gut microbiota. Ageing Research Reviews, 2021, 68, 101317.	5.0	81
1523	Plasmonic Interferometers as TREM2 Sensors for Alzheimerâ€™s Disease. Biosensors, 2021, 11, 217.	2.3	1
1524	Genome-scale metabolic network reconstruction of model animals as a platform for translational research. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	48
1525	Novel Rare SORL1 Variants in Early-Onset Dementia. Journal of Alzheimer's Disease, 2021, 82, 761-770.	1.2	2

#	Article	IF	Citations
1526	Role of TREM2 in Alzheimerâ€™s Disease: A Long Road Ahead. Molecular Neurobiology, 2021, 58, 5239-5252.	1.9	15
1527	Selection and structural characterization of anti-TREM2 scFvs that reduce levels of shed ectodomain. Structure, 2021, 29, 1241-1252.e5.	1.6	9
1528	Diversity of transcriptomic microglial phenotypes in aging and Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 360-376.	0.4	46
1529	Development of grape polyphenols as multi-targeting strategies for Alzheimer's disease. Neurochemistry International, 2021, 147, 105046.	1.9	16
1530	The complexity of Alzheimerâ€™s disease: an evolving puzzle. Physiological Reviews, 2021, 101, 1047-1081.	13.1	110
1531	THY-Tau22 mouse model accumulates more tauopathy at late stage of the disease in response to microglia deactivation through TREM2 deficiency. Neurobiology of Disease, 2021, 155, 105398.	2.1	14
1532	Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimerâ€™s disease. Molecular Neurodegeneration, 2021, 16, 50.	4.4	65
1536	Microbial Infections Are a Risk Factor for Neurodegenerative Diseases. Frontiers in Cellular Neuroscience, 2021, 15, 691136.	1.8	41
1537	A Computational Exploration of the Molecular Network Associated to Neuroinflammation in Alzheimerâ€™s Disease. Frontiers in Pharmacology, 2021, 12, 630003.	1.6	5
1538	Exploiting dynamic enhancer landscapes to decode macrophage and microglia phenotypes in health and disease. Molecular Cell, 2021, 81, 3888-3903.	4.5	29
1539	Family-based exome sequencing identifies RBM45 as a possible candidate gene for frontotemporal dementia and amyotrophic lateral sclerosis. Neurobiology of Disease, 2021, 156, 105421.	2.1	2
1540	Modulation of Glial Function in Health, Aging, and Neurodegenerative Disease. Frontiers in Cellular Neuroscience, 2021, 15, 718324.	1.8	22
1541	Strategic approaches to target the enzymes using natural compounds for the management of Alzheimerâ€™s disease: A review. CNS and Neurological Disorders - Drug Targets, 2021, 20, .	0.8	1
1542	Proteomic landscape of Alzheimerâ€™s Disease: novel insights into pathogenesis and biomarker discovery. Molecular Neurodegeneration, 2021, 16, 55.	4.4	95
1543	TrendyGenes, a computational pipeline for the detection of literature trends in academia and drug discovery. Scientific Reports, 2021, 11, 15747.	1.6	4
1544	Investigation of the Molecular Role of Brain-Derived Neurotrophic Factor in Alzheimerâ€™s Disease. Journal of Molecular Neuroscience, 2022, 72, 173-186.	1.1	19
1545	Neuroinflammatory Signaling in the Pathogenesis of Alzheimerâ€™s Disease. Current Neuropharmacology, 2022, 20, 126-146.	1.4	28
1546	Differential interaction with <scp>TREM2</scp> modulates microglial uptake of modified AÎ² species. Glia, 2021, 69, 2917-2932.	2.5	9

#	Article	IF	Citations
1548	The Locus Coeruleus in Aging and Alzheimerâ€™s Disease: A Postmortem and Brain Imaging Review. Journal of Alzheimer's Disease, 2021, 83, 5-22.	1.2	52
1549	TREM2 is thyroid hormone regulated making the TREM2 pathway druggable with ligands for thyroid hormone receptor. Cell Chemical Biology, 2022, 29, 239-248.e4.	2.5	11
1551	NEK1-mediated retromer trafficking promotes bloodâ€“brain barrier integrity by regulating glucose metabolism and RIPK1 activation. Nature Communications, 2021, 12, 4826.	5.8	20
1552	Trends in incidence of dementia among patients with rheumatoid arthritis: A population-based cohort study. Seminars in Arthritis and Rheumatism, 2021, 51, 853-857.	1.6	11
1553	Role of Oxidative Damage in Alzheimerâ€™s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery. Antioxidants, 2021, 10, 1353.	2.2	57
1554	The Amyloid-Î² Pathway in Alzheimerâ€™s Disease. Molecular Psychiatry, 2021, 26, 5481-5503.	4.1	478
1556	Probability of Alzheimerâ€™s disease based on common and rare genetic variants. Alzheimer's Research and Therapy, 2021, 13, 140.	3.0	10
1558	Microglial TREM2 at the Intersection of Brain Aging and Alzheimerâ€™s Disease. Neuroscientist, 2023, 29, 302-316.	2.6	7
1559	Association of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimerâ€™s disease. Brain Pathology, 2022, 32, e13016.	2.1	13
1560	Transcriptome analysis of human dorsal striatum implicates attenuated canonical WNT signaling in neuroinflammation and in age-related impairment of striatal neurogenesis and synaptic plasticity. Restorative Neurology and Neuroscience, 2021, 39, 247-266.	0.4	2
1561	Reduced TREM2 activation in microglia of patients with Alzheimer's disease. FEBS Open Bio, 2021, 11, 3063-3080.	1.0	12
1562	DNA Repair Inhibition Leads to Active Export of Repetitive Sequences to the Cytoplasm Triggering an Inflammatory Response. Journal of Neuroscience, 2021, 41, 9286-9307.	1.7	13
1563	The Role of Adaptive and Innate Immunity in Alzheimerâ€™s Disease. , 2021, , 213-232.		0
1564	Biological Significance of the Protein Changes Occurring in the Cerebrospinal Fluid of Alzheimerâ€™s Disease Patients: Getting Clues from Proteomic Studies. Diagnostics, 2021, 11, 1655.	1.3	5
1565	Effects of microglial depletion and TREM2 deficiency on AÎ² plaque burden and neuritic plaque tau pathology in 5XFAD mice. Acta Neuropathologica Communications, 2021, 9, 150.	2.4	19
1566	The transcriptional landscape of Alzheimerâ€™s disease and its association with Wnt signaling pathway. Neuroscience and Biobehavioral Reviews, 2021, 128, 454-466.	2.9	8
1567	Successful and Unsuccessful Brain Aging in Pets: Pathophysiological Mechanisms behind Clinical Signs and Potential Benefits from Palmitoylethanolamide Nutritional Intervention. Animals, 2021, 11, 2584.	1.0	5
1568	Rare variants in the endocytic pathway are associated with Alzheimerâ€™s disease, its related phenotypes, and functional consequences. PLoS Genetics, 2021, 17, e1009772.	1.5	1

#	Article	IF	Citations
1569	Inflammatory Cascade in Alzheimerâ€™s Disease Pathogenesis: A Review of Experimental Findings. Cells, 2021, 10, 2581.	1.8	42
1570	Adult-onset CNS myelin sulfatide deficiency is sufficient to cause Alzheimerâ€™s disease-like neuroinflammation and cognitive impairment. Molecular Neurodegeneration, 2021, 16, 64.	4.4	52
1571	The Effect of Systemic Inflammation on Cognitive Function and Neurodegenerative Disease. , 2021, , 164-189.		0
1572	The potential roles of genetic factors in predicting ageing-related cognitive change and Alzheimerâ€™s disease. Ageing Research Reviews, 2021, 70, 101402.	5.0	9
1573	A 3-Gene-Based Diagnostic Signature in Alzheimerâ€™s Disease. European Neurology, 2022, 85, 6-13.	0.6	7
1574	Alternative Splicing Regulation of Low-Frequency Genetic Variants in Exon 2 of TREM2 in Alzheimerâ€™s Disease by Splicing-Based Aggregation. International Journal of Molecular Sciences, 2021, 22, 9865.	1.8	10
1575	Potentiation of amyloid beta phagocytosis and amelioration of synaptic dysfunction upon FAAH deletion in a mouse model of Alzheimer's disease. Journal of Neuroinflammation, 2021, 18, 223.	3.1	11
1576	Microglia, TREM2, and Therapeutic Methods of Alzheimerâ€™s Disease. , 0, , .		0
1577	Roles of microglia in Alzheimerâ€™s disease and impact of new findings on microglial heterogeneity as a target for therapeutic intervention. Biochemical Pharmacology, 2021, 192, 114754.	2.0	24
1578	Potential associations between immune signaling genes, deactivated microglia, and oligodendrocytes and cortical gray matter loss in patients with long-term remitted Cushingâ€™s disease. Psychoneuroendocrinology, 2021, 132, 105334.	1.3	6
1579	Functional co-activation of the default mode network in APOE Îµ4-carriers: A replication study. NeuroImage, 2021, 240, 118304.	2.1	9
1580	Applications of single-cell genomics and computational strategies to study common disease and population-level variation. Genome Research, 2021, 31, 1728-1741.	2.4	11
1581	Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways. Free Radical Biology and Medicine, 2021, 175, 42-55.	1.3	12
1582	The microglial lysosomal system in Alzheimerâ€™s disease: Guardian against proteinopathy. Ageing Research Reviews, 2021, 71, 101444.	5.0	16
1583	Microglial â€˜fat shamingâ€™ in development and disease. Current Opinion in Cell Biology, 2021, 73, 105-109.	2.6	5
1584	The contribution of inflammation to Alzheimer's disease in Down syndrome. , 2022, , 45-62.		1
1585	Fluid Biomarkers of Frontotemporal Lobar Degeneration. Advances in Experimental Medicine and Biology, 2021, 1281, 123-139.	0.8	7
1586	Sex Differences in Neurodegeneration: The Role of the Immune System in Humans. Biological Psychiatry, 2022, 91, 72-80.	0.7	31

#	Article	IF	Citations
1587	Microglial Hyperreactivity Evolved to Immunosuppression in the Hippocampus of a Mouse Model of Accelerated Aging and Alzheimerâ€™s Disease Traits. Frontiers in Aging Neuroscience, 2020, 12, 622360.	1.7	9
1588	Prior activation state shapes the microglia response to antihuman TREM2 in a mouse model of Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	66
1589	MEK1/2 activity modulates TREM2 cell surface recruitment. Journal of Biological Chemistry, 2021, 296, 100218.	1.6	4
1590	Sex differences in Alzheimerâ€™s disease animal models. , 2021, , 3-22.		0
1591	Differential effects of chronic immunosuppression on behavioral, epigenetic, and Alzheimerâ€™s disease-associated markers in 3xTg-AD mice. Alzheimer's Research and Therapy, 2021, 13, 30.	3.0	7
1592	The search for novel targets in Alzheimer's diseaseâ€"The 90s redux. Progress in Molecular Biology and Translational Science, 2021, 177, 123-135.	0.9	1
1593	Macrophage reprogramming for therapy. Immunology, 2021, 163, 128-144.	2.0	30
1595	Autosomal Dominant Alzheimerâ€™s Disease: Underlying Causes. , 2014, , 27-47.		2
1596	Neurodegenerative Diseases. , 2014, , 437-453.		3
1597	Microglial Physiology. , 2014, , 47-79.		1
1598	DNA Methylation in Neuronal Development and Disease. RNA Technologies, 2019, , 103-140.	0.2	1
1599	The Ubiquitin System in Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2020, 1233, 195-221.	0.8	47
1600	The Role of Aging in Alzheimerâ€™s Disease. , 2016, , 197-227.		12
1601	Genetics of the Connectome and the ENIGMA Project. Research and Perspectives in Neurosciences, 2016, , 147-164.	0.4	10
1602	Assessing Virtual Reality Environments as Cognitive Stimulation Method for Patients with MCI. Studies in Computational Intelligence, 2014, , 39-74.	0.7	44
1603	Amyloid-Î² and Tau at theÂCrossroads of Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2019, 1184, 187-203.	0.8	115
1604	Genetic Markers of Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2019, 1192, 27-52.	0.8	49
1605	Altered lipid metabolic homeostasis in the pathogenesis of Alzheimerâ€™s disease. , 2020, , 469-504.		5

#	Article	IF	Citations
1606	Transcriptional Signatures of Tau and Amyloid Neuropathology. Cell Reports, 2020, 30, 2040-2054.e5.	2.9	45
1607	Genetic architecture of common non-Alzheimerâ€™s disease dementias. Neurobiology of Disease, 2020, 142, 104946.	2.1	27
1608	The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease. Scientific Data, 2018, 5, 180185.	2.4	320
1609	Inflammation: major denominator of obesity, Type 2 diabetes and Alzheimerâ€™s disease-like pathology?. Clinical Science, 2020, 134, 547-570.	1.8	31
1610	TREM2 and neurodegenerative disease. New England Journal of Medicine, 2013, 369, 1564-5.	13.9	28
1611	TREM2 and neurodegenerative disease. New England Journal of Medicine, 2013, 369, 1565-7.	13.9	51
1612	TREM2 and neurodegenerative disease. New England Journal of Medicine, 2013, 369, 1567-8.	13.9	81
1613	A comprehensive analysis of methods for assessing polygenic burden on Alzheimerâ€™s disease pathology and risk beyond APOE. Brain Communications, 2020, 2, fcz047.	1.5	45
1649	Weighted burden analysis of exomeâ€sequenced lateâ€onset Alzheimer's cases and controls provides further evidence for a role for PSEN1 and suggests involvement of the PI3K/Akt/GSKâ€3Î² and WNT signalling pathways. Annals of Human Genetics, 2020, 84, 291-302.	0.3	24
1650	Electroconvulsive stimulation attenuates chronic neuroinflammation. JCI Insight, 2020, 5, .	2.3	21
1651	Impact of TREM2R47H variant on tau pathologyâ€“induced gliosis and neurodegeneration. Journal of Clinical Investigation, 2020, 130, 4954-4968.	3.9	139
1652	Thinking laterally about neurodegenerative proteinopathies. Journal of Clinical Investigation, 2013, 123, 1847-1855.	3.9	98
1653	Effector function of anti-pyroglutamate-3 AÎ² antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimerâ€™s-like mice. Alzheimer's Research and Therapy, 2020, 12, 12.	3.0	26
1654	New treatment modalities in Alzheimer's disease. World Journal of Clinical Cases, 2019, 7, 1764-1774.	0.3	12
1655	Is Apolipoprotein E4 an Important Risk Factor for Dementia in Persons with Down Syndrome?. Journal of Parkinson's Disease and Alzheimer's Disease, 2014, 1, .	1.5	15
1656	Rare Functional Variant in TM2D3 is Associated with Late-Onset Alzheimer's Disease. PLoS Genetics, 2016, 12, e1006327.	1.5	47
1657	Fine-mapping of the human leukocyte antigen locus as a risk factor for Alzheimer disease: A caseâ€“control study. PLoS Medicine, 2017, 14, e1002272.	3.9	67
1658	Strong Evidence for a Genetic Contribution to Late-Onset Alzheimerâ€™s Disease Mortality: A Population-Based Study. PLoS ONE, 2013, 8, e77087.	1.1	14

#	Article	IF	Citations
1659	Gene-Based Rare Allele Analysis Identified a Risk Gene of Alzheimerâ€™s Disease. PLoS ONE, 2014, 9, e107983.	1.1	11
1660	Examination of Candidate Exonic Variants for Association to Alzheimer Disease in the Amish. PLoS ONE, 2015, 10, e0118043.	1.1	13
1661	A Subset of Cerebrospinal Fluid Proteins from a Multi-Analyte Panel Associated with Brain Atrophy, Disease Classification and Prediction in Alzheimerâ€™s Disease. PLoS ONE, 2015, 10, e0134368.	1.1	26
1662	TREM2 mRNA Expression in Leukocytes Is Increased in Alzheimerâ€™s Disease and Schizophrenia. PLoS ONE, 2015, 10, e0136835.	1.1	31
1663	Can Genetic Analysis of Putative Blood Alzheimerâ€™s Disease Biomarkers Lead to Identification of Susceptibility Loci?. PLoS ONE, 2015, 10, e0142360.	1.1	13
1664	Influence of Coding Variability in APP-AÎ² Metabolism Genes in Sporadic Alzheimerâ€™s Disease. PLoS ONE, 2016, 11, e0150079.	1.1	34
1665	Incorporating Non-Coding Annotations into Rare Variant Analysis. PLoS ONE, 2016, 11, e0154181.	1.1	10
1666	Drug Repositioning for Alzheimerâ€™s Disease Based on Systematic â€˜omicsâ€™ Data Mining. PLoS ONE, 2016, 11, e0168812.	1.1	95
1667	PRECISION MEDICINE - THE GOLDEN GATE FOR DETECTION, TREATMENT AND PREVENTION OF ALZHEIMERâ€™S DISEASE. journal of prevention of Alzheimer's disease, The, 2016, 3, 1-17.	1.5	67
1668	REST rs3796529 Genotype and Rate of Functional Deterioration in Alzheimerâ€™s Disease. , 2019, 10, 94.		3
1669	Association of MS4A6A, CD33, and TREM2 gene polymorphisms with the late-onset Alzheimerâ€™s disease. BioImpacts, 2019, 9, 219-225.	0.7	11
1670	Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2017, 37, 637-647.	1.7	52
1671	New Insight in The Molecular Mechanisms of Neurodegenerative Disease. Indonesian Biomedical Journal, 2018, 10, 16.	0.2	3
1672	Alzheimerâ€™s disease as a multistage process: an analysis from a population-based cohort study. Aging, 2019, 11, 1163-1176.	1.4	12
1673	White matter hyperintensities and neurodegenerative dementias. Aging, 2019, 11, 2912-2913.	1.4	1
1674	Decreased levels of circulating trimethylamine N-oxide alleviate cognitive and pathological deterioration in transgenic mice: a potential therapeutic approach for Alzheimerâ€™s disease. Aging, 2019, 11, 8642-8663.	1.4	62
1675	Concomitant memantine and Lactobacillus plantarum treatment attenuates cognitive impairments in APP/PS1 mice. Aging, 2020, 12, 628-649.	1.4	75
1676	TREM2 ameliorates neuroinflammatory response and cognitive impairment via PI3K/AKT/FoxO3a signaling pathway in Alzheimer’s disease mice. Aging, 2020, 12, 20862-20879.	1.4	72

#	Article	IF	Citations
1677	Overexpression of TREM2 enhances glioma cell proliferation and invasion: a therapeutic target in human glioma. Oncotarget, 2016, 7, 2354-2366.	0.8	50
1679	The genetics of Alzheimer's disease. Clinical Interventions in Aging, 2014, 9, 535.	1.3	131
1680	The Panomics Approach in Neurodegenerative Disorders. Current Medicinal Chemistry, 2019, 26, 1712-1720.	1.2	3
1681	Clinical, Genetic, and Neuroimaging Features of Early Onset Alzheimer Disease: The Challenges of Diagnosis and Treatment. Current Alzheimer Research, 2014, 11, 909-917.	0.7	14
1682	Distinctive Effects of Aerobic and Resistance Exercise Modes on Neurocognitive and Biochemical Changes in Individuals with Mild Cognitive Impairment. Current Alzheimer Research, 2019, 16, 316-332.	0.7	82
1683	Systemic and CNS Inflammation Crosstalk: Implications for Alzheimerâ€™s Disease. Current Alzheimer Research, 2019, 16, 559-574.	0.7	72
1684	Role of TREM2 in Alzheimer's Disease and its Consequences on Î²- Amyloid, Tau and Neurofibrillary Tangles. Current Alzheimer Research, 2020, 16, 1216-1229.	0.7	28
1685	Brain Arrhythmias Induced by Amyloid Beta and Inflammation: Involvement in Alzheimerâ€™s Disease and Other Inflammation-related Pathologies. Current Alzheimer Research, 2020, 16, 1108-1131.	0.7	13
1686	Microglia in Alzheimerâ€™s Disease. Current Alzheimer Research, 2020, 17, 29-43.	0.7	13
1687	Exploring the Potential of Neuroproteomics in Alzheimer's Disease. Current Topics in Medicinal Chemistry, 2020, 20, 2263-2278.	1.0	12
1688	Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology. Current Neuropharmacology, 2017, 15, 595-619.	1.4	10
1689	YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimerâ€™s Disease. Current Neuropharmacology, 2017, 15, 906-917.	1.4	58
1690	Neuropsychiatric genomics in precision medicine: diagnostics, gene discovery, and translation. Dialogues in Clinical Neuroscience, 2016, 18, 237-252.	1.8	6
1691	Towards defining the Mechanisms of Alzheimer's disease based on a contextual analysis of molecular pathways. AIMS Genetics, 2016, 03, 025-048.	1.9	3
1692	Headmasters: Microglial regulation of learning and memory in health and disease. AIMS Molecular Science, 2018, 5, 63-89.	0.3	5
1693	Application of next-generation sequencing technologies in Neurology. Annals of Translational Medicine, 2014, 2, 125.	0.7	28
1694	Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. Annals of Translational Medicine, 2015, 3, 136.	0.7	593
1695	Shifting equilibriums in Alzheimerâ€™s disease: the complex roles of microglia in neuroinflammation, neuronal survival and neurogenesis. Neural Regeneration Research, 2020, 15, 1208.	1.6	49

#	Article	IF	Citations
1696	Immunology primer for neurosurgeons and neurologists part 2: Innate brain immunity. , 2013, 4, 118.		21
1697	New genetic players in late-onset Alzheimer's disease: Findings of genome-wide association studies. Indian Journal of Medical Research, 2018, 148, 135.	0.4	24
1698	Cellular and Molecular Mediators of Neuroinflammation in Alzheimer Disease. International Neurourology Journal, 2019, 23, S54-62.	0.5	44
1699	Emerging perspectives on mitochondrial dysfunction and inflammation in Alzheimerâ€™s disease. BMB Reports, 2020, 53, 35-46.	1.1	44
1700	Fibrillar AÎ² triggers microglial proteome alterations and dysfunction in Alzheimer mouse models. ELife, 2020, 9, .	2.8	80
1701	Microglia TREM2R47H Alzheimer-linked variant enhances excitatory transmission and reduces LTP via increased TNF-Î± levels. ELife, 2020, 9, .	2.8	33
1702	The Neurogenetic Substructures of Human Consciousness. Essays in Philosophy, 2014, 15, 266-278.	0.2	7
1703	Identification of target genes in neuroinflammation and neurodegeneration after traumatic brain injury in rats. PeerJ, 2019, 7, e8324.	0.9	13
1704	The development and physiological and pathophysiological functions of resident macrophages and glial cells. Advances in Immunology, 2021, 151, 1-47.	1.1	2
1705	Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy. Frontiers in Neuroscience, 2021, 15, 742065.	1.4	171
1707	Investigating Pathogenetic Mechanisms of Alzheimerâ€™s Disease by Systems Biology Approaches for Drug Discovery. International Journal of Molecular Sciences, 2021, 22, 11280.	1.8	3
1708	TREM2 modulates differential deposition of modified and non-modified AÎ² species in extracellular plaques and intraneuronal deposits. Acta Neuropathologica Communications, 2021, 9, 168.	2.4	12
1709	Differential Stimulation of Pluripotent Stem Cell-Derived Human Microglia Leads to Exosomal Proteomic Changes Affecting Neurons. Cells, 2021, 10, 2866.	1.8	6
1710	Effect of APOE alleles on the glial transcriptome in normal aging and Alzheimerâ€™s disease. Nature Aging, 2021, 1, 919-931.	5.3	13
1711	Apolipoprotein E and Alzheimer's disease. Acta Pharmaceutica Sinica B, 2022, 12, 496-510.	5.7	30
1713	PLCÎ³2 regulates TREM2 signalling and integrin-mediated adhesion and migration of human iPSC-derived macrophages. Scientific Reports, 2021, 11, 19842.	1.6	13
1715	Interdependence of neural network dysfunction and microglial alterations in Alzheimerâ€™s disease-related models. IScience, 2021, 24, 103245.	1.9	11
1716	Connexin43 hemichannels contribute to working memory and excitatory synaptic transmission of pyramidal neurons in the prefrontal cortex of rats. Life Sciences, 2021, 286, 120049.	2.0	4

#	Article	IF	Citations
1719	Degenerative Brain Diseases and White Matter Injury. , 2014, , 281-319.		1
1720	Microglia in the Alzheimers brain: a help or a hindrance?. AIMS Neuroscience, 2014, 1, 210-224.	1.0	0
1721	Trem2 Variants and Risk of Alzheimerâ€™s Disease. Brain Disorders & Therapy, 2014, 03, .	0.1	0
1722	Genetic Risk Factors for Alzheimerâ€™s Disease. , 2014, , 49-64.		0
1723	Can Microbes Play a Role in the Pathogenesis of Alzheimer Disease?. , 2014, , 129-146.		0
1724	An Overview of Methods Used in Neurogenomics and Their Applications. Neuromethods, 2015, , 1-59.	0.2	0
1725	Genetics of Dementia with Lewy Bodies. , 2015, , 65-74.		0
1726	Genetic Risk Factors for Neurodegenerative Diseases. , 2015, , 117-134.		0
1727	â€œPersonal Trainingâ€• Advances in Psychology, Mental Health, and Behavioral Studies, 2015, , 18-36.	0.1	0
1728	Glial Cells. , 2015, , 1-12.		0
1729	Biomarkers in Alzheimerâ€™s Disease: From Pathogenic Initiation to Downstream Outcomes. , 2015, , 341-354.		0
1730	Microglia â€“ Role in Immunity. , 2016, , 302-308.		0
1731	Glial Cells. , 2016, , 527-537.		0
1736	Genetics of Alzheimerâ€™s Disease and Research Models. Materials and Methods, 0, 7, .	0.0	1
1741	Immune Senescence and Inflammaging in Neurological Diseases. , 2018, , 1-21.		0
1743	Loss of Ataxin-1 Elevates BACE1 Expression and Impairs Axonal Targeting in the Cerebrum. SSRN Electronic Journal, 0, , .	0.4	0
1744	A Selected Reaction Monitoring Protocol for the Measurement of sTREM2 in Cerebrospinal Fluid. Neuromethods, 2018, , 169-177.	0.2	0
1746	Mitochondrial Function and Neurodegenerative Diseases. , 2018, , 369-414.		1

#	Article	IF	Citations
1747	Solving the Puzzle of Neurodegeneration. , 2018, , 1-22.		2
1755	PROGRAMA PARA EL ENTRENAMIENTO DE LA ACTIVIDAD COGNITIVA EN EL ADULTO MAYOR. Impetus, 2018, 11, 113-122.	0.1	0
1759	Transcriptional Signatures of Progressive Neuropathology in Transgenic Models of Tau and Amyloid Pathology. SSRN Electronic Journal, 0, , .	0.4	0
1761	Immune Senescence and Inflammaging in Neurological Diseases. , 2019, , 2283-2303.		0
1764	3D profiling of amyloid plaque-associated microglia and neuronal damage on confocal fluorescence images to aid drug discovery in Alzheimer's disease. , 2019, , .		1
1765	Is Alzheimer disease a failure of mobilizing immune defense? Lessons from cognitively fit oldest-old. Dialogues in Clinical Neuroscience, 2019, 21, 7-19.	1.8	6
1767	Novel Somatostatin Receptor Subtypeâ€4 Agonist Mitigates Microglia Inflammatory Activation. FASEB Journal, 2019, 33, 501.3.	0.2	0
1776	Differential role of triggering receptors expressed on myeloid cells 2 R47H in 3 neurodegenerative diseases based on a systematic review and meta-analysis. Medicine (United States), 2020, 99, e18921.	0.4	3
1777	Mild Cognitive Impairment and Early Dementia. , 2020, , 215-236.		0
1783	Glutamate and GABA in Microglia-Neuron Cross-Talk in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 11677.	1.8	54
1784	Alzheimerâ€™s Disease, Sleep Disordered Breathing, and Microglia: Puzzling out a Common Link. Cells, 2021, 10, 2907.	1.8	10
1785	Genomics of Alzheimerâ€™s disease implicates the innate and adaptive immune systems. Cellular and Molecular Life Sciences, 2021, 78, 7397-7426.	2.4	32
1789	Alzheimerâ€™s Disease: Etiology, Neuropathology and Pathogenesis. , 0, , 1-22.		22
1791	Structural and functional properties of meprin Î² metalloproteinase with regard to cell signaling. Biochimica Et Biophysica Acta - Molecular Cell Research, 2022, 1869, 119136.	1.9	2
1792	Chemical Probes in Cellular Assays for Target Validation and Screening in Neurodegeneration. Chemical Biology, 2020, , 276-319.	0.1	0
1793	Executive Summary of the 2019 International Conference of Korean Dementia Association: Exploring the Novel Concept of Alzheimer's Disease and Other Dementia: a Report from the Academic Committee of the Korean Dementia Association. Dementia and Neurocognitive Disorders, 2020, 19, 39.	0.4	1
1794	Heterozygous TREM2 Mutation in Semantic Variant of Primary Progressive Aphasia. Journal of Clinical		

#	Article	IF	Citations
1796	Genomics of Alzheimerâ€™s disease. , 2020, , 3-18.		0
1797	Implication of microRNAs in Alzheimer's disease pathogenesis. , 2020, , 131-145.		3
1799	A functional variant of SHARPIN confers increased risk of late-onset Alzheimerâ€™s disease. Journal of Human Genetics, 2022, 67, 203-208.	1.1	8
1800	Microglia and its Genetics in Alzheimer's Disease. Current Alzheimer Research, 2021, 18, 676-688.	0.7	10
1801	Exciting new tools for studying TREM2 in dementia. Structure, 2021, 29, 1215-1216.	1.6	0
1802	The semantics of microglia activation: neuroinflammation, homeostasis, and stress. Journal of Neuroinflammation, 2021, 18, 258.	3.1	198
1807	Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders. American Journal of Neurodegenerative Disease, 2013, 2, 145-75.	0.1	116
1809	Dementia. Ulster Medical Journal, 2015, 84, 79-87.	0.2	44
1810	Taming Alzheimer's disease: New perspectives, newer horizons. Iranian Journal of Neurology, 2017, 16, 146-155.	0.5	4
1811	Bilobalide alleviates neuroinflammation and promotes autophagy in Alzheimer's disease by upregulating lincRNA-p21. American Journal of Translational Research (discontinued), 2021, 13, 2021-2040.	0.0	3
1812	Engagement of vascular early response genes typifies mild cognitive impairment. Alzheimer's and Dementia, 2022, 18, 1357-1369.	0.4	5
1813	Dysregulated phosphoinositide 3-kinase signaling in microglia: shaping chronic neuroinflammation. Journal of Neuroinflammation, 2021, 18, 276.	3.1	36
1814	Structural biology of cell surface receptors implicated in Alzheimerâ€™s disease. Biophysical Reviews, 2022, 14, 233-255.	1.5	5
1815	It Is Time to Study Overlapping Molecular and Circuit Pathophysiologies in Alzheimerâ€™s and Lewy Body Disease Spectra. Frontiers in Systems Neuroscience, 2021, 15, 777706.	1.2	8
1816	Age Matching Is Essential for the Study of Cerebrospinal Fluid sTREM2 Levels and Alzheimerâ€™s Disease Risk: A Meta-Analysis. Frontiers in Aging Neuroscience, 2021, 13, 775432.	1.7	3
1817	Hydroxysafflor Yellow A Inhibits AÎ²1â€“42-Induced Neuroinflammation by Modulating the Phenotypic Transformation of Microglia via TREM2/TLR4/NF-ÎºB Pathway in BV-2 Cells. Neurochemical Research, 2022, 47, 748-761.	1.6	17
1818	Tau activates microglia via the PQBP1-cGAS-STING pathway to promote brain inflammation. Nature Communications, 2021, 12, 6565.	5.8	70
1819	Biological and methodological complexities of betaâ€amyloid peptide: Implications for Alzheimerâ€™s disease research. Journal of Neurochemistry, 2022, 160, 434-453.	2.1	12

#	Article	IF	Citations
1821	AD-linked R47H- TREM2 mutation induces disease-enhancing microglial states via AKT hyperactivation. Science Translational Medicine, 2021, 13, eabe3947.	5.8	55
1822	Largeâ€scale sequencing studies expand the known genetic architecture of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12255.	1.2	4
1823	Challenge accepted: uncovering the role of rare genetic variants in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2022, 17, 3.	4.4	19
1824	Inflammation in obesity, diabetes, and related disorders. Immunity, 2022, 55, 31-55.	6.6	489
1825	The association between plasma soluble triggering receptor expressed on myeloid cells 2 and cognitive impairment after acute ischemic stroke. Journal of Affective Disorders, 2022, 299, 287-293.	2.0	6
1826	Biomarkers used in Alzheimerâ€™s disease diagnosis, treatment, and prevention. Ageing Research Reviews, 2022, 74, 101544.	5.0	60
1827	Synapses, Microglia, and Lipids in Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2021, 15, 778822.	1.4	10
1828	Remembering your A, B, C's: Alzheimer's disease and ABCA1. Acta Pharmaceutica Sinica B, 2022, 12, 995-1018.	5.7	15
1829	Fighting fire with fire: The immune system might be key in our fight against Alzheimerâ€™s disease. Drug Discovery Today, 2022, 27, 1261-1283.	3.2	10
1832	Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise. FEBS Journal, 2023, 290, 1420-1453.	2.2	61
1833	Does Soluble TREM2 Protect Against Alzheimer's Disease?. Frontiers in Aging Neuroscience, 2021, 13, 834697.	1.7	12
1834	Functional insight into LOAD-associated microglial response genes. Open Biology, 2022, 12, 210280.	1.5	5
1835	Implication of Adult Hippocampal Neurogenesis in Alzheimerâ€™s Disease and Potential Therapeutic Approaches. Cells, 2022, 11, 286.	1.8	9
1836	Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency. EMBO Journal, 2022, 41, e109108.	3.5	38
1837	The role of efferocytosis in neuro-degenerative diseases. Neurological Sciences, 2022, 43, 1593-1603.	0.9	4
1839	<scp>MAC2</scp> is a longâ€lasting marker of peripheral cell infiltrates into the mouse <scp>CNS</scp> after bone marrow transplantation and coronavirus infection. Glia, 2022, 70, 875-891.	2.5	11
1840	Targeting the immune system towards novel therapeutic avenues to fight brain aging and neurodegeneration. European Journal of Neuroscience, 2022, 56, 5413-5427.	1.2	2
1841	Soluble TREM2 inhibits secondary nucleation of AÎ² fibrillization and enhances cellular uptake of fibrillar AÎ². Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	14

#	Article	IF	Citations
1842	Variant TREM2 Signaling in Alzheimer's Disease. Journal of Molecular Biology, 2022, 434, 167470.	2.0	10
1843	scTenifoldKnk: An efficient virtual knockout tool for gene function predictions via single-cell gene regulatory network perturbation. Patterns, 2022, 3, 100434.	3.1	17
1844	Persistent Acidic Environment Induces Impaired Phagocytosis via ERK in Microglia. Neurochemical Research, 2022, , 1.	1.6	2
1845	Neuroinflammation in Gaucher disease, neuronal ceroid lipofuscinosis, and commonalities with Parkinsonâ€™s disease. Brain Research, 2022, 1780, 147798.	1.1	8
1846	Soluble TREM2: Innocent bystander or active player in neurological diseases?. Neurobiology of Disease, 2022, 165, 105630.	2.1	41
1847	Alzheimerâ€™s Disease: From Pathogenesis to Mesenchymal Stem Cell Therapy â€“ Bridging the Missing Link. Frontiers in Cellular Neuroscience, 2021, 15, 811852.	1.8	11
1848	The P522R protective variant of PLCG2 promotes the expression of antigen presentation genes by human microglia in an Alzheimer's disease mouse model. Alzheimer's and Dementia, 2022, 18, 1765-1778.	0.4	19
1849	APOE genetics influence murine gut microbiome. Scientific Reports, 2022, 12, 1906.	1.6	17
1850	Phagocytic astrocytes: Emerging from the shadows of microglia. Glia, 2022, 70, 1009-1026.	2.5	30
1851	Mutation analysis of disease causing genes in patients with early onset or familial forms of Alzheimerâ€™s disease and frontotemporal dementia. BMC Genomics, 2022, 23, 99.	1.2	7
1852	Microglia in Alzheimerâ€™s Disease: An Unprecedented Opportunity as Prospective Drug Target. Molecular Neurobiology, 2022, 59, 2678-2693.	1.9	17
1853	Long-term running exercise improves cognitive function and promotes microglial glucose metabolism and morphological plasticity in the hippocampus of APP/PS1 mice. Journal of Neuroinflammation, 2022, 19, 34.	3.1	44
1854	Machine learning prediction and tau-based screening identifies potential Alzheimerâ€™s disease genes relevant to immunity. Communications Biology, 2022, 5, 125.	2.0	18
1855	Identification of the minimal active soluble TREM2 sequence for modulating microglial phenotypes and amyloid pathology. Journal of Neuroinflammation, 2021, 18, 286.	3.1	8
1856	A Review of the Current Mammalian Models of Alzheimerâ€™s Disease and Challenges That Need to Be Overcome. International Journal of Molecular Sciences, 2021, 22, 13168.	1.8	31
1857	Development of early biomarkers of Alzheimer's disease: A precision medicine perspective. , 2024, , 511-525.		0
1858	Microglia and Astrocyte Function and Communication: What Do We Know in Humans?. Frontiers in Neuroscience, 2022, 16, 824888.	1.4	39
1859	An association test of the spatial distribution of rare missense variants within protein structures identifies Alzheimer's diseaseâ€“related patterns. Genome Research, 2022, 32, 778-790.	2.4	5

#	Article	IF	Citations
1860	Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimerâ€™s disease CSF profile of neuronal injury and inflammation. Molecular Psychiatry, 2022, 27, 1990-1999.	4.1	9
1861	Microglia Polarization From M1 to M2 in Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 2022, 14, 815347.	1.7	212
1862	Tanshinone Î™Î™A-Incubated Mesenchymal Stem Cells Inhibit Lipopolysaccharide-Induced Inflammation of N9 Cells through TREM2 Signaling Pathway. Stem Cells International, 2022, 2022, 1-7.	1.2	1
1863	Circular RNA detection identifies circPSEN1 alterations in brain specific to autosomal dominant Alzheimer's disease. Acta Neuropathologica Communications, 2022, 10, 29.	2.4	11
1864	Biobanking and Biomarkers in the Alzheimerâ€™s Disease Drug-Development Ecosystem. , 2022, , 123-134.		0
1865	ENT-A010, a Novel Steroid Derivative, Displays Neuroprotective Functions and Modulates Microglial Responses. Biomolecules, 2022, 12, 424.	1.8	2
1867	Waste Clearance in the Brain and Neuroinflammation: A Novel Perspective on Biomarker and Drug Target Discovery in Alzheimerâ€™s Disease. Cells, 2022, 11, 919.	1.8	12
1868	Microglia and Neuroinflammation: Crucial Pathological Mechanisms in Traumatic Brain Injury-Induced Neurodegeneration. Frontiers in Aging Neuroscience, 2022, 14, 825086.	1.7	46
1869	Microglial activation in Alzheimer's disease: The role of flavonoids and microRNAs. Journal of Leukocyte Biology, 2022, 112, 47-77.	1.5	7
1870	ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease. Neurobiology of Aging, 2022, 115, 20-28.	1.5	20
1871	Isoform- and cell-state-specific lipidation of ApoE in astrocytes. Cell Reports, 2022, 38, 110435.	2.9	35
1872	Role of Animal Models in Alzheimerâ€™s Disease Drug Development. , 2022, , 73-94.		0
1873	Region-based analysis of rare genomic variants in whole-genome sequencing datasets reveal two novel Alzheimerâ€™s disease-associated genes: DTNB and DLG2. Molecular Psychiatry, 2022, 27, 1963-1969.	4.1	9
1874	AÎ² oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2022, 10, 31.	2.4	28
1875	Amygdala and anterior cingulate transcriptomes from individuals with bipolar disorder reveal downregulated neuroimmune and synaptic pathways. Nature Neuroscience, 2022, 25, 381-389.	7.1	27
1876	Effects of electroacupuncture on DNA methylation of the TREM2 gene in senescence-accelerated mouse prone 8 mice. Acupuncture in Medicine, 2022, 40, 463-469.	0.4	3
1878	TREM2 and CD163 Ameliorate Microglia-Mediated Inflammatory Environment in the Aging Brain. Journal of Molecular Neuroscience, 2022, 72, 1075-1084.	1.1	5
1879	Microglia in Alzheimer's Disease: a Key Player in the Transition Between Homeostasis and Pathogenesis. Neurotherapeutics, 2022, 19, 186-208.	2.1	19

#	Article	IF	Citations
1880	Microglial large extracellular vesicles propagate early synaptic dysfunction in Alzheimerâ€™s disease. Brain, 2022, 145, 2849-2868.	3.7	32
1881	Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes. Nature Reviews Neurology, 2022, 18, 323-332.	4.9	29
1882	Whole-genome analysis of human embryonic stem cells enables rational line selection based on genetic variation. Cell Stem Cell, 2022, 29, 472-486.e7.	5.2	27
1883	Alzheimerâ€™s disease â€“ the journey of a healthy brain into organ failure. Molecular Neurodegeneration, 2022, 17, 18.	4.4	41
1884	The meningeal lymphatic vasculature in neuroinflammation. FASEB Journal, 2022, 36, e22276.	0.2	6
1885	Solving neurodegeneration: common mechanisms and strategies for new treatments. Molecular Neurodegeneration, 2022, 17, 23.	4.4	83
1886	A neurodegenerative disease landscape of rare mutations in Colombia due to founder effects. Genome Medicine, 2022, 14, 27.	3.6	16
1887	Inhibition of colony stimulating factor-1 receptor (CSF-1R) as a potential therapeutic strategy for neurodegenerative diseases: opportunities and challenges. Cellular and Molecular Life Sciences, 2022, 79, 219.	2.4	64
1888	Editorial: Degenerative and cognitive diseases. Current Opinion in Neurology, 2022, 35, 208-211.	1.8	0
1889	Glycolytic metabolism supports microglia training during age-related neurodegeneration. Pharmacological Reports, 2022, 74, 818-831.	1.5	4
1890	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. Lancet Neurology, The, 2022, 21, 329-341.	4.9	72
1891	Microglia as therapeutic targets for central nervous system remyelination. Current Opinion in Pharmacology, 2022, 63, 102188.	1.7	10
1892	Positive feedback regulation of microglial glucose metabolism by histone H4 lysine 12 lactylation in Alzheimerâ€™s disease. Cell Metabolism, 2022, 34, 634-648.e6.	7.2	152
1894	Exploring the potential role of rab5 protein in endo-lysosomal impairment in Alzheimerâ€™s disease. Biomedicine and Pharmacotherapy, 2022, 148, 112773.	2.5	6
1895	Downregulation of TREM2/NF-ÐºB signaling may damage the blood-brain barrier and aggravate neuronal apoptosis in experimental rats with surgically injured brain. Brain Research Bulletin, 2022, 183, 116-126.	1.4	6
1896	Identification of potential lead compounds against BACE1 through in-silico screening of phytochemicals of Medhya rasayana plants for Alzheimer's disease management. Computers in Biology and Medicine, 2022, 145, 105422.	3.9	4
1897	Glial-Neuronal Interactions in Pathogenesis and Treatment of Spinal Cord Injury. International Journal of Molecular Sciences, 2021, 22, 13577.	1.8	30
1898	TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration. Nature Neuroscience, 2022, 25, 26-38.	7.1	52

#	Article	IF	Citations
1899	Association of daily sleep duration with the incident dementia by serum soluble <scp>TREM2</scp> in a community. Journal of the American Geriatrics Society, 2022, 70, 1147-1156.	1.3	1
1900	Microglia and astrocyte involvement in neurodegeneration and brain cancer. Journal of Neuroinflammation, 2021, 18, 298.	3.1	32
1901	The Implication of Glial Metabotropic Glutamate Receptors in Alzheimerâ€™s Disease. Current Neuropharmacology, 2023, 21, 164-182.	1.4	3
1902	Alzheimerâ€™s disease modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in mouse model of amyloidosis. Nature Aging, 2022, 2, 60-73.	5.3	12
1903	Impaired Retromer Function in Niemann-Pick Type C Disease Is Dependent on Intracellular Cholesterol Accumulation. International Journal of Molecular Sciences, 2021, 22, 13256.	1.8	9
1904	Microglial TREM2 in amyotrophic lateral sclerosis. Developmental Neurobiology, 2022, 82, 125-137.	1.5	16
1905	Systems Biology to Address Unmet Medical Needs in Neurological Disorders. Methods in Molecular Biology, 2022, 2486, 247-276.	0.4	4
1906	The Role of the Gut Microbiota and Microbial Metabolites in the Pathogenesis of Alzheimerâ€™s Disease. CNS and Neurological Disorders - Drug Targets, 2023, 22, 577-598.	0.8	4
1907	Treadmill exercise improve recognition memory by TREM2 pathway to inhibit hippocampal microglial activation and neuroinflammation in Alzheimer's disease model. Physiology and Behavior, 2022, 251, 113820.	1.0	7
1908	Amyloid Î², Tau, and Î±-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. Progress in Neurobiology, 2022, 214, 102270.	2.8	77
1909	Allele-specific analysis reveals exon- and cell-type-specific regulatory effects of Alzheimerâ€™s disease-associated genetic variants. Translational Psychiatry, 2022, 12, 163.	2.4	10
1910	Glial cells in Alzheimerâ€™s disease: From neuropathological changes to therapeutic implications. Ageing Research Reviews, 2022, 78, 101622.	5.0	39
1945	Different Age Related Neurological and Cardiac Effects of Verapamil on a Transgenic Mouse Model of Alzheimer's Disease. Current Health Sciences Journal, 2021, 47, 263-269.	0.2	0
1946	Molecular recognition of the interaction between ApoE and the TREM2 protein. Translational Neuroscience, 2022, 13, 93-103.	0.7	5
1947	Myeloid LXR (Liver X Receptor) Deficiency Induces Inflammatory Gene Expression in Foamy Macrophages and Accelerates Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 719-731.	1.1	31
1948	Alzheimerâ€™s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint. Frontiers in Neuroscience, 2022, 16, 837390.	1.4	12
1949	Hippocampal but Not Serum Cytokine Levels Are Altered by Traffic-Related Air Pollution in TgF344-AD and Wildtype Fischer 344 Rats in a Sex- and Age-Dependent Manner. Frontiers in Cellular Neuroscience, 2022, 16, 861733.	1.8	2
1950	Transgenic Mouse Models of Alzheimerâ€™s Disease: An Integrative Analysis. International Journal of Molecular Sciences, 2022, 23, 5404.	1.8	36

#	Article	IF	Citations
1951	Beware of Misdelivery: Multifaceted Role of Retromer Transport in Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 2022, 14, .	1.7	2
1952	Recent Advances Towards Diagnosis and Therapeutic Fingerprinting for Alzheimerâ€™s Disease. Journal of Molecular Neuroscience, 2022, , 1.	1.1	6
1953	Peripheral sTREM2-Related Inflammatory Activity Alterations in Early-Stage Alzheimerâ€™s Disease. Journal of Immunology, 2022, 208, 2283-2299.	0.4	2
1954	Serum sTREM2: A Potential Biomarker for Mild Cognitive Impairment in Patients With Obstructive Sleep Apnea. Frontiers in Aging Neuroscience, 2022, 14, .	1.7	2
1955	Changes in glial cell phenotypes precede overt neurofibrillary tangle formation, correlate with markers of cortical cell damage, and predict cognitive status of individuals at Braak III-IV stages. Acta Neuropathologica Communications, 2022, 10, 72.	2.4	5
1956	An Alternatively Spliced TREM2 Isoform Lacking the Ligand Binding Domain is Expressed in Human Brain. Journal of Alzheimer's Disease, 2022, 87, 1647-1657.	1.2	10
1958	Rare Variant Analysis and Molecular Dynamics Simulation in Alzheimerâ€™s Disease Identifies Exonic Variants in FLG. Genes, 2022, 13, 838.	1.0	6
1959	Chronic Ethanol Causes Persistent Increases in Alzheimerâ€™s Tau Pathology in Female 3xTg-AD Mice: A Potential Role for Lysosomal Impairment. Frontiers in Behavioral Neuroscience, 2022, 16, .	1.0	7
1960	Alzheimerâ€™s neuroinflammation: A crosstalk between immune checkpoint PD1-PDL1 and ApoE-Heparin interactions?. Medical Hypotheses, 2022, 164, 110865.	0.8	0
1961	What contribution can genetics make to predict the risk of Alzheimer's disease?. Revue Neurologique, 2022, 178, 414-421.	0.6	6
1962	Alzheimerâ€™s disease associated AKAP9 I2558M mutation alters posttranslational modification and interactome of tau and cellular functions in CRISPRâ€edited human neuronal cells. Aging Cell, 2022, 21, e13617.	3.0	7
1963	Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) R47H Variant Causes Distinct Age- and Sex-Dependent Musculoskeletal Alterations in Mice. Journal of Bone and Mineral Research, 2020, 37, 1366-1381.	3.1	10
1964	Microglia as a Hub for Suicide Neuropathology: Future Investigation and Prevention Targets. Frontiers in Cellular Neuroscience, 2022, 16, .	1.8	10
1965	Neuroinflammatory Markers: Key Indicators in the Pathology of Neurodegenerative Diseases. Molecules, 2022, 27, 3194.	1.7	78
1966	Microglia in traumatic brain injury. , 2022, , 121-133.		0
1967	Peripheral Inflammatory Biomarkers of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 88, 389-398.	1.2	2
1968	GW5074 Increases Microglial Phagocytic Activities: Potential Therapeutic Direction for Alzheimerâ€™s Disease. Frontiers in Cellular Neuroscience, 0, 16, .	1.8	3
1969	TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target. Molecular Neurodegeneration, 2022, 17, .	4.4	36

#	Article	IF	Citations
1970	Microglia in Alzheimerâ€™s Disease: A Favorable Cellular Target to Ameliorate Alzheimerâ€™s Pathogenesis. Mediators of Inflammation, 2022, 2022, 1-17.	1.4	3
1971	Altered neural cell junctions and ion-channels leading to disrupted neuron communication in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2022, 8, .	2.5	15
1972	Genetics of Alzheimerâ€™s disease: an East Asian perspective. Journal of Human Genetics, 2023, 68, 115-124.	1.1	13
1975	In Vivo Detection of Changes Related to Cortical Columnar Organization and Neuroinflammation Across the AD Continuum. journal of prevention of Alzheimer's disease, The, 0, , .	1.5	2
1976	Neuroimmune contributions to Alzheimerâ€™s disease: a focus on human data. Molecular Psychiatry, 2022, 27, 3164-3181.	4.1	20
1977	Primary Microglia Dysfunction or Microgliopathy: A Cause of Dementias and Other Neurological or Psychiatric Disorders. Neuroscience, 2022, 497, 324-339.	1.1	4
1978	Cholesterol and matrisome pathways dysregulated in astrocytes and microglia. Cell, 2022, 185, 2213-2233.e25.	13.5	123
1979	Non-Communicable Neurological Disorders and Neuroinflammation. Frontiers in Immunology, 0, 13, .	2.2	1
1980	Dynamic insights into the effects of nonsynonymous polymorphisms (nsSNPs) on loss of TREM2 function. Scientific Reports, 2022, 12, .	1.6	5
1981	Disease Modeling of Neurodegenerative Disorders Using Direct Neural Reprogramming. Cellular Reprogramming, 0, , .	0.5	4
1982	PhenGenVar: A User-Friendly Genetic Variant Detection and Visualization Tool for Precision Medicine. Journal of Personalized Medicine, 2022, 12, 959.	1.1	3
1983	Sulfavant A as the first synthetic TREM2 ligand discloses a homeostatic response of dendritic cells after receptor engagement. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	7
1984	The role of triggering receptor expressed on myeloid cells 2 in Parkinsonâ€™s disease and other neurodegenerative disorders. Behavioural Brain Research, 2022, 433, 113977.	1.2	4
1985	Mouse Models of Alzheimerâ€™s Disease. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	50
1986	Exploring the Impact of TREM2 in Tumor-Associated Macrophages. Vaccines, 2022, 10, 943.	2.1	16
1987	New Insights into Neuroinflammation Involved in Pathogenic Mechanism of Alzheimerâ€™s Disease and Its Potential for Therapeutic Intervention. Cells, 2022, 11, 1925.	1.8	29
1988	Genetics of Alzheimer Disease. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 852-871.	0.4	6
1989	Overview of therapeutic targets in management of dementia. Biomedicine and Pharmacotherapy, 2022, 152, 113168.	2.5	15

#	Article	IF	Citations
1990	Microglia: Friend and foe in tauopathy. Progress in Neurobiology, 2022, 216, 102306.	2.8	13
1991	Studies of neurodegenerative diseases using Drosophila and the development of novel approaches for their analysis. Fly, 2022, 16, 275-298.	0.9	22
1992	Pathophysiology of neurodegenerative diseases: An interplay among axonal transport failure, oxidative stress, and inflammation?. Seminars in Immunology, 2022, 59, 101628.	2.7	13
1993	A Dichotomous Role for FABP7 in Sleep and Alzheimerâ€™s Disease Pathogenesis: A Hypothesis. Frontiers in Neuroscience, 0, 16, .	1.4	6
1994	Excessive/Aberrant and Maladaptive Synaptic Plasticity: A Hypothesis for the Pathogenesis of Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	4
1996	Biological correlates of elevated soluble TREM2 in cerebrospinal fluid. Neurobiology of Aging, 2022, 118, 88-98.	1.5	8
1997	Iron and Alzheimerâ€™s Disease: From Pathology to Imaging. Frontiers in Human Neuroscience, 0, 16, .	1.0	17
1999	An overview on microglial origin, distribution, and phenotype in Alzheimer's disease. Journal of Cellular Physiology, 0, , .	2.0	3
2002	<scp>TREM2</scp>â€induced activation of microglia contributes to synaptic integrity in cognitively intact aged individuals with Alzheimer's neuropathology. Brain Pathology, 2023, 33, .	2.1	18
2003	Crossing borders in Alzheimerâ€™s disease: A T cellâ€™s perspective. Advanced Drug Delivery Reviews, 2022, 188, 114398.	6.6	13
2004	Stigmasterol attenuates inflammatory response of microglia via NF-ÎºB and NLRP3 signaling by AMPK activation. Biomedicine and Pharmacotherapy, 2022, 153, 113317.	2.5	29
2005	Directed evolution of adeno-associated virus for efficient gene delivery to microglia. Nature Methods, 2022, 19, 976-985.	9.0	56
2006	Targeted BACE-1 inhibition in microglia enhances amyloid clearance and improved cognitive performance. Science Advances, 2022, 8, .	4.7	23
2007	If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?. PLoS Biology, 2022, 20, e3001694.	2.6	67
2008	Development of Î²-sheet structure in AÎ² aggregation intermediates diminishes exposed hydrophobic surface area and enhances proinflammatory activity. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2022, 1870, 140817.	1.1	1
2009	Microglia and microglial-based receptors in the pathogenesis and treatment of Alzheimerâ€™s disease. International Immunopharmacology, 2022, 110, 109070.	1.7	10
2010	Current understanding of the interactions between metal ions and Apolipoprotein E in Alzheimerâ€™s disease. Neurobiology of Disease, 2022, 172, 105824.	2.1	13
2011	The cholesteryl ester transfer protein (CETP) raises cholesterol levels in the brain. Journal of Lipid Research, 2022, 63, 100260.	2.0	7

#	Article	IF	Citations
2012	The role of genetic risk factors of Alzheimer's disease in synaptic dysfunction. Seminars in Cell and Developmental Biology, 2023, 139, 3-12.	2.3	13
2013	Amaryllidaceae, Lycopodiaceae Alkaloids and Coumarinsâ€"A Comparative Assessment of Safety and Pharmacological Activity. Journal of Clinical Medicine, 2022, 11, 4291.	1.0	1
2014	Identification of risk genes for Alzheimerâ€™s disease by gene embedding. Cell Genomics, 2022, 2, 100162.	3.0	12
2015	Mutations in SORL1 and MTHFDL1 possibly contribute to the development of Alzheimerâ€™s disease in a multigenerational Colombian Family. PLoS ONE, 2022, 17, e0269955.	1.1	1
2016	Neuronal cell death mechanisms in Alzheimerâ€™s disease: An insight. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	36
2017	Potential anti neuroâ€inflammatory effect of BioCenâ€128 in animal models of dementia. Animal Models and Experimental Medicine, 0, , .	1.3	1
2018	Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimerâ€™s disease. Journal of Neuroinflammation, 2022, 19, .	3.1	80
2019	Dual ontogeny of disease-associated microglia and disease inflammatory macrophages in aging and neurodegeneration. Immunity, 2022, 55, 1448-1465.e6.	6.6	106
2020	Induction of A Disintegrin and Metalloproteinase with Thrombospondin motifs 1 by a rare variant or cognitive activities reduces hippocampal amyloid-Î² and consequent Alzheimerâ€™s disease risk. Frontiers in Aging Neuroscience, 0, 14, .	1.7	3
2023	Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice. MAbs, 2022, 14, .	2.6	5
2024	TREM2 Gene Compound Heterozygosity in Neurodegenerative Disorders. Journal of Alzheimer's Disease, 2022, , 1-9.	1.2	0
2025	Toll-Like Receptor 4: A Promising Therapeutic Target for Alzheimerâ€™s Disease. Mediators of Inflammation, 2022, 2022, 1-20.	1.4	15
2026	TREMble Before TREM2: The Mighty Microglial Receptor Conferring Neuroprotective Properties in TDP-43 Mediated Neurodegeneration. Neuroscience Bulletin, 0, , .	1.5	0
2027	Apolipoprotein E4 impairs the response of neurodegenerative retinal microglia and prevents neuronal loss in glaucoma. Immunity, 2022, 55, 1627-1644.e7.	6.6	33
2028	Microglial TYROBP/DAP12 in Alzheimerâ€™s disease: Transduction of physiological and pathological signals across TREM2. Molecular Neurodegeneration, 2022, 17, .	4.4	36
2029	Pharmacological targeting of microglia dynamics in Alzheimerâ€™s disease: Preclinical and clinical evidence. Pharmacological Research, 2022, 184, 106404.	3.1	4
2030	Simultaneous imaging of redox states in dystrophic neurites and microglia at Aî² plaques indicate lysosome accumulation not microglia correlate with increased oxidative stress. Redox Biology, 2022, 56, 102448.	3.9	4
2031	TREM2 Is Associated with Advanced Stages and Inferior Prognosis in Oral Squamous Cell Carcinoma. Cancers, 2022, 14, 4635.	1.7	2

#	Article	IF	Citations
2032	Pathogenesis, therapeutic strategies and biomarker development based on â€œomicsâ€•analysis related to microglia in Alzheimerâ€™s disease. Journal of Neuroinflammation, 2022, 19, .	3.1	12
2033	How the immune system shapes neurodegenerative diseases. Trends in Neurosciences, 2022, 45, 733-748.	4.2	17
2034	Genome integrity and inflammation in the nervous system. DNA Repair, 2022, 119, 103406.	1.3	4
2035	Peripheral inflammatory markers during an acute bacterial infection in older patients with and without cognitive dysfunction: A case control study. Brain, Behavior, & Immunity - Health, 2022, 25, 100503.	1.3	1
2036	Targeting neuroinflammation in Alzheimerâ€™s disease: from mechanisms to clinical applications. Neural Regeneration Research, 2023, 18, 708.	1.6	41
2037	æ€¥æ€§å†ç—‡å€™ç¾¤å¼•ãèµ·ã•ã™ãƒ—ãƒ©ãƒ¼ã‚¯è³ªã‚¿ãƒ³ãƒ‘ã‚¯ã«ã‚‚ã‚ˆã‚‹ Journal of JCS Cardiologists, 2022, 31, 10-16.		
2038	Emerging Roles of TREM2 in Neurodegenerative Diseases. , 2022, , 169-195.		0
2039	Epigenetic drugs based on antiaging approach: an overview. , 2022, , 127-138.		2
2040	FSTL1-knockdown improves neural oscillation via decreasing neuronal-inflammation regulating apoptosis in AÎ²1â€“42 induced AD model mice. Experimental Neurology, 2023, 359, 114231.	2.0	2
2041	Shared Risk Factors between Dementia and Atherosclerotic Cardiovascular Disease. International Journal of Molecular Sciences, 2022, 23, 9777.	1.8	22
2042	Connectome-based biophysics models of Alzheimerâ€™s disease diagnosis and prognosis. Translational Research, 2023, 254, 13-23.	2.2	1
2043	Complement component 3 and complement factor H protein levels are altered in brain tissues from people with human immunodeficiency virus: A pilot study. Frontiers in Aging Neuroscience, 0, 14, .	1.7	0
2044	The role of TREM2 N-glycans in trafficking to the cell surface and signal transduction of TREM2. Journal of Biochemistry, 2022, 172, 347-353.	0.9	5
2045	Mechanistic Role of Jak3 in Obesity-Associated Cognitive Impairments. Nutrients, 2022, 14, 3715.	1.7	2
2046	Elevating microglia TREM2 reduces amyloid seeding and suppresses disease-associated microglia. Journal of Experimental Medicine, 2022, 219, .	4.2	20
2047	Spatiotemporal patterns of gliosis and neuroinflammation in presenilin 1/2 conditional double knockout mice. Frontiers in Aging Neuroscience, 0, 14, .	1.7	4
2048	Weakly activated core neuroinflammation pathways were identified as a central signaling mechanism contributing to the chronic neurodegeneration in Alzheimerâ€™s disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	7
2049	Trem2 deletion enhances tau dispersion and pathology through microglia exosomes. Molecular Neurodegeneration, 2022, 17, .	4.4	35

#	Article	IF	Citations
2050	Landscape of immune infiltration in entorhinal cortex of patients with AlzheimerÊ¼s disease. Frontiers in Pharmacology, 0, 13, .	1.6	5
2051	The Innate and Adaptive Immune Cells in Alzheimerâ€™s and Parkinsonâ€™s Diseases. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-12.	1.9	9
2054	PLCÎ³2 impacts microglia-related effectors revealing variants and pathways important in Alzheimerâ€™s disease. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	2
2055	Innate immune activation: Parallels in alcohol use disorder and Alzheimerâ€™s disease. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	8
2056	Glial Cell-Mediated Neuroinflammation in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 10572.	1.8	27
2057	A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimerâ€™s disease. Science Translational Medicine, 2022, 14, .	5.8	33
2058	Advanced therapeutic strategies targeting microglia: beyond neuroinflammation. Archives of Pharmacal Research, 2022, 45, 618-630.	2.7	6
2059	Geneâ€“environment interactions in Alzheimer disease: the emerging role of epigenetics. Nature Reviews Neurology, 2022, 18, 643-660.	4.9	55
2060	Novel Anti-Neuroinflammatory Properties of a Thiosemicarbazoneâ€“Pyridylhydrazone Copper(II) Complex. International Journal of Molecular Sciences, 2022, 23, 10722.	1.8	5
2061	TREM2 risk variants are associated with atypical Alzheimerâ€™s disease. Acta Neuropathologica, 2022, 144, 1085-1102.	3.9	7
2062	Complement C1q-dependent excitatory and inhibitory synapse elimination by astrocytes and microglia in Alzheimerâ€™s disease mouse models. Nature Aging, 2022, 2, 837-850.	5.3	60
2063	APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimerâ€™s disease pathology and brain diseases. Molecular Neurodegeneration, 2022, 17, .	4.4	62
2064	Not just neurological stamp collecting: when rare diagnoses lead to fundamental advances. Practical Neurology, 2023, 23, 98-99.	0.5	0
2066	Cerebrospinal Fluid sTREM2 in Alzheimerâ€™s Disease Is Associated with Both Amyloid and Tau Pathologies but not with Cognitive Status. Journal of Alzheimer's Disease, 2022, 90, 1123-1138.	1.2	3
2067	Microglial response in triggering receptor expressed on myeloid cells 2 (TREM2) knock-out mice after systemic stimulation with Escherichia coli. Neuroscience Letters, 2022, 790, 136894.	1.0	0
2068	The relationships between neuroglial alterations and neuronal changes in Alzheimerâ€™s disease, and the related controversies I: Gliopathogenesis and glioprotection. Journal of Central Nervous System Disease, 2022, 14, 117957352211287.	0.7	1
2069	Chronic TREM2 activation exacerbates AÎ²-associated tau seeding and spreading. Journal of Experimental Medicine, 2023, 220, .	4.2	43
2070	Circulating Soluble TREM2 and Cardiovascular Outcome in Cohort Study of Coronary Atherosclerosis Patients. International Journal of Molecular Sciences, 2022, 23, 13121.	1.8	4

#	Article	IF	Citations
2071	Role of TREM2 in the Development of Neurodegenerative Diseases After Traumatic Brain Injury. Molecular Neurobiology, 2023, 60, 342-354.	1.9	6
2072	TLR4-Pathway-Associated Biomarkers in Subarachnoid Hemorrhage (SAH): Potential Targets for Future Anti-Inflammatory Therapies. International Journal of Molecular Sciences, 2022, 23, 12618.	1.8	7
2074	The Role of Clusterin Transporter in the Pathogenesis of Alzheimerâ€™s Disease at the Bloodâ€“Brain Barrier Interface: A Systematic Review. Biomolecules, 2022, 12, 1452.	1.8	6
2075	Apoptosis-associated speck-like protein containing a CARD-mediated release of matrix metalloproteinase 10 stimulates a change in microglia phenotype. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	0
2076	Myelin repair in Alzheimerâ€™s disease: a review of biological pathways and potential therapeutics. Translational Neurodegeneration, 2022, 11, .	3.6	14
2077	The Hidden Role of Non-Canonical Amyloid Î² Isoforms in Alzheimerâ€™s Disease. Cells, 2022, 11, 3421.	1.8	3
2078	TPM1 mediates inflammation downstream of TREM2 via the PKA/CREB signaling pathway. Journal of Neuroinflammation, 2022, 19, .	3.1	12
2079	Multi-omics analysis reveals neuroinflammation, activated glial signaling, and dysregulated synaptic signaling and metabolism in the hippocampus of aged mice. Frontiers in Aging Neuroscience, 0, 14, .	1.7	7
2080	The industrial genomic revolution: A new era in neuroimmunology. Neuron, 2022, 110, 3429-3443.	3.8	2
2081	Soluble TREM2 and Alzheimer-related biomarker trajectories in the blood of patients with diabetes based on their cognitive status. Diabetes Research and Clinical Practice, 2022, 193, 110121.	1.1	4
2082	Triggering receptor expressed on myeloid cells 2 deficiency exacerbates injury-induced inflammation in a mouse model of tauopathy. Frontiers in Immunology, 0, 13, .	2.2	2
2083	The relationships between neuroglial and neuronal changes in Alzheimerâ€™s disease, and the related controversies II: gliotherapies and multimodal therapy. Journal of Central Nervous System Disease, 2022, 14, 117957352211238.	0.7	0
2084	Fluid biomarkers in Alzheimer's disease. Advances in Clinical Chemistry, 2023, , 249-281.	1.8	7
2085	Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimerâ€™s Disease and Identifying Promising Drug Targets. Biomolecules, 2022, 12, 1676.	1.8	24
2087	Integrated bioinformatics-based identification of diagnostic markers in Alzheimer disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	4
2088	Macrophages in health and disease. Cell, 2022, 185, 4259-4279.	13.5	123
2089	Emerging roles of innate and adaptive immunity in Alzheimerâ€™s disease. Immunity, 2022, 55, 2236-2254.	6.6	49
2090	Late-long-term potentiation magnitude, but not AÎ² levels and amyloid pathology, is associated with behavioral performance in a rat knock-in model of Alzheimer disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	3

#	Article	IF	Citations
2091	Association between Porphyromonas Gingivalis and systemic diseases: Focus on T cells-mediated adaptive immunity. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	9
2094	Friend turned foe: TREM2 agonist in battles against tau. Journal of Experimental Medicine, 2023, 220, .	4.2	2
2095	Gut microbiota, pathogenic proteins and neurodegenerative diseases. Frontiers in Microbiology, 0, 13, .	1.5	5
2096	TREM-2: friend or foe in infectious diseases?. Critical Reviews in Microbiology, 2024, 50, 1-19.	2.7	2
2097	A Review of CRISPR Cas9 for Alzheimerâ€™s Disease: Treatment Strategies and Could target APOE e4, APP, and PSEN-1 Gene using CRISPR cas9 Prevent the Patient from Alzheimerâ€™s Disease?. Open Access Macedonian Journal of Medical Sciences, 2022, 10, 745-757.	0.1	1
2098	Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimerâ€™s disease pathology. Nature Aging, 2022, 2, 1138-1144.	5.3	19
2099	Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimerâ€™s disease. Nature Genetics, 2022, 54, 1786-1794.	9.4	51
2100	Plaque contact and unimpaired Trem2 is required for the microglial response to amyloid pathology. Cell Reports, 2022, 41, 111686.	2.9	10
2102	Enhanced activity of Alzheimer disease-associated variant of protein kinase CÎ± drives cognitive decline in a mouse model. Nature Communications, 2022, 13, .	5.8	9
2103	TREM2 R47H variant and risk for Alzheimerâ€™s disease: assessment in a Greek population and updated meta-analysis. International Journal of Neuroscience, 0, , 1-9.	0.8	1
2104	Amyloid-Î² in Alzheimerâ€™s disease â€“ front and centre after all?. Neuronal Signaling, 2023, 7, .	1.7	9
2105	Iron and Alzheimerâ€™s Disease. , 2023, , 139-170.		1
2106	Synaptic degeneration in Alzheimer disease. Nature Reviews Neurology, 2023, 19, 19-38.	4.9	84
2108	Accumulation of amyloid-Î² in the brain of mouse models of Alzheimer's disease is modified by altered gene expression in the presence of human apoE isoforms during aging. Neurobiology of Aging, 2023, 123, 63-74.	1.5	2
2109	Inflammation context in Alzheimerâ€™s disease, a relationship intricate to define. Biological Research, 2022, 55, .	1.5	29
2110	Differential transcriptomic changes in the central nervous system and urinary bladders of mice infected with a coronavirus. PLoS ONE, 2022, 17, e0278918.	1.1	2
2111	Alzheimer's diseaseâ€associated <scp>R47H TREM2</scp> increases, but wildâ€type <scp>TREM2</scp> decreases, microglial phagocytosis of synaptosomes and neuronal loss. Glia, 2023, 71, 974-990.	2.5	8
2112	Amyloid-beta and tau pathologies act synergistically to induce novel disease stage-specific microglia subtypes. Molecular Neurodegeneration, 2022, 17, .	4.4	16

#	Article	IF	Citations
2113	Beyond the classical amyloid hypothesis in Alzheimer's disease: Molecular insights into current concepts of pathogenesis, therapeutic targets, and study models. WIREs Mechanisms of Disease, 2023, 15, .	1.5	3
2114	TREM2 dependent and independent functions of microglia in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2022, 17, .	4.4	25
2115	Inhibition of histone methyltransferase Smyd3 rescues NMDAR and cognitive deficits in a tauopathy mouse model. Nature Communications, 2023, 14, .	5.8	6
2116	Research Progress on the Role of DAP12 Mediated Microglia Activation in Nervous System. Advances in Clinical Medicine, 2022, 12, 11992-11999.	0.0	0
2117	Alzheimer's disease and synapse Loss: What can we learn from induced pluripotent stem Cells?. Journal of Advanced Research, 2023, 54, 105-118.	4.4	5
2118	Microglial Expression of the Wnt Signaling ModulatorDKK2Differs between Human Alzheimerâ€™s Disease Brains and Mouse Neurodegeneration Models. ENeuro, 2023, 10, ENEURO.0306-22.2022.	0.9	6
2119	Antidepressants as a potential candidate to reduce microglia activation in neurodegenerative diseases. A systematic review and meta-analysis of preclinical studies. Journal of Affective Disorders Reports, 2023, 11, 100465.	0.9	0
2120	A TREM2-activating antibody with a bloodâ€“brain barrier transport vehicle enhances microglial metabolism in Alzheimerâ€™s disease models. Nature Neuroscience, 0, , .	7.1	18
2121	TREM2 signalling as a multifaceted player in brain homoeostasis and a potential target for Alzheimer's disease treatment. European Journal of Neuroscience, 2023, 57, 718-733.	1.2	5
2122	Novel CSF Biomarkers Tracking Autoimmune Inflammatory and Neurodegenerative Aspects of CNS Diseases. Diagnostics, 2023, 13, 73.	1.3	2
2123	Emerging Roles of Extracellular Vesicles in Alzheimerâ€™s Disease: Focus on Synaptic Dysfunction and Vesicleâ€“Neuron Interaction. Cells, 2023, 12, 63.	1.8	6
2124	The neuroimmune axis of Alzheimerâ€™s disease. Genome Medicine, 2023, 15, .	3.6	59
2125	Convergent transcriptomic and genomic evidence supporting a dysregulation of CXCL16 and CCL5 in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2023, 15, .	3.0	4
2126	Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology. Molecular Neurodegeneration, 2023, 18, .	4.4	5
2127	Untangling the Role of TREM2 in Conjugation with Microglia in Neuronal Dysfunction: A Hypothesis on a Novel Pathway in the Pathophysiology of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2023, 94, S319-S333.	1.2	4
2128	Differential splicing of neuronal genes in a Trem2*R47H mouse model mimics alterations associated with Alzheimerâ€™s disease. BMC Genomics, 2023, 24, .	1.2	2
2129	The pollutome-connectome axis: a putative mechanism to explain pollution effects on neurodegeneration. Ageing Research Reviews, 2023, 86, 101867.	5.0	4
2130	Reduction in GABAB on glia induce Alzheimerâ€™s disease related changes. Brain, Behavior, and Immunity, 2023, 110, 260-275.	2.0	1

#	Article	IF	Citations
2131	Newer modalities in the management of Alzheimer's dementia along with the role of aducanumab and lecanemab in the treatment of its refractory cases. Disease-a-Month, 2023, 69, 101547.	0.4	4
2132	TREM2: A new player in the tumor microenvironment. Seminars in Immunology, 2023, 67, 101739.	2.7	4
2133	Prenatally VPA exposure is likely to cause autistic-like behavior in the rats offspring via TREM2 down-regulation to affect the microglial activation and synapse alterations. Environmental Toxicology and Pharmacology, 2023, 99, 104090.	2.0	4
2134	Microglial Cell Dysregulation in the Aged Brain and Neurodegeneration. , 2022, , 57-69.		0
2135	Profiling TREM2 expression in amyotrophic lateral sclerosis. Brain, Behavior, and Immunity, 2023, 109, 117-126.	2.0	6
2136	The biology of TREM receptors. Nature Reviews Immunology, 2023, 23, 580-594.	10.6	45
2137	Rare variant aggregation in 148,508 exomes identifies genes associated with proxy dementia. Scientific Reports, 2023, 13, .	1.6	3
2138	The Amyloid-Beta Clearance: From Molecular Targets to Glial and Neural Cells. Biomolecules, 2023, 13, 313.	1.8	8
2139	A TREM2 antibody energizes microglia. Nature Neuroscience, 0, , .	7.1	3
2140	The genetic basis of multiple system atrophy. Journal of Translational Medicine, 2023, 21, .	1.8	5
2141	Role of sex hormones in neuroinflammation in <scp>Alzheimer's</scp> disease. Clinical and Experimental Neuroimmunology, 2023, 14, 100-109.	0.5	2
2142	Multifactorial glial responses and their contributions to Alzheimer's disease continuum. Clinical and Experimental Neuroimmunology, 2023, 14, 82-91.	0.5	1
2144	Neurodegeneration cell per cell. Neuron, 2023, 111, 767-786.	3.8	8
2145	TDP-43 Proteinopathy Specific Biomarker Development. Cells, 2023, 12, 597.	1.8	4
2146	Co-occurring pathogenic variants in 6q27 associated with dementia spectrum disorders in a Peruvian family. Frontiers in Molecular Neuroscience, 0, 16, .	1.4	0
2147	Reconsidering the role of blood-brain barrier in Alzheimerâ€™s disease: From delivery to target. Frontiers in Aging Neuroscience, 0, 15, .	1.7	11
2148	Hallmarks of neurodegenerative diseases. Cell, 2023, 186, 693-714.	13.5	222
2149	Exploration of novel biomarkers in Alzheimerâ€™s disease based on four diagnostic models. Frontiers in Aging Neuroscience, 0, 15, .	1.7	3

#	Article	IF	Citations
2150	A Trem2R47H mouse model without cryptic splicing drives age- and disease-dependent tissue damage and synaptic loss in response to plaques. Molecular Neurodegeneration, 2023, 18, .	4.4	6
2151	TREM2 splice isoforms generate soluble TREM2 species that disrupt long-term potentiation. Genome Medicine, 2023, 15, .	3.6	6
2152	Frontotemporal dementia presentation in patients with heterozygous p.H157Y variant ofTREM2. Journal of Medical Genetics, 2023, 60, 894-904.	1.5	2
2153	<scp>Association</scp> of rs2062323 in the TREM1 gene with Alzheimer's disease and cerebrospinal fluidâ€soluble <scp>TREM2</scp>. CNS Neuroscience and Therapeutics, 0, , .	1.9	1
2154	Depletion and activation of microglia impact metabolic connectivity of the mouse brain. Journal of Neuroinflammation, 2023, 20, .	3.1	2
2155	Complement receptor 1 is expressed on brain cells and in the human brain. Glia, 2023, 71, 1522-1535.	2.5	7
2156	Zinc Finger Protein 90 Knockdown Promotes Cisplatin Sensitivity via Nrf2/HO-1 Pathway in Ovarian Cancer Cell. Cancers, 2023, 15, 1586.	1.7	2
2157	Cerebrospinal Fluid sTREM-2, GFAP, and Î²-S100 in Symptomatic Sporadic Alzheimerâ€™s Disease: Microglial, Astrocytic, and APOE Contributions Along the Alzheimerâ€™s Disease Continuum. Journal of Alzheimer's Disease, 2023, 92, 1385-1397.	1.2	3
2159	Beyond the amyloid cascade: An update of Alzheimer's disease pathophysiology. Revue Neurologique, 2023, 179, 812-830.	0.6	6
2160	INPP5D modulates TREM2 loss-of-function phenotypes in a Î²-amyloidosis mouse model. IScience, 2023, 26, 106375.	1.9	9
2161	Soluble TREM2 in body fluid in Alzheimerâ€™s disease and Parkinsonâ€™s disease. Neurological Sciences, 0, , .	0.9	1
2162	Tissue-specific macrophages: how they develop and choreograph tissue biology. Nature Reviews Immunology, 2023, 23, 563-579.	10.6	65
2163	The innate immune response in tauopathies. European Journal of Immunology, 2023, 53, .	1.6	2
2166	Beyond the amyloid hypothesis: how current research implicates autoimmunity in Alzheimerâ€™s disease pathogenesis. Critical Reviews in Clinical Laboratory Sciences, 2023, 60, 398-426.	2.7	3
2168	Dendrimers and Derivatives as Multifunctional Nanotherapeutics for Alzheimerâ€™s Disease. Pharmaceutics, 2023, 15, 1054.	2.0	6
2169	TREM2 gene expression associations with Alzheimerâ€™s disease neuropathology are region-specific: implications for cortical versus subcortical microglia. Acta Neuropathologica, 2023, 145, 733-747.	3.9	6
2170	TREM2 deficiency in microglia accelerates photoreceptor cell death and immune cell infiltration following retinal detachment. Cell Death and Disease, 2023, 14, .	2.7	2
2172	Genetic Phenotypes of Alzheimerâ€™s Disease: Mechanisms and Potential Therapy. Phenomics, 2023, 3, 333-349.	0.9	5

#	Article	IF	Citations
2173	Insights from new in vivo models of TREM2 variants. Molecular Neurodegeneration, 2023, 18, .	4.4	2
2174	APOE Îµ4 associates with microglial activation independently of AÎ² plaques and tau tangles. Science Advances, 2023, 9, .	4.7	20
2175	A global view of the genetic basis of Alzheimer disease. Nature Reviews Neurology, 2023, 19, 261-277.	4.9	19
2177	Exploring the genetic and genomic connection underlying neurodegeneration with brain iron accumulation and the risk for Parkinsonâ€™s disease. Npj Parkinson's Disease, 2023, 9, .	2.5	2
2178	The TREM2 H157Y Variant Influences Microglial Phagocytosis, Polarization, and Inflammatory Cytokine Release. Brain Sciences, 2023, 13, 642.	1.1	1
2179	Regulation of TREM2 expression by transcription factor YY1 and its protective effect against Alzheimerâ€™s disease. Journal of Biological Chemistry, 2023, 299, 104688.	1.6	1
2180	Recent Development in the Understanding of Molecular and Cellular Mechanisms Underlying the Etiopathogenesis of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2023, 24, 7258.	1.8	7
2182	TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer. Nature Immunology, 2023, 24, 792-801.	7.0	28
2183	The Functions and Phenotypes of Microglia in Alzheimerâ€™s Disease. Cells, 2023, 12, 1207.	1.8	4
2184	Aging microglia. Cellular and Molecular Life Sciences, 2023, 80, .	2.4	13
2190	Step by step: towards a better understanding of the genetic architecture of Alzheimerâ€™s disease. Molecular Psychiatry, 2023, 28, 2716-2727.	4.1	14
2192	Towards a future where Alzheimerâ€™s disease pathology is stopped before the onset of dementia. Nature Aging, 2023, 3, 494-505.	5.3	13
2208	Physiology and diseases of tissue-resident macrophages. Nature, 2023, 618, 698-707.	13.7	40
2210	The COVID-19â€“related neuroinflammation model may reveal relevant information on healthy longevity. , 2023, , 47-73.		0
2212	Immune dysregulation and neurodegenerative diseases. , 2023, , 267-285.		0
2229	Brain macrophage development, diversity and dysregulation in health and disease. , 2023, 20, 1277-1289.		10
2238	Beyond APP, PSEN1, PSEN2, and APOE: What Else Does the Genome Tell Us?. , 2023, , 351-384.		0
2239	Alzheimerâ€™s Research Gains Momentum and Spreads Out. , 2023, , 285-307.		0

#	Article	IF	Citations
2248	Pathological Roles of INPP5D in Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2023, , 289-301.	0.8	0
2253	Neurogenetic motor disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 183-250.	1.0	0
2265	Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	23